antiproliferative compounds, conjugates, substance composition and use thereof

专利摘要:
ANTIPROLIFERATIVE COMPOUNDS, CONJUGATES OF THE SAME, METHODS FOR THE SAME, AND USE OF THE SAMEAntiproliferative compounds having a structure represented by formula (ll), where n, R ', R2, R3, R´, and R5 are as defined herein, can be used to treat tumors, optionally when conjugated to a linker such as an antibody.
公开号:BR112012002615A2
申请号:R112012002615-1
申请日:2010-08-02
公开日:2020-11-03
发明作者:Heng Cheng；Qiang Cong；Sanjeev Gangwar；Qian Zhang
申请人:Medarex, Inc.；
IPC主号:

专利说明:

Descriptive report of the patent for "ANTIPROLIFERATIVE COMPOUNDS, CONJUGATES, SUBSTANCE COMPOSITION AND USE OF THE SAME".
BACKGROUND OF THE INVENTION The present invention relates to compounds structurally related to tubulisins, conjugated to a ligand, methods for making and using such compounds and conjugates, and compositions comprising such compounds and conjugates. Tubulisins are cytotoxins originally isolated from 10 "cultures of myxobacteria Archangium gephyra or Angiococcus disciformis,. - with each organism producing a different mixture of tubulisins (Sasse et al. 2000; Reichenbach et al. 1998). Its crystalline structure and pathway biosynthetics have been elucidated (Steinmetz et al. 2004) and their biosynthesis genes have been sequenced (Hoefle et al. 2006b). Pretubulisine, a synthetic biosynthetic precursor to tubulisins, has also been shown to have significant activity in itself (Ullrich et al 2009). (Complete citations for the documents cited here '' by the first author or inventor and year are listed at the end of this descriptive report.) Tubulisins belong to a group of naturally occurring antimitotic polypeptides and depsypeptides that include fomopsins, dolastatins, and cryptofinishes (Hamel 2002) Antimitotic agents other than polypeptides or depsipeptides also exist, for example pacli - taxel, maytansines, and epothilones. During mitosis, a cell's microtubules reorganize to form the mitotic spindle, a process that requires rapid arrangement and breakdown of the constituent proteins of microtubule a and B-tubulin. Antimitotic agents block this process and prevent a cell from undergoing mitosis, although at the molecular level the exact blocking mechanism may differ from one agent to another. Tubulisins prevent the arrangement of tubulins in microtubules, causing the affected cells to accumulate in the G7 / M phase and undergo apoptosis (Khalil et al. 2006). Conversely, paclitaxel achieves the same end result by binding to microtubules and preventing their breakdown.
- -..——— 0çess - «<- n ———-—--—-———-————-— = ——— 2/114 Fr Tubulisins have a tetrapeptidyl scaffold built of subunits amino acid being one proteinogenic and three non-proteinogenic: N-methylpipecolinic acid (Mep), isoleucine (Ile), tubuvaline (Tuv), and or tubphenylalanine (Tup, Rº equal to H in formula (1) below) or tubutirosine ( Tut Rº equals OH). About a dozen naturally occurring tubulisins (named A, B, etc.) are known, the sites of structural variation among them being in the residues Rº, Rº and Rº as shown in Formula (1) and Table 1: | | . Mep 'dle Tuv' Tup / Tut j j; Rº "qo Rº oi O, | oe; Rº Ss: with Irunurisin ras ge A OH OC (= O) Me CH2OC (= O) i-Bu B OH OC (= O) Me CH2OC (= O) n-Pr c OH OC (= O) Me CH2OC (= 0O) Et DH OC (= O) Me CH2OC (= 0O) i-Bu EH OC (= O) Me CH2OC (= O) n-Pr FH OC (= O) Me CH2OC (= O) Et G OH OC (= O) Me CHOC (= 0) CH = CH, HH OC (= O) Me CH2OC (= O) Me | OH OC (= O) Me CH2OC (= O) Me UH OC (= O) Me H Vv H OH H Zz OH OH H Pretubulisin HH Me Kaur et al. 2006 studied the antiproliferative properties of tubulisin A and found that it was more potent than other antimitotic agents such as paclitaxel and vinblastine and was active in xenograft assays against a variety of cancer cell lines.
Still, tubulis-
DDD 3/114 ur na A induced apoptosis in cancer cells but not normal cells and showed significant potential antiangiogenic properties in in vitro assays.
The antimitotic properties of the other tubulisins were also evaluated and it was found that they generally compare generally favorably to those of the non-tubulisin antimitotic agents (see, for example, Balasubramanian et al. 2009; Steinmetz et al. 2004; Wipf et al. 2004; Wipf et al. al. 2004). For these reasons, there is considerable interest in tubulisins as anticancer agents (see, for example, Domling et al. 2005c; Hamel 2002). Numerous publications describe efforts directed towards the synthesis of tubulisins, including: Balasubramanian et al. 2009; Domling et al. 2006; Hoefle et al. 2003; Neri et al. 2006; Peltier et al. 2006; Sani et al. 2007; - Sasse et al. 2007; Shankar et al. 2009; Shibue et al. 2009; and Wipf et al. 2004. + Other publications describe studies of the structure-activity relationship '(SAR), through the preparation and evaluation of tubulisin analogues or derivatives: Balasubramanian et al. 2008 and 2009; Domling 2006; Domling et al. 2005a; Ellman et al. 2009; Hoefle et al. 2001 &2006a; Patterson et al. 2007 &2008; Richter 2008; Vlahov et al. 2009; Wang et al. 2007; and Wipf et al. 2007 and 2010. SAR studies mainly explored the structural variations in the Mep ring, Rº and Rº residues of the Tuv subunit, and the non-atomic or aliphatic carbon chain of the Tup / Tut subunit.
Domling et al. 2005 describe conjugates of tubulisins with a molecule of the pair generally described as a polymer or a biomolecule, but with current examples limited to polyethylene glycol (PEG) as the molecule of the pair.
Other documents that describe tubulysin conjugates are Boyd et al. 2008 and 2010; Vlahov et al. 2008a, 2008b and 2010; Leonam et al. 2008 and 2009; Reddy et al. 2009; and Low et al. 2009. Leung et al. 2002 describe polyanionic polypeptides that can be conjugated to drugs (including tubulisins) to improve their bioactivity and solubility in water.
Davis et al. 2008 and Schluep et al. 2009 describe formulations based on cyclodextrin in which tubulisins are covalently linked to a cyclodextrin by means of a ligand-ligating portion of hydrazide.
”S.SONNNNNNNNNCEN EE 4/114 a and disulfide linked to the Tup / Tut carboxyl group.
BRIEF SUMMARY OF THE INVENTION The present invention describes new antiproliferative compounds that are structurally related to tubulisins, are cytotoxic or cytostatic against many cancer cells, and are believed to act by an antimitotic mechanism. These compounds can be conjugated to binders such as antibodies for targeted release against cancer cells.
In one embodiment, this invention provides a compound having a structure represented by the formula (11) Qu o o o a and, ALT nd a b RR O Rm s / + »10 where E ne oO, 1.0u2; R ', R and Rº are independently H, C1-C19 unsubstituted or substituted alkyl, C2x-C1.5 unsubstituted or substituted alkenyl, C2> -C19 unsubstituted or substituted alkenyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, (CH2) 1-20 (C1-C10 alkyl) unsubstituted or substituted, (CH>) 1-2O (C2-C105 alkenyl) unsubstituted or substituted, (CH2), - 20 (C2-C1o alkynyl) unsubstituted or substituted, (CH2 ) .- 2OC (= O) (C1-C1o alkyl), (CH2) 1.-2OC (= 0) (C2-C19 alkenyl) unsubstituted or substituted, (CH), 20C (= 0) (C2-C10 alkynyl ) unsubstituted or substituted, C (= O) (C1-C10 alkyl) unsubstituted or substituted, C (= O) (C2-C10 alkenyl) unsubstituted or substituted, C (= O) (C2-C10 alkynyl) unsubstituted or substituted, unsubstituted or substituted cycloaliphatic, unsubstituted or substituted heterocycloaliphatic, unsubstituted or substituted arylalkyl, or unsubstituted or substituted alkylaryl; D NH, NH, NH) with H CoH COLH;
- E - 5/114 to NH) & E (CH2) a.3CHs3 23> COLH; 2 COH; or with and Rº is H, C1-Cs alkyl, C2-Cs alkenyl, C2-Cs alkynyl, CO (C1-Cs alkyl), CO (C2-C5 alkenyl), or CO (C2-C; alkynyl); or a pharmaceutically acceptable ester thereof, a pharmaceutically acceptable amino acid thereof in the carboxyl group of R as an α-amino group of an α-amino acid, or a pharmaceutically acceptable salt thereof.
A preferred Rº is "NH2 'CO2H with the stereochemistry in the alpha methyl group for carboxyl being more preferably that torsponds to natural tubulisins, that is: 2 COo2H. This invention also provides new intermediates useful to synthesize compounds according to the formula (Il).
In another embodiment, this invention provides a compound of this invention conjugated via a ligand-ligand moiety to a ligand (preferably an antibody, more preferably a monoclonal antibody preferably a human monoclonal antibody) for its selective release to a target cell such as a cancer cell.
In another embodiment, a substance composition comprising a compound of this invention and a binder portion, suitable for conjugation with a binder, is provided.
In another embodiment, this invention provides a method for
——— CC 6/114 to inhibit the proliferation of cancer cells in a subject suffering from cancer, comprising administering to the subject a therapeutically effective amount of a compound of this invention or a conjugate thereof with a linker (particularly an antibody). In another embodiment, a method is provided to inhibit the proliferation of cancer cells, comprising contacting such cells with a compound of this invention or a conjugate thereof with a ligand (particularly an antibody), under conditions sufficient to inhibit the growth of such cancer cells. Cancer cells can be colorectal cancer, liver cancer, prostate cancer, breast cancer, melanoma, glioblastoma, lung cancer, pancreatic cancer, ovarian cancer, multiple myeloma, kidney cancer, leukemia, or cells. lymphoma. Where the linker is an antibody, it is preferred that the antibody binds to an antigen expressed by cancer cells. In another embodiment, a method of treating a cancer in a subject suffering from such cancer is provided, comprising administering to the subject a therapeutically effective amount of a compound of this invention or a conjugate thereof with a ligand (particularly an antibody) . In another embodiment, the use of a compound of this invention (or a conjugate of it with a ligand (particularly an antibody) for the preparation of a drug for the treatment of cancer is provided. In these modalities, the cancer may be colorectal cancer , liver cancer, prostate cancer, breast cancer, melanoma, glioblastoma, lung cancer, pancreatic cancer, ovarian cancer, multiple myeloma, kidney cancer, leukemia, or lymphoma. Where the ligand is an antibody, it is preferred that the antibody binds to an antigen expressed by the cancer cells.
In another embodiment, the use of a compound of this invention or a conjugate thereof with a linker (preferably an antibody) is provided for the preparation of a medicament to treat cancer in a subject suffering from such cancer.
BRIEF DESCRIPTION OF THE DRAWING (S) Figures 1a and 1b describe, in combination, Scheme 1 for making the compounds of this invention.
and Figures 2 and 3 describe Schemes 2 and 3, respectively, also for making the compounds of this invention.
Figure 4 depicts a Scheme 4 suitable for linking a peptidyl linker and a reactive maleimide group to the compounds of this invention.
Figures 5, 6, and 7 depict Schemes 5, 6, and 7, respectively, for making the compounds of this invention.
Figures 8a, 8b, and 8c show Schemes 8, 9, and 10, respectively, for making intermediates useful for preparing the invention compounds.
Figures 9 and 10 show Schemes 11 and 12, respectively, illustrating how intermediates such as those shown in Figures 8a-8c can be made in the compounds of this invention. Figures 11a and 11b show the diagrams for * H thymidine proliferation assays for a first set of compounds of this invention, against two different types of cancer cells.
Figures 12a and 12b show the diagrams for ATP luminescence proliferation assays for a second set of compounds of this invention, against two different types of cancer cells.
Figures 12c and 12d show the diagrams for * H thymidine proliferation assays for the same second set of compounds and against the same two types of cancer cells.
Figure 13 shows the activity against renal cancer cells of conjugates of the compounds of this invention in Hymidine proliferation assays.
Figure 14 shows the activity against renal cancer cells of conjugates of the compounds of this invention in xenograft studies.
Figure 15 shows a Scheme 13 for making intermediates useful for making the compounds of this invention.
Figure 16 shows a Scheme 14 for making the compounds of this invention from intermediates made by Scheme 13.
Figures 17 and 18 show Schemes 15 and 16, respectively.
- w —.— "—- ss« ———... <s — sssss— 8/114 the mind, to make compounds ready for conjugation of this invention. Figure 19 shows Scheme 17 for making a useful intermediate to make the compounds of this invention Figures 20a and 20b show in the Scheme of combination 18 for the preparation of the compounds of this invention from the intermediate of Scheme 17. Figure 21 shows Scheme 19 for making an intermediate used in Scheme 18. Figure 22 shows Scheme 20 for the synthesis of an intermediate used in making the compounds of this invention Figure 23 shows Scheme 21 for making the compounds of this invention from the Scheme 20 intermediate. Figure 24 shows Scheme 22 for making yet another useful intermediate intermediate for making the compounds of this invention Figure 25 shows Scheme 23 for making the compounds of this invention from the intermediate of Scheme 22. DETAILED DESCRIPTION OF THE INVENTION
DEFINITIONS "Antibody" means whole antibodies and any antigen binding fragment (i.e., "antigen binding portion") or single strands thereof. An entire antibody is a glycoprotein comprising at least two heavy chains (H) and two light chains (L) interconnected by disulfide bonds. Each heavy chain comprises a variable region of the heavy chain (VH) and a constant region of the heavy chain comprising three domains, CH,;, CH; and CH3. Each light chain comprises a light chain variable region (V, or Vy) and a light chain constant region comprising a single domain, Cr. The Vu and V. regions can be further subdivided into regions of hypervariability, called complementarity determination regions (CDRs), interspersed with regions of more conserved structure (FRs). Each VH and VL comprises three CDRs and four FRs, arranged at the amino terminus for carboxy in the following order: FR ', CDR', FR ', CDR', FR ', CDR', and FR. At
NNNNNNLSS -——--- snmnms — d dr 9/114 and variable regions contain a binding domain that interacts with an antigen.
The constant regions can mediate the binding of the antibody with tissues or host factors, including several cells of the immune system (for example, effector cells) and the first component (Clq) of the classic complement system.
An antibody is said to "specifically bind" to an X antigen if the antibody binds to X antigen with a Kp of 5 x 10 ° M or less, more preferably 1 x 10 ° M or less, more preferably 6 x 10 ° M or less, more preferably 3 x 10 ° M or less, even more preferably 2 x 10 ° M or less.
The antibody can be chimeric, humanized, or, preferably, human.
The heavy chain constant region can be engineered to affect the type or extent of glycosylation, to extend the half-life of the antibody, to enhance or reduce interactions with effector cells or the complement system, or modu- own some other property.
Engineering can be carried out by substituting, adding, or deleting one or more amino acids or by replacing a domain with a domain of another type of immunoglobulin, or a combination of the background. "Antibody fragment" and "antigen binding portion" of an antibody (or simply "antibody portion") mean one or more fragments of an antibody that retain the ability to specifically bind to an antigen.
It has been shown that the antigen binding function of an antibody can be performed by fragments of a complete antibody, such as (i) a Fab fragment, a monovalent fragment consisting of the V ,, Vu, CL and Cu domains; (ii) an F (ab ') fragment, a divalent fragment comprising two Fab fragments linked by a disulfide bridge in the hinge region; (iii) a Fab 'fragment being essentially a Fab with part of the hinge region (see, for example, Abbas et al., Cellular and Molecular Immunology, 6th Ed., Saunders Elsevier 2007); (iv) an Fd fragment consisting of the Vy and Cu domains; (v) an Fv fragment consisting of the V, and Vx4 domains of a single arm of an antibody, (vi) a dAb fragment (Ward et al., (1989) Nature 341: 544-546) consisting of a domain Vu; (vii) a region for determining
| «QÀÇc00QÇQÓDÓso0000000T0010110000000000009090000 SCSI 10/114 air isolated complementarity (CDR); and (viii) a nanobody, a variable region of the heavy chain containing a single variable domain and two constant domains. In addition, although the two Fv fragment domains, V, and Vu, are encoded by separate genes, they can be joined, using recombinant methods, by a synthetic linker that allows them to be made as a simple protein chain in which the V, and Vhy regions pause to form monovalent molecules (known as single chain Fv, or scFv); see, for example, Bird et al. (1988) Science 242: 423-426; and Huston et al. (1988) Proc. Natl. Acad. Sci. USA 85: 5879-5883). Such single chain antibodies are also encompassed within the term "antigen binding portion" of an antibody.
r An "isolated antibody" means an antibody that is substantially free of other antibodies having different antigen specificities (eg, an isolated antibody that specifically binds the antigenX is substantially free of antibodies that specifically bind antigens other than the antigen X). An isolated antibody that specifically binds antigen X may, however, cross-react with other antigens, such as molecules of antigen X from other species. In certain embodiments, an isolated antibody specifically binds to the human X antigen and does not cross-react with other antigen X antigens (non-human). In addition, an isolated antibody can be substantially free of other cellular and / or chemical material.
"Monoclonal antibody" or "monoclonal antibody composition" means a preparation of antibody molecules of simple molecular composition that exhibits a single binding specificity and affinity for a particular epitope.
"Human antibody" means an antibody having variable regions in which the framework and CDR regions (and the constant region, if present) are derived from human germline immunoglobulin sequences. Human antibodies can include later modifications, including natural or synthetic modifications. Human antibodies may include amino acid residues not encoded by immunoglobulin sequences
ÉS 11/114 PR: human germline (for example, mutations introduced by random or specific mutagenesis in vitro or via somatic mutation in vivo). However, "human antibody" does not include antibodies in which the CDR sequences derived from the germline of other mammalian species, such as a mouse, have been grafted onto the sequences of human structure.
"Human monoclonal antibody" means an antibody that exhibits a single binding specificity having variable regions in which the structure and CDR regions are derived from human germline immunoglobulin sequences. In one embodiment, human monoclonal antibodies are produced by a hybridoma that includes a B cell obtained from a transgenic non-human animal, for example, a transgenic mouse, having a genome comprising a human heavy chain transgene and a light chain transgene fused to an immortalized cell.
"Aliphatic" means a portion of straight or branched, saturated or unsaturated, non-aromatic hydrocarbon having the specified number of carbon atoms (for example, as in "C; aliphatic", "aliphatic C1-Cs", or "C, the aliphatic Cs", the following two phrases being synonymous with an aliphatic portion having 1 to 5 carbon atoms) or, where the number of carbon atoms is not specified explicitly, 1 to 4 carbon atoms ( 2 to 4 carbons in the event of unsaturated aliphatic portions).
"Alkyl" means a saturated aliphatic portion, with the same convention for designating the number of carbon atoms that are applicable. By way of illustration, portions of Ci-Caalquila include, but are not limited to, methyl, ethyl, propyl, isopropyl, isobutyl, t-butyl, 1-butyl, 2-butyl, and others.
"Alkenyl" means an aliphatic moiety having at least one carbon-carbon double bond, with the same convention for designating the number of carbon atoms that are applicable. By way of illustration, portions of C2-Caalkenyl include, but are not limited to, ethylene (vinyl),
It is AEE 12/114 ar 2-propenyl (ally or prop-2-enyl), cis-1-propenyl, trans-1-propenyl, E (or Z) 2-butenyl, 3-butenyl, 1,3-butadienyl ( but-1,3-dienyl) and others. "Alquinyl" means an aliphatic moiety having at least one carbon-carbon triple bond, with the same convention for designating the —number of carbon atoms that are applicable. By way of illustration, Cz-Caalquinyl groups include ethinyl (acetylenyl), propargyl (prop-2-inyl), 1-propynyl, but-2-inyl, and others. "Cycloaliphatic" means a saturated or unsaturated, non-aromatic hydrocarbon portion having 1 to 3 rings, each ring having 3 to 8 (preferably 3 to 6) carbon atoms. "Cycloalkyl" means a cycloaliphatic portion in which each ring is saturated. "Cycloalkenyl" means - a cycloaliphatic moiety in which at least one ring has at least one carbon-carbon double bond. "Cycloalkynyl" means a cycloaliphatic moiety in which at least one ring has at least one carbon-carbon triple bond. By way of illustration, the cycloaliphatic moieties include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, and adamantyl. Preferred cycloaliphatic moieties are those of cycloalkyl, especially cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
"Heterocycloaliphatic" means a cycloaliphatic portion in which, in at least one ring thereof, up to three (preferably 1 to 2) carbons have been independently replaced with a heteroatom selected from N, O, or S, where N and S can be optionally oxidized and N can be optionally quaternized. Similarly, "heterocycloalkyl", "heterocycloalkenyl", and "heterocycloalkyl" mean a portion of cycloalkyl, cycloalkenyl, or cycloalkyl, respectively, in which at least one ring thereof has been modified in this way. Exemplary heterocycloaliphatic moieties include aziridinyl, azetidinyl, 1,3-dioxanyl, oxetanil, tetrahydrofuryl, pyrrolidinyl, piperidinyl, piperazinyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrothiopyranyl sulfone, triforphine, hydrophilicine, chloroform , thiomorpholinyl sulfone, 1,3-dioxolanyl, tetrahydro-1,1-dioxothienyl, 1,4-dioxanyl, tietanyl, and others.
MO —— »————— ÚÚ —————————» Ú —————————— Ú ———— nmnmmm — mp nt 13/114 nr "Aloxy", "aryloxy "," alkylthio ", and" arylthio "mean -O (alkyl), Of (aryl), S (alkyl), and S (aryl), respectively. Examples are methoxy, phenoxy, methylthio, and phenylthio, respectively. "Halogen" or "halo" means fluorine, chlorine, bromine or iodine.
"Aryl" means a hydrocarbon moiety having a mono, bi, or tricyclic ring system in which each ring has 3 to 7 carbon atoms and at least one ring is aromatic. The rings in the ring system can be fused together (as in naphthyl) or bonded to each other (as in biphenyl) and can be fused or bonded to non-aromatic rings (as in indanyl or cyclohexylphenyl) . By way of illustration further, the portions of aryl include, but are not limited to, phenyl, naphthyl, tetrahydronaphyl, indanyl, biphenyl, phenanthryl, anthracenyl, and acenaphthyl.
"Heteroaryl" means a portion having a ring system It is mono, bi, or tricyclic in which each ring has 3 to 7 carbon atoms and at least one ring is an aromatic ring containing from 1 to 4 hetero atoms independently selected from N, O , or S, where N and S can be optionally oxidized and N can be optionally quaternized. Such at least one heteroatom containing aromatic ring can be fused to other types of rings (as in benzofuranyl or tetrahydroisoquinolyl) or directly linked to other types of rings (as in phenylpyridyl or 2-cyclopentylpyridyl). By way of illustration, the heteroaryl portions include pyrrolyl, furanyl, thiophenyl (thienyl), imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, tetrazolyl, pyridyl, N-oxy-pyridine, pyridine, pyridine, pyridine, pyridine, pyridine, pyridine, pyridine, pyridine, pyridine, pyridine, pyrimidinyl, pyrazinyl, quinolinyl, isoquinolinite, quinazolinyl, kinolinin, quinozalinyl, naphthyridinyl, benzofuranyl, indolyl, benzothiophenyl, oxadiazolyl, thiadiazolyl, phenothiazolyl, benzimididolol, denzotinol, benzothiazolyl, dbotriazolyl, benzotriazolyl, dbotriazolyl, benzothria
Where it is indicated that a portion may be substituted, such as using the phrase "substituted or unsubstituted" or "optionally substituted" as in "C; -Cs substituted or unsubstituted alkyl" or "optionally substituted heteroaryl", such portion may have one or more substituents independently selected, preferably one to five in number,
VCL 14/114 mr more preferably one or two in number. Substituents and substitution patterns can be selected by someone skilled in the art, taking into account the portion to which the substituent is attached, to provide compounds that are chemically stable and that can be synthesized by techniques known in the art as well as by methods exposed here. "Arylalkyl", (heterocycloaliphatic) alkyl "," arylalkenyl "," "arylalkynyl", "biarylalkyl", and others mean a portion of alkyl, alkenyl, or alkynyl, as may be the case, replaced with a portion of aryl , heterocycloaliphatic, biaryl, etc., as may be the case, with the valence open (unsatisfied) for the alkyl, alkenyl, or alkynyl portion, for example as in benzyl, phenethyl, N-imidazoylethyl, N-morpholinoethyl, and others. Conversely, "alkylaryl", "someoneylcycloalkyl", and others mean a portion of aryl, cycloalkyl, etc., as may be the case, replaced with a portion of alkyl, alkenyl, etc., as may be the case, for example as in methylphenyl (tolyl) or allylcyclohexyl. "Hydroxyalkyl", "haloalkyl", "alkylaryl", "cyanoaryl", and others mean a portion of alkyl, aryl, etc., as may be the case, replaced with one or more of the identified substituent (hydroxyl, halo, etc., as may be the case).
By way of illustration, permissible substituents include, but are not limited to, alkyl (especially methyl or ethyl), alkenyl (especially allyl), alkynyl, aryl, heteroaryl, cycloaliphatic, heterocycloaliphatic, halo (especially fluoro), haloalkyl (especially trifluoromethyl), hydroxyl, hydroxyalkyl (especially hydroxyethyl), cyano, nitro, alkoxy, O (hydroxyalkyl), O (haloalkyl) (especially OCF; 3), O (cycloalkyl), —O (heterocycloalkyl), O (aryl) , alkylthio, arylthio, = O, = NH, = N (alkyl), = NOH, = NoO (alkyl), C (= O) (alkyl), C (= O) H, CO2H, C (= O) NHOH , C (= 0) O (alkyl), C (= O) O (hydroxyalkyl),) C (= O) NH2, C (= O) NH (alkyl), C (= O) N (alkyl) ,, OC (= O) (alkyl), OC (= O) (hydroxyalkyl), OC (= 0) O (alkyl), OC (= 0O) O (hydroxyalkyl), OC (= O) NH ,, OC (= O ) NH (alkyl), —OC (= O) N (alkyl), azido, NH, NH (alquilay) and N (alkyl), NH (aryl), NHí (hydroxyalkyl), NHC (= O) (alkyl), NHC (= O) H, NHC (= O) NH,;, NHC (= O) NH (alkyl), NHC (= O) N (alkyl)> -, NHC (= NH) NH2, OSO, (alkyl) ,
YOUR ss ss ss. ss 15/114 NE. SH, S (alkyl), S (aryl), S (cycloalkyl), S (= O) alkyl, SO> (alkyl), SO-NH>, SO2NH (alkyl), SO> xN (alkyl)>, and others .
Where the portion being replaced is an aliphatic portion, preferred substitutes are aryl, heteroaryl, cycloaliphatic, heterocycloaliphatic, halo, cyano hydroxylay, nitro, alkoxy O (hydroxyalkyl),) O (haloalkyl), O (cycloalkyl), O (heterocycloalkyl), O (aryl), alkylthio, arylthio, = O, = NH, = N (alkyd),) = NOH, = NO (alkyl),) COxH, C (= O) NHOH, C (= 0O) O (alkyl), C (= O) O (hydroxyalkyl),) C (= O) NH2, C (= O) NH (alkyl),) C (= O) N (alkyl)>, OC (= O) (alkyl), OC (= O) (hydroxyalkyl), OC (= 0O) O (alkyl), OC (= O) O (hydroxyalkyl), OC (= O) NH ,, OC (= O) NH (alkyl) , OC (= O) N (alkyl) -, azido, NH, NH (alkyl)); N (alkyl>, NH (aryl), and NH (hydroxyalkyl), NHC (= O) (alkyl), NHC (= O) H, NHC (= O) NH ,, NHC (= O) NH (alkyl), ), NHC (= O) N (alkyl) -, NHC (= NH) NH ,, OSO, (alkyl), IS SH, S (alkyd), S (aryl), S (= O) alkyl, S (cycloalkyl) ), SOz (alkyl), SO-NH,>, SOxNH (alkyl), and SOxN (alkyl) -. Most preferred substituents are halo, hydroxyl, cyano, nitro, alkoxy, iO (arilay = O, = NOH, = NO (alkyl), OC (= O) (alkyl),) - OC (= O) O (alkyl) ,) - OC (= O) NH ,, - OC (= O) NH (alkyl), OC (= O) N (alkyl) -, = azido, NH, NH (alkyl); N (alkyl), NH (aryl), NHC (= O) (alkyl) - NHC (= O) H, - NHC (= O) NH ,, - NHC (= O) NH (alkyl), —NHC (= O) N (alkyl) ,, and NHC (= NH) NH ,.
Where the portion being replaced is a cycloaliphatic, heterocycloaliphatic, aryl, or heteroaryl portion, the preferred substituents are alkyl, alkenyl, alkynyl, halo, haloalkyl, hydroxyl, hydroxyalkyl, cyano, nitro, alkoxy, O (hydroxyalkyl), O (haloalkyl), Of (aryl), O (cycloalkyl), —O (heterocyclealkyl), alkylthio, arylthio, C (= O) (alkyl)) C (= O) H, CO> H, C (= O) NHOH , - C (= 0) O (alkyl), C (= 0O) O (hydroxyalkyl),) - C (= O) NH>, C (= O) NH (alkyl), C (= O) N (alkyl )., OC (= O) (alkyl), OC (= O) (hydroxyalkyl), OC (= 0) O (alkyl), OC (= 0O) O (hydroxyalkyl), OC (= O) NH,>, OC (= O) NH (alkyl), OC (= O) N (alkyl) ,, azido, NH, NH (alkyl), N (alkyl) ,, —NH (aryl),) NH (hydroxyalkyl)) NHC ( = O) (alkyl),) NHC (= O) H, NHC (= O) NH ,, NHC (= O) NH (alkyl),), NHC (= O) N (alkyl) -, NHC (= NH ) NH>, OSO> (alkyl), SH, S (alkyl), S (aryl), S (cycloalkyl), S (= O) alkyl, SO> (alkyl), SO-NH ,,
..—————— SSSSS 16/114 AND SO2NH (alkyl), and SOxN (alkyl). Most preferred substituents are alkyl, alkenyl, halo, haloalkyl, hydroxyl, hydroxyalkyl, cyano, nitro, alkoxy, O (hydroxyalkyl), C (= O) (alkyl), C (= O) H, COZ2H, C (= O) NHOH, C (= 0) O (alkyl),) C (= O) O (hydroxyalkyl),) C (FO) NH2o, - C (= O) NH (alkyl), C (= O) N (alkyl) ,, OC (= O) (alkyl), OC (= O) (hydroxyalkyl), OC (= 0) O (alkyl), OC (= 0O) O (hydroxyalkyl), OC (= O) NH ,, OC ( = O) NH (alkyl),) OC (= O) N (alkyl)> -, NH, NH (alkyl)) and N (alkyl) s, NH (aryl), NHC (= O) (alkyl), NHC (= O) H, NHC (= O) NH ,, NHC (= O) NH (alkyl), NHC (= O) N (alkyl)., And NHC (= NH) NH ,. Where a range is declared, as in "C, -Cs alkyl" or "5 to 10%", that range includes the end points of the range, as in C; and Cs' in the first place and 5% and 10% in the second circumstance.
Unless particular stereoisomers are specifically indicated (for example, by a bold or dotted bond in a relevant stereocenter in a structural formula, by representing a double bond as having an E or Z configuration in a structural formula, or using stereochemistry designation nomenclature), all stereoisomers are included within the scope of the invention, as pure compounds as well as mixtures thereof.
Unless otherwise indicated, individual enantiomers, diastereomers, geometric isomers, and combinations and mixtures thereof are all covered by the present invention.
Those skilled in the art will appreciate that the compounds may have tautomeric forms (for example, keto and enol forms), resonance forms, and zwitterionic forms that are equivalent to those described in the structural formulas used here and that the structural formulas cover - such tautomeric, resonance, or zwitterionic forms. "Pharmaceutically acceptable ester" means an ester that hydrolyzes in vivo (for example, in the human body) to produce the parent compound or a salt thereof or has activity per se similar to that of the parent compound.
Suitable esters include esters of C,; - C; alkyl, C2-C5 alkenyl or C2-C; alkynyl, especially methyl, ethyl or n-propyl.
SS 17/114 nm "Pharmaceutically acceptable salt" means a salt of a compound suitable for pharmaceutical formulation.
Where a compound has one or more basic groups, the salt may be an acid addition salt, such as a sulphate, hydrobromide, tartrate, mesylate, maleate, citrate, phosphate, acetate, pamoate (embonate), ihydrate, nitrate, hydrochloride , lactate, methyl sulfate, fumarate, benzoate, succinate, mesylate, lactobionate, suberate, tosylate, and others.
Where a compound has one or more acidic groups, the salt may be a salt such as a calcium salt, potassium salt, magnesium salt, meglumine salt, ammonium salt, zinc salt, piperazine salt, tromethamine salt - —na, lithium salt, choline salt, diethylamine salt, 4-phenylcyclohexylamine salt, benzathine salt, sodium salt, tetramethylammonium salt, and others.
Polymorphic crystalline forms and solvates are also included within the scope of this invention. : COMPOUNDS A preferred embodiment of the compounds of the formula (11) is represented by the formula (Il-a) a uno oo ÇA, LILI Are -a) lo R Rm 8 + where n, R ', Rº, and Rº are as previously defined in relation to formula (II) and Rº is NH, & E (CH2) o-2CH3 2 COH 2 Co, "” con In the compounds of formula (Il-a), the subunit that corresponds to Tup / Naturally occurring tubulisine tutnas were reduced in size and lipophilicity by at least two carbons, by deleting the two aliphatic carbon atoms immediately following the carboxylic acid group - that is, the amino group is now the one for the carboxylic acid group , instead of y.
In the circumstance where R * is 4-aminophenylalanine, the amine group constituted a polar portion that still reduces lipophilicity.
SAR studies show that lipophilicity is an important factor in the biological activity of
MN 18/114 Pr tubulisins and their analogs or derivatives.
Steinmetz et al. 2004 and Neri et al. 2006 both describe that the most lipophilic naturally occurring tubulisins - that is, those having a Tup subunit (RÔ equal to H in the formula |) instead of a Tut subunit (Rº equal to OH in the formula |) - have more or biological activity.
In addition, the differences in activities were kept independent of the size and lipophilicity of the 11-acyloxy residue (RC group in formula (1)) in the Tuv subunit (Steinmetz et al. 2004). These results indicate that a lipophilic Tup / Tut subunit is a particularly important SAR element.
The above observations are partially confirmed in two studies by Balasubramanian et al.
In the first one (Balasubramanian et - al. 2008), analogues dimethylated on the alpha carbon for the carboxyl group in the Tup subunit were compared to the analogues otherwise identical Ú demethylated in the same position.
The dimethylated analogs had greater antiproliferative activity - although in vitro tubulin inhibition ICs5 were comparable - as might be expected based on their relative lipophilicity.
However, this trend was not followed in the second study (Balasubramanian et al. 2009) in which three analogs (a demethylated a-carbon, a monomethylated and a dimethylated) were compared.
In this respect, the most active analogue was demethylated while monomethylated - that is, with the natural Tup subunit - was undoubtedly the least active.
However, the later analogue had additional modifications elsewhere in the molecule making it essentially inactive, making it unclear what SAR conclusions, if any, can be deduced.
Patterson et al. 2007 and Ellman et al. 2009 compared the cytotoxicities of tubulisin D and analogues in only the phenethyl group or the y-carboxy was retained in the Tup subunit.
The retained phenethyl analog was 3.6 to 13.6 times less active than tubulisin D against three cancer cell lines but when the less lipophilic y-carboxyl group was retained, there was an even greater loss of activity, 25.7 to 62.5 times less active.
That is, the order of the activity was:
—— -> ————————— 19/114: P À, É. THE, CR N H H COoH T 'Tubulisina D The above documents suggest, individually and in combination, that lipophilicity in the Tup locus is especially important for the biological activity of tubulisins. However, the prior art suggests that replacing the Tup subunit with a phenylalanine (Phe), 4-aminophenylalanine (4-NH2Phe), norvaline or another Rº subunit according to the formula (Il-a) is undesirable, as each would lead to the loss of - at least two aliphatic carbons and a consequent reduction in lipophilicity at the Tup / Tut locus. - The NH Nº: q COH O nho H H H H
COH Tup Phe 4-NH, Phe Norvalina Another preferred embodiment of the compounds of the formula (II) is represented by the formula (IlI-b): NH hu o o O RR IS coH where n, R, R , and Rº are as previously defined with respect to formula (11). Although chemical formulas can be found in the literature covering a group -NH> at position 4 of Tup's aromatic ring (Domling 2005a and 2005b), there was no description of how a compound having such a characteristic could be done. In formulas (11), (Il-a), and (Il-b), R 'is preferably H, C1-C; s alkyl, C2-Cs alkenyl, or C27-Cs alkenyl, and is most preferably a isoleucyl residue being:
NS sssum — m— 20/114 In formulas (11), (Il-a), and (Il-b), R preferably it is H, C1-C; alkyl, CC; alkenyl CH2O (Cr-Cs alkylila) and CH2O (C27-Cs alkenyl), CH2O (C = 0) (C1-Cs alkyl), or CHOC (= 0) (C2-C5 alkenyl); and most preferably it is H, Me, Et, n-Pr, CHrOMe, CH2OEt, CH2O (n-Pr), CHOC (= O) i-Bu, CH OC (= O) n-Pr, CHOC (= 0 ) CH = CH7, or CHOC (= O) Me, with Me, n-Pr, CH; OMe, CH2OC (= 0O) i-Bu, and CH; O (n-Pr) being especially preferred.
In formulas (11), (Il-a), and (Il-b), R ° is preferably H, C1-Cs alkyl, C2-C; alkenyl, C (= 0) C1-C5 alkyl, or C (= 0) C7-C5 alkenyl; and most preferably it is H, Me, Et, or C (= O) Me. 7 Ao Preferably, in formulas (II) and (Il-a), Rº and R * º are: 2 7 E, t COH; e eo, or SEE In formulas (II), (ll-a), and (Il-b), n is preferably 1 and, in the circumstances of formula (11), R ° is preferably methyl; that is, the ring on the Mep subunit is preferably an N-methyl piperidinylone.
A preferred embodiment of the compounds according to formula (ll-a) is described by the formula (1l-a ') H ooo ok RR s / HA where R * º is as defined above in relation to the formula (ll-a ), R is H, C1-C; alkyl, C2-C; alkenyl, CH2O (C1-Cs alkyl), CH2O (C2-Cs5 alkenyl), CHO (C = O) (C1-C5 alkyl), or CHOC (= 0) (C2-Cs alkenyl); and R ° is H, C, 1-Cs alkyl, C2-C; 5 alkenyl, C (= 0) C1-Cs alkyl, or C (= 0) C2-C; alkenyl.
Preferably, Rº is H, Me, Et, n-Pr, CH> OMe, CH2OEt, CH3OC (= O); i-Bu, CH2OC (= O) n-Pr, CHOC (= 0) CH = CH72, or CHOC (= O) Me; more preferably Me, n-Pr, CH> OMe, CH2OC (= O) i-Bu, or CH2O (n-Pr). Preferably, R is H, Me, Et, or C (= O) Me.
MN 21/114 E A preferred embodiment of the compounds according to formula (1l-b) is described by the formula (II-b ”) NHz H o o o; DONE f CO2H where R is H, C1-Cs alkyl, C2-Cs alkenyl, CH2O (C1-Cs alkyl), CH20 (C2-C5 alkenyl), CHO (C = O) (C1-Cs alkyl), or CHOC (= O) (C2 -Cs —alkenyl); eR is H, C1-Cs alkyl, Ca-Cs alkenyl, C (= O) C1-Cs alkyl, or C (= 0) C2-C5 alkenyl.
Preferably, R º is H, Me, Et, n-Pr, CHOMe, CH2OEt, CH2OC (= O) i-Bu, CHOC (= O) n-Pr, CHxOC (= O0) CH = CH7 », or CH2OC (= O) Me and R is H, Me, Et, or C (= O) Me. - Where a carboxyl group in Rº is esterified, preferably the ester is a C1-C ester; alkyl, such as an ester of Me, Et, or Pr.
Alternatively, the carboxyl group can be amidated with ammonia or an alkyl amine.
In another embodiment, this invention provides a compound having a structure represented by the formula (II-c) No. 2 No. or ”o ME) AA (Io) ok gs s COR where R" * is Me, n-Pr, CH2OMe, or CHOC (= 0) CH2CH (Me) s; R '* is Me or C (= O) Me; and R' * is H or C1-Cs alkyl (preferably H, Me, or Et). b), (II-b "), and (ll-c), the stereochemistry in alpha alpha for carboxyl is preferably that corresponding to naturally occurring tubulisins, that is: the Arcom In a preferred embodiment, a compound of this invention is in the form of an amide of the carboxyl group in Rº (or R * º, as may be the case) with the α-amine group of an α-amino acid.
The a-amino acid can be sp 22/114
2. selected from the group consisting of a proteinogenic amino acid, 4-aminophenylalanine, norvaline, norleucine, and citrulline. Preferably, the α-amino acid is selected from the group consisting of alanine, norvaline, glycine, lysine, arginine, citrulline, norleucine, 4-aminophenylalanine, and phenylalanine. Also preferably, the absolute configuration of the a-amino acid is the protein, that is, L. In this preferred embodiment, Rº (or R *) is preferably: x e; Leon, or a Specific examples of the compounds of this invention according to formula (II) include compounds (Ill-a) to (Ill-y). Some of the compounds are described as a pharmaceutically acceptable ester or an amide. It is pharmaceutically acceptable of the carboxyl group of Rº with the α-amine group of an α-amino acid or methyl ester thereof. the NH H o x o ME LEA, Do No »'COH Mas,
AA the NH H o A o ME LIA, (N-b), DO NS | : COo2H in fo o Tt. LETTER COMe (Ito), DO "| S / A.
OAONCONSNNNNNREENNCENNEEEEEEESNSEEENCNENNENCNEEUEEEEREEEEEENEEEEEEEEEE 23/114
NH o and O e - H EA, with À AN,
GL SS EX 1d. O: L. (le), HS EA, O Nº ie Ç, N Do CoHs Qt o AA A Li eo (Io, O 7 à CEA D Sn; | Oo es D | CeHs H LIA A co (U1g), À N, 2: q CC Ss) H õ Do CoHs OH o RA N AS ou e WU So H DERA,
AA o CH, A Oo CL 5 N À 2N Nº “CO, Me UI, ae AN, Cx A ok, AA
The 11/24
NH nu ooo NEN x (1), Po S * COH M 2 "ooo US NS a CoMe (1), ok 8 R | no oou | pe NA MA A As cone (ID, Po Ss no“ Nor 65 o no A o O NES ANA OR 'COaMe (Um), Pak Ss | no OH o O net NA x COaMe (-n), Do to Ss | a. oo US NEN PY' COH (lll-o), Po Ss n e. oo 5 Sah SANA x COMe (I1-p), Do ho Ss |
VN ... ss 25/1114 o f à o Ps o E ah nº NON ER CO Me (-g), ok, S | B NH, no À no N, n x UM, ow $ 'COH o NH No) O o nº N ,, NO (ls), Ow S “"> coH> NH> no ao nº N, n EA (1), 9 IS COMe NH> o fo o A, N To. T 7 (Io ), W or COLEt AA NH
CL IX ON, N N - X YO (Il-v), o . 'COLZEt
Ó ——-— CN -—— ..————————— "" * "* = mmmmm — DnÓ -" ———— 26/114 í NH | OUERCOS.
ECOS: dog, Wo tC CO, ZEt KW oAc y o [No. “CN A CO Me (Illx), and Do“ s a NH HW oAc nv o O PY (My. Ow “$ COLEt This invention also provides new intermediates that can be used for the synthesis of compounds of this invention.
Compounds according to the formula (VIII-a) can be used for the manufacture of compounds according to the formula (II) or (Il-b), as taught in the figures and examples here.
NO, (VIII-a) R7HN COR. In the formula (VIII-a), R 'is H or an amine protecting group and Rê is H, C1-C1o alkyl, C2-C1.9 alkenyl, Cx-C1o alkynyl, aryl, cycloaliphatic, alkylcycloaliphatic, arylalkyl, or alkylaryl.
Preferably, R 'is H, Boc (t butoxycarbonyl), Troc (2,2,2-trichloroethoxy carbonyl), Bpoc ((1-methyl-1- (4-bipheni) ethoxycarbonyl)), Cbz (benzyloxy carbonyl), Aloc (allyloxycarbonyl), methyl amine, or Fmoc (9-fluorenylmethoxycarbonyl). Preferably, Rê is H or Cr-
RNNNNNNNrnthnuhuhunu — uuhueth — u — u ———————— *> 27/1114 o Cs alkyl (especially Me).
Another new intermediate useful for the synthesis of the compounds of this invention has a structure according to the formula (VIII-b). The use of the compounds of the formula (VIII-b) to make the compounds of this invention is taught in the figures and examples here. NHRº (VIII-b) R! ºHN ”i COR! ) In the formula (VIII-b), Rº and R'º are independently H or an amine protecting group and R '* is H, C1-C; the alkyl, C2-C19 alkenyl, C2-' C10 alkynyl, aryl , cycloaliphatic, alkylcycloaliphatic, arylalkyl, or alkylaryl.
. Preferably, Rº and R "º are independently selected from H, Boc, Troc, Bpoc, Cbz, Aloc, methylamine, and Fmoc. Preferably, R'éHouCr Cs alkyl (especially Me). Preferably, where Rº and R" º are, each, an amine protection group, they are different amine protection groups.
Additional suitable amine protecting groups for the compounds of the formula (Vill-a) and (VIll-b) are described in Greene and Wuts, Protective Groups in Organic Synthesis, 3rd edition, pages. 464-653 (John Wi-ley & Sons, New York, 1999), the description of which is incorporated herein by reference.
CONJUGATES In another aspect, a conjugate is provided comprising a cytotoxic compound according to this invention and a linker, represented by the formula (IV) [DOP) COOLLIMZ - (IV) where Z is a linker; D is a cytotoxic compound according to this invention; and (P) .CPÔ), are collectively referred to as a "ligand-ligand moiety" or "ligand" because they bind Z and D. Within the ligand, C is a cleavable group designed to be cleaved at the site of the intended biological action of the compound D; Xº and Xº are referred to as spacer portions
MN 28/114 air (or "spacer") because they space from D and C and C and Z, respectively; subscripts a and b are independently 0 or 1 (that is, the presence of x and / or X are optional); and the subscript m is 1, 2, 3, 4, 5,6,7,8, 9, or 10 (preferably 1, 2, 3, or 4). D, X , C, X * and Z are completely defined below.
Linker Z - for example an antibody - serves a targeting function. Binding to a target tissue or cell where its antigen or receptor is located, the Z ligand directs the conjugate there. Preferably, the target tissue or cell is a cancer tissue or cell and the antigen or receptor is a tumor-associated antigen being an antigen being expressed exclusively by cancer cells or overexpressed by cancer cells, - compared to non-cancer cells . Cleavage of group C with the target tissue or cell releases compound D to exert its local cytotoxic effect. In some circumstances, the conjugate is internalized in a target cell by endocytosis and cleavage occurs within the target cell. In this way, the precise release of compound D is achieved at the intended site of action, reducing the required dosage. Also, compound D is normally biologically inactive (or significantly less active) in its conjugated state, thereby reducing unwanted toxicity against non-target tissue or cells. As anticancer drugs are often highly toxic to cells in general, this is an important consideration.
As reflected by the superscript m, each molecule of ligand Z can conjugate with more than one compound D, depending on the number of Dtem sites available for conjugation and the experimental conditions employed. Those skilled in the art will appreciate that, although each individual molecule of the Z linker is conjugated to an integer number of D compounds, a preparation of the conjugate can analyze a ratio of non-integer number of compounds D to linker Z, reflecting a statistical average Ligand Z and Conjugation of the Same Preferably, ligand Z is an antibody. For convenience and
PNI 29/114 and brevity and not limitation, the subsequent detailed debate here on the conjugation of the ligand Z is written in the context of being an antibody, but those skilled in the art will understand that other types of ligand Z can be conjugated, mutatis mutandis . For example, conjugates with folic acid as the ligand can target cells with the folate receptor on their surfaces (Vlahov et al. 2008a, 2008b and 2010; Leamon et al. 2009). For the same reason, the debate detailed below is written primarily in terms of a 1: 1 ratio of antibody Z to compound D. Preferably, ligand Z is an antibody against a tumor-associated antigen, allowing a conjugate comprising such a ligand Z selectively target cancer cells. Examples of such antigens include: mesothelin, prostate specific membrane antigen (PSMA), CD19, CD22, CD30, CD70, B7H4 (also known as O8E), protein "tyrosine kinase 7 (PTK7), RG1, CTLAH, and CD44 The antibody may be animal (e.g., murine), chimeric, humanized, or, preferably, human.The antibody is preferably monoclonal, especially a human monoclonal antibody. The preparation of human monoclonal antibodies against some of the antigens mentioned above is described in Korman et al., US 2009/0074660 A1 (B7H4); Rao-Naik et al., US 2009/0142349 A1 A2 (CD19); King et al, WO 2008/070569 A2 (CD22 ); Keler et al, US
7,387,776 B2 (2008) (CD30); Terrett et al., US 2009/0028872 A1 (CD70); Korman et al, US 6,984,720 B1 (2006) (CTLA-4); Korman et al, US 2009/0217401 A1 (PD-1); Huang et al., US 2008/0279868 A1 (PSMA); Lu et al., US 2010/0034826 A1 (PTK7); Harkins et al., US 7,335,748 B2 (2008) (RG1); Terrett et al, WO 2009/045957 A1 (mesothelin); and Xu et al, US 2010/0092484 A1 (CD44); their descriptions are hereby incorporated by reference. The Z-linker can also be an antibody fragment or mimetic antibody, such as an antibody, a domain antibody (dAb), a - nanobody, a body, a DARPin, an anthelin, a versace, a duocalin, a lipocalin. , or an avimer. Any of several different reactive groups on Z linker
CC. Aeo ——— «——— <- 2— eq ——————————— === - = - == 2— 30/114 MN can be a conjugation site, including e-amino groups in lysine residues, pending carbohydrate moieties, carboxylic acid groups, disulfide groups, and thiol groups. Each type of reactive group represents a dilemma, with some advantages and some disadvantages. For reviews on antibody groups suitable for conjugation, see, for example, Garnett, Adv. Drug Delivery Rev. 53 (2001), 171-216 and Dubowchik and Walker, Pharmacology & Therapeutics 83 (1999), 67-123, descriptions these are hereby incorporated by reference. In one embodiment, ligand Z is conjugated via an e-amino group of lysine. Most antibodies have multiple € - amino groups of lysine, which can be conjugated via amide bonds, and urea, thiourea, or carbamate using techniques known in the art, including modification with a heterobifunctional agent (as also described ' lower). However, it is difficult to control what and how much the e-amino groups react, leading to the potential batch-to-batch variability in the conjugate preparations. Also, the conjugation can cause neutralization of an important protonated e-amino group to maintain the native conformation of the antibody or it can happen in a nearby lysine or in the antigen binding site, both being a desirable occurrence.
In another embodiment, ligand Z can be conjugated through a carbohydrate side chain, since many antibodies are glycosylated. The carbohydrate side chain can be oxidized with periodate to generate aldehyde groups, which in turn can be reacted with amines to form an imine group, such as in a semicarbazone, oxime, or —hydrazone. If desired, the imine group can be converted to a more stable amine group by reduction with sodium cyanoborohydride. For additional descriptions on conjugation by means of carbohydrate side chains, see, for example, Rodwell et al., Proc. Nat'l Acad. Sci. USA 83, 2632-2636 (1986); its description is hereby incorporated by reference. As with the e-amino groups of lysine, there are concerns that consider the reproducibility of the location of the conjugation site (s) and the stoichiometry.
mr In yet another embodiment, the linker Z can be conjugated by means of a carboxylic acid group. In one embodiment, a terminal carboxylic acid group is functionalized to generate a carbohydrazide, which is then reacted with a conjugation portion carrying aldehyde. See Fischetal, Bioconjugate Chemistry 1992, 3, 147-153.
In yet another embodiment, antibody Z can be conjugated by means of a disulfide group that bonds a cysteine residue in antibody Z and a sulfur in the other portion of the conjugate. Some antibodies lack free thiol groups (sulfhydryl), but they have disulfide groups, for example in the hinge region. In such a case, free thiol groups can be generated by reducing native disulfide groups. The thiol groups thus generated can then be used for conjugation. See, for example, Packard et al., Biochemistry 1986, 25, 3548-3552; King et al., Cancer Res. 54, 6176- '6185 (1994); and Doronina et al., Nature Biotechnol. 21 (7), 778-784 (2003); their descriptions are hereby incorporated by reference. Again, there are concerns regarding the location of the conjugation site and stoichiometry and the possible disruption of the antibody's native conformation. Several methods are known to introduce free thiol groups into antibodies without disrupting the native disulfide bonds, the methods of which can be practiced with a Z linker of this invention. Depending on the employee's method, it may be possible to introduce a predictable number of free sulfhydryls at predetermined locations. In one approach, mutated antibodies are prepared in which one cysteine is replaced by another amino acid. See, for example, Eigenbrot et al., US 2007/0092940 A1; Chilkotietal, Bioconjugate Chem. 1994, 5, 504-507; Urnovitz et al., US
4,698,420 (1987); Stimmel et al., J. Biol. Chem., 275 (39), 30445-30450 (2000); Bam et al., US 7,311,902 B2 (2007); Kuan et al., J. Biol. Chem., 269 (10), 7610-7618 (1994); Poon et al., J. Biol. Chem., 270 (15), 8571-8577 (1995). In another approach, an extra cysteine is added at the end of C. See, for example Cumber et al., J. Immunol., 149, 120-126 (1992); King et al, Cancer Res., 54, 6176-6185 (1994); Li et al., Bioconjugate Chem., 13, 985-995 (2002); Yang et al., Protein Engineering, 16, 761-770 (2003); and ur Olafson et al., Protein Engineering Design & Selection, 17, 21-27 (2004). A preferred method for introducing free cysteines is that taught by Liu et al., WO 2009/026274 A1 in which a cysteine that carries an amino acid sequence is added to the C end of an antibody heavy chain. - This method introduces a known number of cysteine residues (one per heavy chain) at a known location remote from the antigen binding site. The descriptions of the documents cited in this paragraph are all incorporated here by reference.
In yet another embodiment, the e-amino groups of lysine can be modified with robifunctional reagents such as 2-iminothiolane or N-succinimidyl-3- (2-pyridyldithio) -propionate (SPDP), converting an e- - amino group into one thiol or disulfide group - creating a cysteine substitute, such as. However, this method suffers from the same limitations of location A of conjugation and stoichiometry associated with the appropriate amino groups.
In yet another preferred embodiment, linker Z is conjugated via the nucleophilic addition product of a thiol group to an acceptor moiety. A preferred accepting moiety is a maleimide group whose reaction with a thiol group of the antibody is generally illustrated below. The thiol group can be a native serum, or one introduced as described above.
R r THs-z R Ss, cpoana a =, oneaa O o Ligand - PO) ACEO), - As noted above, the ligand-ligand portion of a conjugate of this invention comprises up to three elements: a cleavable group C and optional spacers Xº and XP.
Cleavable group C is a cleavable group under physiological conditions, preferably selected so that it is relatively stable as long as the conjugate is in general circulation in the blood plasma, but is easily cleaved once the conjugate reaches its intended site of action. that is, near, on or within the target cell. Preferably, the
urine is internalized by endocytosis by a target cell under binding of antibody Z to an antigen displayed on the surface of the target cell. Subsequently, cleavage of group C occurs in a vesicular body of the target cell (a premature endosome, a late endosome, or, especially, a lysosome).
In one embodiment, group C is a pH sensitive group. The pH in the blood plasma is slightly above neutral, while the pH within a lysosome is acidic, about 5. Thus, a group C whose cleavage is catalyzed acid will cleave at a rate of several orders of magnitude faster within of a lysosome that in the blood plasma rate.
Examples of suitable acid-sensitive groups include cis- amides. aconityl and hydrazones, as described in Shen et al., US 4,631,190 (1986); Shen et al., US 5,144,011 (1992); Shen et al., Biochem. Biophys. Res.
ii Commun. 102, 1048-1054 (1981) and Yang et al., Proc. Natl Acad. Sci (USA), 85,1189-1193 (1988); their descriptions are hereby incorporated by reference.
In another embodiment, group C is a disulfide. Disulfides can be cleaved by a thiol-disulfide exchange mechanism, at a rate dependent on the thiol concentration in the environment. As the intracellular concentration of glutathione and other thiols is higher than its concentration in serum, the cleavage rate of a disulfide will be intracellularly higher. Furthermore, the thiol-disulfide exchange rate can be modulated by adjusting the steric and electronic characteristics of the disulfide (for example, an alkyl-aryl disulfide versus an alkyl-alkyl disulfide; substitution in the aryl ring, etc.), allowing the design of disulfide bonds that have enhanced stability in serum or a particular rate of cleavage. For additional descriptions regarding cleavable disulfide groups in the conjugates, see, for example, Thorpe et al., Cancer Res. 48, 6396-6403 (1988); Santi et al., US 2005/0287155 A1; Ng et al., US 6,989,452 B2 (2006); Ng et al, WO 2002/096910 A1; Boyd et al., US 7,691,962 B2; and Sufi et al, WO 2008/083312 A2; their descriptions are hereby incorporated by reference.
A preferred group C comprises a peptide bond that
TE -, -> õ cs oa 34/114 RL. it is cleaved, preferably by a protease, at the intended site of action, rather than by a protease in the serum. Typically, group C comprises 1 to 20 amino acids, preferably 1 to 6 amino acids, more preferably 1 to 3 amino acids. The amino acid (s) can (are) natural and / or unnatural amino acid (s). Natural amino acids are those encoded by the genetic code, as well as amino acids derived therefrom, for example, hydroxyproline, y-carboxyglutamate, citrulline, and O-phosphoserine. The term amino acid also includes amino acid analogs and mimetics. Analogs are compounds having the same general HAN (R) CHCO> 2H structure as a natural amino acid, except that the R group is not found among the natural amino acids. Examples of analogs include: homoserine, norleucine, methionine sulfoxide, and methylene methyl sulfonium. An amino acid mimetic is a compound having a different structure from the general chemical structure of an α-amino acid, but it works in a similar way to one. The term "unnatural amino acid" is intended to represent the stereochemical form "D", the natural amino acids being of the form "L".
Preferably, group C contains an amino acid sequence which is a cleavage recognition sequence for a protein. Many cleavage recognition sequences are known in the art. See, for example, Matayoshi et al. Science 247: 954 (1990); Dunn et. al. Meth. Enzymol. 241: 254 (1994); Seidah et. al. Meth. Enzymol. 244: 175 (1994); Thornberry, Meth. Enzymol. 244: 615 (1994); Weber et. al. Meth. Enzymol. 244: 595 (1994); Smith et. al., Meth. Enzymol. 244: 412 (1994); and —Bouvier et. al. Meth. Enzymol. 248: 614 (1995); their descriptions are hereby incorporated by reference.
For conjugates that are not intended to be internalized by a cell, a group C can be selected so that it is cleaved by a protease present in the extracellular matrix in the vicinity of the target tissue, for example, a protease released by nearby dying cells or an associated protease to the tumor. Exemplary extracellular tumor-associated proteases are matrix metalloproteases (MMP), timetable oligopeptides
NNE »35/114 Le dase (TOP) and CD10.
For conjugates that are designed to be internalized by a cell, group C preferably comprises an amino acid sequence selected for cleavage by an endosomal or lysosomal protease, especially the latter. Non-limiting examples of such proteases include cathepsins B, C, D, H Le S, especially cathepsin B. Cathepsin B cleaves the peptides preferentially in an AA -AA 'sequence where AA * is a basic or strong hydrogen bonding amino acid (such as such as lysine, arginine, or citrulline) and AA it is a hydrophobic amino acid (such as phenylalanine, valine, alanine, leucine, or isoleucine), for example Val-Cit (where Cit denotes citrulline) or Val-Lys. (Here, the amino acid sequences are written in the direction: from N to C, as in HoN-AAÇAA -CO2H, unless otherwise clearly indicated by the context.). For additional information regarding E cleavable cathepsin groups, see Dubowchik et al., Biorg. Med. Chem. Lett.
8,3341-3346 (1998); Dubowchik et al., Bioorg. Med. Chem. Lett., 8, 3347-3352 (1998); and Dubowchik et al., Bioconjugate Chem. 13, 855-869 (2002); their descriptions are incorporated by reference. Another enzyme that can be used to cleave peptidyl ligands is legumaine, a lysosomal protease cysteine that preferably cleaves in Ala-Ala-Asn.
In one embodiment, group C is a peptide comprising the sequence of two amino acids AA -AA 'where AA' is lysine, arginine, or citrulline and AA is phenylalanine, valine, alanine, leucine or isoleucine. In another modality, C consists of a sequence of one to five amino acids, selected from the group consisting of Val-Cit, Ala-Val, Val-Ala-Val, Lys-Lys, —Ala-Asn-Val, Val- Leu-Lys, Cit-Cit, Val-Lys, Ala-Ala-Asn, Lys, Cit, Ser, and Glu.
The preparation and design of the cleavable groups C consisting of a simple amino acid are described in Chen et al., US 2010/0113476 A1, the description of which is incorporated herein by reference.
Group C can also be a photocleavable, for example a nitrobenzyl ether being cleaved under exposure to light.
Group C can be directly linked to antibody Z or compound D; that is, spacer Xº and XP, as may be the case, may be absent.
N ——————— 36/114 PN For example, if group C is a disulfide, one of the two sulfur may be a cysteine residue or its substitute in antibody Z.
Or, group C may be a hydrazone attached to an aldehyde in an antibody carbohydrate side chain.
Or, group C can be a peptide bond formed with a lysine amino group of antibody Z.
In a preferred embodiment, compound D is directly linked to group C via a peptidyl bond to a carboxyl or amine group in compound D.
When present, the Xº spacer provides spatial separation between group C and antibody Z, so that the first non-sterically interferes with the antigen binding by the second or the first sterically interferes with the cleavage of the second.
Furthermore, the Xº spacer can be used - to give properties of increased solubility or decreased aggregation to the conjugates.
An X spacer it can comprise one or more modular segments, which can be assembled in any number of combinations.
Examples of suitable segments for an XxX spacer are: thin Tt Eno EA, tera, then: tl (crerno) -cHera-EA, where the superscript is 1 to 24, preferably 2 to 4. These segments can be combined to make the X2 spacers, such as: oo E (CHa) sEN (CH3CH2O) -CHZCH2-EN (CH9a-NR; Ertonas-Eltens-te | "” ttoraaeE tera NA The Xº spacer, if present, provides spatial separation between group C and compound D, so that the first non-steric or electronically interferes with the cleavage of the second.
The Xº spacer can also serve to introduce additional molecular weight and chemical functionality into a conjugate.
Generally, additional mass and functionality will affect serum half-life and other properties of the conjugate.
Thus, through judicious selection of the spacer groups, the half-life in serum of
Dur a conjugate can be modulated.
The Xº spacer can also be assembled from modular segments, as described above in the context of the Xº Spacer. Or the X spacer or XP, or both, can comprise an auto-immolating portion.
A self-immolating moiety is a moiety that (1) is linked to group C and either antibody Z or cytotoxin D and (2) has a structure so that cleavage of group C initiates a reaction sequence that results in itself shutting down the auto-immolating portion of antibody Z or cytotoxin D, as may be the case.
In other words, the reaction at a distal site of antibody Z or cytotoxin D (group C cleavage) causes X2-Z or XP-D to bind to break as well.
The presence of a self-immolating portion is desirable in the case of spacer X ”because, if, after cleavage of the conjugate, spacer Xº or a portion of it remains attached to cytotoxin D, the biological activity of the first may be impaired .
The use of a self-immolating moiety is especially desirable where the cleavable group C is a polypeptide.
Exemplary self-immolating portions (i) - (v) attached to a hydroxyl or amino group in a molecule of the D pair are shown below: ab () ab (ii) a "SD ed mA E Ns“ TO in “O and O “: RES cet and so E. fetus IS: Me - Me / Hui“ oo pre enpensation of ONES io Fo o; The self-immolating portion is the structure between the dotted lines a and b, with adjacent structural features shown to provide the context .
Self-immolating portions (i) and (v) are attached to a compound D-NH, (i.e., compound D is conjugated via an amino group), while
TE —— ê "=" = - n ——— 38/114 - the self-immolating moieties (ii), (il), and (iv) are linked to a D-OH compound (i.e., compound D is conjugated by hydroxyl or carboxyl group). Cleavage of the amide bond on the dotted line b releases the nitrogen from the amide as an amine nitrogen, initiating a reaction sequence that results in the cleavage of the bond on the dotted line a and the consequent release of D-OH or D-NH>, as it may be the case. For additional descriptions regarding the self-immolating portions, see Carl et al., J. Med.
Chem., 24 (3), 479-480 (1981); Carl et al., WO 81/01145 (1981); Dubowchik et al., Pharmacology & Therapeutics, 83, 67-123 (1999); Firestone et al., US
6,214,345 B1 (2001); Toki et al. J. Org. Chem. 67, 1866-1872 (2002); Doronina et al., Nature Biotechnology 21 (7), 778-784 (2003) (errata, p. 941); y Boyd et al., US 7,691,962 B2; Boyd et al., US 2008/0279868 A1; Sufi et al., WO 2008/083312 A2; Feng, US 7,375,078 B2; and Senter et al, US À 2003/0096743 A1; their descriptions are incorporated by reference.
Compound D - Binding Compositions The conjugates of this invention are preferably prepared first by joining a compound D and the binder (XP) .C (X "), to form a drug-binder composition represented by the formula (Va): D- (XP) aCOXE) -R * (Va) where R ** is a functional group suitable for reacting with a functional group on antibody Z to form the conjugate. Examples of suitable groups include: O “O EL o, N POA, 9º or FA ÇN A A RO i-n = c = o I-N = c = FT ONHO OQ and O. where R * º is CI, Br, F, mesylate, or tosylate and R ** is CI, Br, |, F, OH, ON-succinimidyl, O- (4-nitrophenyl), O-pentafluorophenyl, or O- tetrafluorophenyl . Chemistry generally usable for the preparation of the appropriate portions D (XP ”). C (XÔ), - R ** is described in Ng et al., US 7,087,600 B2
And on 39/114 '(2006); Ng et al., US 6,989,452 B2 (2006); Ng et al, US 7,129,261 B2 (2006); Ng et al., WO 02/096910 A1; Boyd et al., US 7,691,962 B2; Chen et al., US 2006/0004081 A1; Gangwar et al., US 2006/0247295 A1; Boyd et al., US 2008/0279868 A1; Gangwar et al., US 2008/0281102 A1; Gangwar et al., US 2008/0293800 A1; Sufi et al, WO 2008/083312 A2; and Chen et al., US 2010/0113476 A1; their descriptions are hereby incorporated by reference.
In a preferred embodiment, R ** is a maleimide group and the molecule of the cytotoxic-ligand compound can be represented by the formula (Vb): there is O o R QUA ALT a À green) (DV) RR O RR Ss H Is where right o, 1, ou2; R ', R and Rº are independently H, C1-C19 unsubstituted or substituted alkyl, Ca-C10 unsubstituted or substituted alkenyl, C2-C19 alkyl unsubstituted or substituted, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, (CH2) 1-20 ( C1-C10 alkyl) unsubstituted or substituted, (CH2) 1-20 (C2-C 1st alkenyl) unsubstituted or substituted, (CH2) 1-20 (C> 2- C10 alkynyl) unsubstituted or substituted, (CH2). -2OC (= O) (C1-C1o alkyl), (CH72): .2OC (= 0) (C2-C1o / alkenyl) unsubstituted or substituted, (CH): 2OC (= O) (C2-C1o alkynyl) unsubstituted or substituted, C (= O) (C1-C1o alkyl) unsubstituted or substituted, C (= O) (C2-C + 19 alkenyl) unsubstituted or substituted, C (= O) (C2-C1o alkynyl) unsubstituted or substituted, unsubstituted or substituted heterocycloaliphatic, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloaliphatic, or unsubstituted or substituted alkylaryl; Re is
CC ssspA ——————— € es —— pQ <———————— 0 - “W [———" 40/114: Ns NH, Ne E | E COR with 'COLOR NH: f Ne: NH : E az co; COR '; co i B Es OO co R' is TCot CO or (CH2) o-3CHz3 SE co where R 'is H, C1-Cs alkyl, C2-Cs5 alkenyl , or C2-Cs alkynyl; and Rº is H, C1-Cs alkyl, C2-Cs alkenyl, C2-Cs alkynyl, CO (C1-Cs5 alkyl), CO (C2-Cs5 alkenyl), or CO (C2- Cs alkynyl); XP 'and X' are spacer groups; C is a cleavable group; ea and b are independently O or 1; where the group R ”'is linked via a carboxyl or amine group to any group Xº in the event of to be 1 or to group C at the event.
Preferably, the bond between the carboxyl or amine group at R * and the X ° or C group, as may be the case, is by means of an amide bond.
In the structures
: Ns NH, COR co: the stereochemistry in the alpha methyl group for the carboxyl group preferably corresponds to that of naturally occurring tubulisins, ie: core or Pcot Preferably, in formula (Vb) n is 1, R 'is an iso residue - leucyl, a is 0, b is 1, and C comprises one to five amino acids (preferably - one to two), and R ”* is linked to C by a peptidyl bond being É enzymatically cleavable, and Rº is Me. This preferred modality is represented by the formula (Vc): Rô OH ooo to e mo (Vo) ok RR sl H o where R , R , and R * are as defined with respect to the formula (V-b) , each AA independently is a natural amino acid, ex is CHCHANHC (= O) (CH2) 2.5 or C (= O0) (CH72) 2-5. Preferred AA amino acids are lysine, citrulline, alanine, valine, glycine, and phenylalanine.
In formula (Vb), R 'is preferably H, C1-Cs5 alkyl, C2-Cs alkenyl, or C2-Cs alkenyl, and is more preferably an iso-leucyl residue, that is: = In formulas (Vb) and ( Vc), R preferably it is H, C1-Cs alkyl, C2Cs —alkenyl - “CH2O (C - C; s —alkyl CH2O (C2-C; - alkenyl), CH2O (C = O0) (C1-Cs alkyl), or CHIOC ( = 0) (C2-Cs5 alkenyl); and most preferably it is H, Me, Et, CH2OMe, CH2OEt, CH2OC (= O) i-Bu, CH2OC (= O) n-Pr, CH2OC (= 0) CH = CH7, or CHOC (= O) Me.
In formulas (V-b) and (V-c), R ° is preferably H, C1-Cs alkyl,
. C7-C5 alkenyl, C (= 0) C1-Cs alkyl, or C (= 0) C72-C5 alkenyl; and most preferably it is H, Me, Et, or C (= O) Me. In formulas (V-b) and (V-c), Rº * 'is preferably
NA Ns: & DP COR COLOR And NCot oo if Lo í with Rº 'equaling
HE No and 'COR' - and R '- equaling H, Me, or Et being especially preferred. In formula (Vb), n is preferably 1 and R is preferably methyl; that is, the ring on the Mep subunit is preferably is an N-methyl piperidinylone In another embodiment, this invention provides a compound having a structure represented by the formula (Vd) o N go ji N (CH). o N 2) 2-57 RU T "R" | O AQ IICA:
NOP Nº "EN EN | À 1 H (VD) o KL * Ss CORRS where R * Is Me, n-Pr, CH2OMe, or CHOC (= 0) CH.CH (Me) 2; R ** is Me or C (= O) Me; and R ** is H or C1-Cs alkyl (preferably H, Me, or Et); R '** is a lysine ((CH2) NH2) side chain group or citrulline
- ((CHo); NHC (= O) NH2); R is a valine (C (Me)>) or alanine (1) side chain group; and foot O or 1. Examples of specific constructs of the cytotoxic-linker compound of this invention are shown below in formulas (VI-a) to (VI-). Compound-linker (VIII-n) is especially preferred. They have a maleimide group and are ready to conjugate with an antibody via a sulfhydryl group, by a procedure such as the one described below. (VI-a) "the
N o AAA A IS O No ooo XxX Ss 2 N ,, N a PERO BO: D 9 - 'COo2H' (VI-b) À (CHo) ANH o NO NH o, no oo É am) -: N w N . ', O is. o "COH (VI-c) np (CHa) aNH Mm No) o: o D oem) NOS ON x o Do, I Ss H" COH (VI-d) np (CH) ANH
É R v N, N CON CON E NODE “COH o O Ç“ o Ss
. (VI-e) CC
N o 4 o ”& fi o | lo es AN A, ALA, MA NH Pos! Ss no Õ O á (VI) H (CH2) aNH o DREAM O no A o - Pena) NE SN x CO2H Ó hoo "1 HS H, (VI-g) CO2H no o E o Dl o AAA AA ÇA di * - O Ss Oo Y o 6 (VI-h) is Css o O. QL A 1 Li LARA A Nº ON É N ONO hoo <Q er H 3 à H TT ”o un) (Vi) HoN ooooo A o
H H H O Ss Oo has 5
Yes) 45/114. (VI) HoN o o o o fo] Bl o q H H O o Ss O has º o (VI)
O Q À t N v Nico g NAN s o Q Os will: —N, | A d (CHo) NH , (SAW)
O N j F N v Nico 3 fo o Ss o “O E The eras N] Nos d i * CHINH2; I came) HAN 2) EX
RACE oA No o o o "CN EN Po S H w COH
—— ..— «- + ——-—--——" Õ — Õ "Õ" "/ ——-. 46/114 '(VIn) HAN R f Lt o
Oo RA and] o N
TO TXT AA III º «ON, N N" CON Á N Pp E CO2H (VI-o) nad f L v o RAIA cen + 'o N 2/8 x SEX. No o o 9 "N, N
EO EO os IS COo2H 2 H (VI-p) E
RACE O NO o fo o À, N AeA NÉ Ó 7 ow f CcoH e (VI-g) O
RACE the Ad
H A o ON o o o o TAC 57 à | the "'CONH,
a ——— & eee 47/114 - (VI-r) nn. NR% 2! Y Lt o use o
NR the SN eras | A o * H Oo o o O: N w No,, A | o y Ss OH! o (VI-s) Han À P Es o S
NATION x hay) H o o Ny o Ô: and AA, Ú oh, Ss NH | o '(VI-t) o pn - (CHI; NH-C-NH, - No A o Tx * (CH) sN | 215 no OAc' o O. "No. N ,. N Je O O. Do" Ss n
W COH Preparation of Conjugates The following is an illustrative procedure, based on the introduction of free thiol groups in an antibody by reacting the e-amino groups of lysine with 2-iminothiolane, followed by reaction with a portion of - drug - maleimide-containing binder as described above. Initially, the antibody is changed to 0.1 M phosphate buffer (pH 8.0) containing 50 mM NaCl and 2 mM diethylene triamine pentaacetic acid (DTPA) and concentrated to 5-10 mg / ml. Thiolation is achieved by adding 2-imino thiolane to the antibody. The amount of 2-iminothiolane to be added can be determined by a preliminary experiment and varies from k antibody to antibody. In the preliminary experiment, a titration of increasing amounts of 2-iminothiolane is added to the antibody, and following incubation with the antibody for 1 h at RT (room temperature, about 25ºC), the antibody is desalted in 50 mM of HEPES buffer pH 6.0 using a SEPHADEXTY G-25 column and the number of introduced thiol groups determined quickly by reaction with dithiodipyridine (DTDP). Reaction of thiol groups with DTDP results in the release of thiopyridine, which can be monitored spectroscopically at 324 nm. Samples in a protein concentration of 0.5-1.0 mg / ml are typically used. The A280nm absorbance can be used to accurately determine the protein concentration in the samples, and then an aliquot of each sample (0.9 ml!) Is - incubated with 0.1 ml of DTDP (5 mM of raw material solution in ethanol) for 10 min in RT. The blank samples of buffer are alone and plus DTDP also incubated. After 10 min, the absorbance at 324 nm is measured and the number of thiol groups is quantified using a 19,800 M ”extinction coefficient for thiopyridine.
i Typically a thiol level of about three thiol groups per antibody is desirable. For example, with some antibodies this can be achieved by adding a 15-fold molar excess of 2-iminothiolane followed by incubation at RT for 1 h. The antibody is then incubated with 2-iminothiolane at the desired molar ratio and then desalted in conjugation buffer (50 mM, pH 6.0, HEPES buffer containing 5 mM glycine and 2 mM DTPA). The thiol material is kept on ice while the number of thioles introduced is quantified as described above.
After checking the number of thioles introduced, the drug-ligand portion is added in a molar excess of 3 times per thiol. The conjugation reaction is allowed to proceed in conjugation buffer also containing a final concentration of 5% of dimethylsulfoxide (DM-SO), or similar alternative solvent. Commonly, the drug-ligand raw material solution is dissolved in 100% DMSO. The raw material solution is added directly to the thiolated antibody with enough DM-SO added to bring the final concentration to 10%, or prediluted in
Soo 49/114 is conjugation buffer containing a final concentration of 10% DMSO, followed by addition to an equal volume of thiolated antibody.
The conjugation reaction mixture is incubated at RT for 2 h with shaking. Following incubation, the conjugation reaction mixture is centrifuged and filtered through a 0.2 µm filter. Purification of the conjugate can be achieved by chromatography using various methods. In one method, the conjugate is purified using size exclusion chromatography on a SEPHACRYL '"S200 column pre-equilibrated with 50 mM HEPES pH 7.2 buffer containing 5 mM glycine and 50 mM NaCl. Chromatography is performed at a linear flow rate of 28 cm / h. Fractions containing conjugate are harvested, grouped and concentrated. In - an alternative method, purification can be achieved by means of ion exchange chromatography. Conditions vary from antibody to antibody and Ú should be optimized in each case, for example, the antibody-drug conjugate reaction mixture is applied to a SP-SEPHAROSE '"Y column pre-equilibrated in 50 mM HEPES pH 5.5 containing 5 µmM glycine. The antibody conjugate is eluted using a 0- N 1 M NaCl gradient in equilibrium buffer at pH 5.5. The relevant fractions containing the conjugate are pooled and subjected to dialysis against the formulation buffer (50 mM HEPES buffer pH 7.2 containing 5 mM glycine and 100 mM NaCl).
Those skilled in the art will understand that the conditions described above and methodology are exemplary and not limiting and that other approaches to conjugation are known in the art and usable in the present invention.
Using the prior art, the compounds of this invention are conjugated using antibodies 2A10, an anti-PSMA antibody (Huang et al., US 2009/0297438); 2H5, an anti-CD70 antibody (Terrett et al. US 2009/0028872); 1F4, an anti-CD70 antibody (Coccia et al, WO 2008/074004); or 6A4, an antimesothelin antibody (Terrett et al, WO | 2009/045957). The resulting conjugates can be described by the formulas | following ones where Ab represents an antibody. Those skilled in the art
A) 50/114 7 ca will understand that in these formulas the ratio of the cytotoxin-antibody compound is shown as 1: 1 for simplicity, but in reality, the ratio is usually higher, such as between 2 to 3. KH o ANA
TA N "o oo ÇP fo N O Ss O Cr
RACE ”CANAS
À T N o o O. o: een A, x MS AN Sd H s sa 'COH AND
Ninth. N o o yyyy
À N es AA,; Po Ss n SS CO2H
H Fans O Xk 2 REA scenes À IX: à o o o 9 “NAN, N Nº“ CON YO) Do! S S COoH
.... 8SSE ———— SS 51/1114 Han '2 3 Hg ET 9 o NO A o A À A) o o No
N and AAA, É Po Ss ii COzH hi Hg E Oo y RA A o * N: "no o o o. O ON, N N N CTN g Po S H 'W' CONH,
HNN [2 HW Y k np TT | ANA - Oo O NO nº o BE “ON, N Nº" ON A d lo. | 5 HW CO2H À (CHINH-C-NH NS NH b C (CH2a) sN 215 o) EA O PAL s "SN AN , N oo
EO EQ Do o
PHARMACEUTICAL COMPOSITIONS In another aspect, the present description provides a composition
aee— —————---———————-— <- p — s-UscR —-------———— ur — nes —————— == - "At. 52/114
Pharmaceutical composition comprising a compound of the present description formulated together with a pharmaceutically acceptable excipient. It may optionally contain one or more additional pharmaceutically active ingredients, such as an antibody or other drug. The pharmaceutical compositions can be administered in combination therapy with another therapeutic agent, especially another anti-cancer agent.
The pharmaceutical composition can comprise one or more excipients. Excipients that can be used include vehicles, surface active agents, thickening or emulsifying agents, solid binders, dispersing or suspending aids, solubilizers, colorants, flavoring agents, coatings, disintegrating agents, lubricants, sweeteners, preservatives , isotonic agents, and combinations thereof. The selection and use of suitable excipients are taught in Gennaro, ed., Richmond: The Science and Practice of Pharmacy, 20th Ed. (Lippincott Williams & Wilkins 2003), the description of which is incorporated herein by reference. Preferably, a pharmaceutical composition is suitable for intravenous, intramuscular, subcutaneous, parenteral, spinal or epidermal administration (for example, by injection or infusion). Depending on the route of administration, the active compound can be coated in a material to protect it from the action of acids and other natural conditions that can inactivate it. The phrase "parenteral administration" means modes of administration different from enteral and topical administration, usually by injection, and include, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intra-articular, subcapsular, subaraquinoid, intraspinal, epidural and intrasternal injection and infusion. Alternatively, the pharmaceutical composition can be administered via a non-parenteral route, such as a topical, epidermal or mucous route of administration, for example, intranasal, oral, vaginal, rectal, sublingual or topically.
Pharmaceutical compositions can be in the form of aqueous solutions or sterile dispersions. They can also be formulated in near 53/114 », a microemulsion, liposome, or other ordered structure suitable for achieving high drug concentration.
The amount of active ingredient that can be combined with a carrier material to produce a simple dosage form will vary, depending on the subject being treated and the particular mode of administration and will generally be that amount of the composition that produces a therapeutic effect. .
Generally, outside one hundred percent, this amount will vary from about 0.01 percent to about ninety nine percent of active ingredient, preferably from about 0.1 percent to about 70 percent, most preferably from about 1 percent to about 30 percent active ingredient in combination with a pharmaceutically acceptable carrier.
Dosage regimens are adjusted to provide a therapeutic response.
For example, a simple cake can be administered, several divided doses can be administered over time, or the dose can be proportionally reduced or increased as indicated by the requirements of the situation.
It is especially advantageous to formulate parenteral compositions in unit dosage form for ease of administration and uniformity of dosage. "Dosage unit form" refers to physically distinct units adapted as unitary dosages for the subjects to be treated; each unit containing a predetermined amount of active compound calculated to produce the desired therapeutic response, in association with the required pharmaceutical carrier.
The dosage ranges from about 0.0001 to 100 mg / kg, and more usually 0.01 to 5 mg / kg, of the host's body weight.
For example dosages can be 0.3 mg / kg body weight, 1 mg / kg body weight, 3 mg / kg body weight, 5 mg / kg body weight or 10 mg / kg body weight. body weight or within the range of 1-10 mg / kg.
Exemplary treatment regimens are administration once a week, once every two weeks, once every three weeks, once every four weeks, once a month, once every 3 months, or once every three to 6 months.
Preferred dosage regimes include 1 mg / kg body weight or 3 mg / kg
»1, body weight through intravenous administration, using one of the following dosing programs: (i) every four weeks for six dosages, then every three months; (ii) every three weeks; (iii) 3 mg / kg of body weight once followed by 1 mg / kg of body weight every three weeks. In some methods, the dosage is adjusted to achieve a plasma antibody concentration of about 1-1000 µg / ml and in some methods about 25-300 µg / ml.
A "therapeutically effective amount" of a compound of the invention preferably results in a decrease in the severity of the symptoms of the disease, an increase in the frequency and duration of periods without symptoms of the disease, or a prevention of impairment or disability due to - distress of the disease. disease. For example, for the treatment of subjects with a tumor, a "therapeutically effective amount" preferably inhibits tumor growth by at least about 20%, more preferably at least about 40%, even more preferably at at least about 60%, and even more preferably at least about 80%] with respect to untreated subjects. A therapeutically effective amount of a therapeutic compound can decrease the size of the tumor, or otherwise improve symptoms in a subject, who is typically a human but can be another mammal.
The pharmaceutical composition can be a controlled or continuous release formulation, including implants, transdermal patches, and microencapsulated delivery systems. Biodegradable, bio-compatible polymers can be used, such as ethylene-vinyl acetate, polyanidides, polyglycolic acid, collagen, poly-polyesters, and polylactic acid. See, for example, Sustained and Controlled Release Drug Delivery Systems, J.R.
Robinson, ed., Marcel Dekker, Inc., New York, 1978. Therapeutic compositions can be administered using medical devices such as (1) needle-free hypodermic injection devices (for example, US 5,399,163; 5,383,851; 5,312,335; 5,064,413;
4,941,880; 4,790,824; and 4,596,556); (2) microinfusion pumps (US
4,487,603); (3) transdermal devices (US 4,486,194); (4) infusion sets (US 4,447,233 and 4,447,224); and (5) osmotic devices (US
4,439,196 and 4,475,196); their descriptions are hereby incorporated by reference.
In certain embodiments, the pharmaceutical composition can be formulated to ensure proper distribution in vivo. For example, to ensure that the therapeutic compounds of the invention cross the blood-brain barrier, they can be formulated in liposomes, which can additionally comprise targeting portions to enhance selective transport to specific cells or organs. See, for example US
4,522,811; 5,374,548; 5,416,016; and 5,399,331; V.V. Ranade (1989) J. Clin. Pharmacol. 29: 685; Umezawa et al., (1988) Biochem. Biophys. Res. Common. 153: 1038; Bloeman et al. (1995) FEBS Lett. 357: 140; M. Owais et al. (1995) Antimicrob. Chemother Agents. 39: 180; Briscoe et al. (1995) Am. J. Á Physiol. 1233: 134; Schreier et al. (1994) J. Biol. Chem. 269: 9090; Keinanen and Laukkanen (1994) FEBS Lett. 346: 123; and Killion and Fidler (1994) Immuno-methods 4: 273.
It is USES AND Compounds of this invention or its conjugates can be used to treat diseases such as, but not limited to, hyperproliferative diseases, including: cancers of the head and neck including tumors of the head, neck, nasal cavity, sinuses paranasal, nasopharynx, oral cavity, oropharynx, larynx, hypopharynx, salivary glands, and paragangliomas; cancers of the liver and biliary tree, particularly hepatocellular carcinoma; intestinal cancers, particularly colorectal cancer; ovarian cancer; small cell and non-small cell lung cancer (SCLC and NSCLC); breast cancer sarcomas, such as fibrosarcoma, malignant fibrous histiocytoma, embryonic rhabdomyosarcoma, leiomyosarcoma, neurofibrosarcoma, osteosarcoma, synovial sarcoma, liposarcoma, and soft alveolar sarcoma; leukemias such as acute promyelocytic leukemia (APL), acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), and chronic myelogenous leukemia (CML); neoplasms of the central nervous systems, particularly brain cancer; multiple myeloma (MM), lymphomas
And —— s «--——. RR RR <=== ———————-— «n—— dn ——.— 56/114 such as Hodgkin's lymphoma, lymphoplasmacytoid lymphoma, follicular lymphoma, mucosal-associated lymphoid tissue lymphoma, mantle cell lymphoma, lineage B large cell lymphoma, Burkitt lymphoma, and anaplastic large T cell lymphoma.
Clinically, practicing the methods of the compositions described here will result in a reduction in the size or number of cancerous growth and / or a reduction in the associated symptoms (where applicable). Pathologically, the practice of the method and use of the compositions described here will produce a pathologically relevant response, such as: inhibition of cancer cell proliferation, reduction - in the size of the cancer or tumor, prevention of further metastasis, and inhibition of tumor angiogenesis.
The method of treating such diseases comprises administering a therapeutically effective amount of an inventive combination to a subject.
The method can be repeated as needed.
Especially, the cancer can be colorectal cancer, liver cancer, prostate cancer, breast cancer, melanoma, glioblastoma, lung cancer, pancreatic cancer, ovarian cancer, multiple myeloma, kidney cancer, leukemia (especially ALL, APL, or AML), or lymphoma. . Compounds of this invention or their conjugates can be administered in combination with other anticancer or cytotoxic agents, including antibodies, alkylating agents, angiogenesis inhibitors, antimetabolites, DNA cleavers, DNA crosslinkers, DNA interleavers, binders secondary DNA groove, enediins, heat shock protein 90 inhibitors, histone deacetylase inhibitors, immunomodulators, microtubule stabilizers, nucleoside analogs (purine or pyrimidine), nuclear export inhibitors, protein-sum inhibitors , topoisomerase inhibitors (1 or Il), tyrosine kinase inhibitors, and serine / threonine kinase inhibitors.
Specific or cytotoxic anti-cancer agents include B-lapacone, ansamitocin P3, auristatin, bicalutamide, bleomycin, bortezomib, busulfan, calistatin A, camptothecin, capecibatine, CC-1065, cisplatin, cryptography, daunorrubicine, disorazol, docorazol, docorazol, docorazol, docorazole, docorazole, docorazole, docorazole, docorazole, docorazole, docorazole, docorazole, docorazole, docorazole, docorazole, docorazole, docorazole, docorazole, docorazole, docorazole, docorazole, docorazole, doxorubicin, duocarmicin, dinemicin A, epothilones, etoposide, floxuridine, floxuridine, fludarabine, fluorouracil, gefitinib, and geldanamycin, 17-
T— «sADURÚÂQAIEAa ——————— pp—— ..À.À .-—" ... 57/114 allylamino-17-demethoxy-geldanamycin (17-AAG), 17- (2-dimethylaminoethyl) amino 17 -demethoxy-geldanamycin (17-DMAG), gemcitabine, hydroxyurea, imatinib, interferons, interleukins, irinotecan, maytansine, methotrexate, mitomycin C, oxaliplatin, paclitaxel, sub-roilanilide hydroxamic acid (SAHA), tihe, topec, tiec tricostatin A, vinblastine, vincristine, vindesine, lenalidomide (REVLIMIDO), bevacizumab (AVASTINO), trastuzumab (HERCEPTINO), and cetuximab (ERBITUXO).
EXAMPLES The practice of this invention can be further understood with reference to the following examples, which are provided by way of illustration and not by way of limitation. - Example 1 - Scheme 1 Scheme 1 (figures 1a and 1b) describes a method for making the compounds of this invention. Tiomide 2. 2,2-Diethoxyacetonitrile 1 (25 g, 193 mmols) was mixed with (NH4) 2S (40 ml, 265 mmols, 45% in aq. Solution) in 300 ml of methanol (MeOH) at temperature environment (RT). After maintaining the reaction mixture overnight, it was concentrated in vacuo and the residue was absorbed in ethyl acetate (EtOAc). The EtOAc solution was washed with “NaHCO; saturated then brine and dried over anhydrous Na7SO. EtOAc was evaporated to give thiomide 2 (26 g, 159 mmols, 82%) as a white solid. * H NMR (400 MHz, CDCl3) 5 5.01 (s, 1H), 3.67 (m, 4H), 1.22 (tl J = 7.2 Hz, 6H). Methyl 2- (dietoxymethyl) thiazol-4-carboxylate 3. 100 g of molecular sieves (3A) were added to a reaction mixture of thiomide 2 (25 g, 153 mmols) and methyl bromopyruvate (20 ml, 163 mmols) in 300 ml of MeOH. After the mixture was refluxed for 1.5 h, it was cooled and filtered through CELITETY. The filtrate was concentrated and passed through a column (dichloromethane (DCM): EtOAc, 8: 1) to give thiazole carboxylate 3 (34.5 g, 140mmols, 91%) as a solid that was used for the next step without another purification. Methyl 2-formylthiazole-4-carboxylate 4. Thiazole-4-carboxylate 3 (30
9.122 mmol) was dissolved in 300 ml of acetone to which aqueous HCI (21 ml, 2M) was added. After keeping the reaction mixture in RT overnight, the reaction mixture was heated and maintained at 60ºC for 2 h. The reaction mixture was then cooled and evaporated in vacuo to give a residue which was absorbed in 200 ml of DCM. DCM solution was then washed with NaHCO solution; saturated and then brine and dried over anhydrous Na-SO. DCM solution was filtered and concentrated in vacuo to give the concentrated solution which was triturated with ether to give methyl 2-formylthiazole-4-carboxylate 4 (14 g, 82 mmol, 54% for two steps) as a solid White. 'H NMR (400 MHz, CDCl3) 5 133-8-p110.16 (d, J = 1.3 Hz, 1H), 8.53 (d, J = 1.3 Hz, 1H), 4.01 ( s, 3H). - Sulfinimine 7. (S) -2-Methylpropane-2-sulfinamide 5 (7.3 ml, 68 mmol) was dissolved in 100 ml! of tetrahydrofuran (THF) to which Ti (OEt), (27 ml, 130 mmol) and 3-methyl-2-butanone 6 (89, 41 mmol) are added in RT. The reaction mixture was refluxed overnight and then cooled and added to a brine solution. The resulting mixture was] filtered and the cake was washed with EtOAc. The organic phase was concentrated to give a residue which was subjected to silica gel column chromatography (DCM: EtOAc, 4: 1) to give sulfinimine 7 (9.5 g, 37 mmols, 75%) as an oil. * H NMR (400 MHz, CDCl3) 5 2.53 (m, 1H), 2.29 (s, 3H), 1.22 (s, 9H), 1.12 (d, J = 4.2 Hz, 3H), 1.10 (d, J = 4.2 Hz, 3H). MS (ES +) m / z, calculated: m + 1, 190.12, found, 190.
Compound 8. Lithium diisopropyl amide ("LDA", 60 ml, 108 mmolis, 1.8 M) was added to 200 ml of ether at 78ºC followed by the addition of sulfinimine7 (18.99, 100 mmols) in 200 ml of ether and the resulting reaction mixture was stirred for 40 min. CITi (OiPr) 3 (203 mmols, 48.4 ml) was added to the reaction mixture and the solution was stirred for 60 min. A solution of methyl 2-formylthiazole-4-carboxylate 4 (12.5 g, 72.6 mmols) in 180 ml of THF was added slowly to the reaction mixture. After an additional 2h at 78ºC, a mixture of acetic acid and THF (1/5 v / v, 4.9 ml) was added. The mixture was heated to 5ºC for 1 h and then poured into brine solution. The desired product was then extracted from the brine solution with ether and EtOAc solution. The organic phase was then dried over MgSOSO, anhydrous, filtered and evaporated. The residue was passed through 2 columns (DCM: EtOAc and hexane: EtOAc) to give compound 8 (19.6 g, 54 mmol, 75%) as an oil. MS (ES +) m / z, calculated: m + 1, 361.12, found, 361.
Compound 9. A solution of compound 8 (19 g, 52.7 mmols) in 200 ml of THF was cooled to 78 ° C after Ti (OEt), (21.7 ml, 105 mmols) was slowly added. After 60 min, when the solution became clear, Na-BH, (31 mmois, 1.17g) was added, after 2 h (longer reaction time caused a reduction in the ester) 10 m! of MeOH were added. The mixture was then heated to 0 ° C, poured into 1 ml of HOAc on a lot of ice. The mixture was filtered and the cake was washed with EtOAc. After separation, the organic phase was dried with NazSO, and evaporated. The final residue was passed through a column (DCM: EtOAc, 1: 4) to give compound 9 (19 g, 52 ml, j 99%) as an oil. 1 H NMR (400 MHz, CDCIz) 5 8.1 (s, 1H), 5.54 (d, J = 6.7 Hz, 1H), 5.168 (m, 1H), 3.92 (s, 3H) , 3.42 ((m, 1H), 3.32 (d, J = 8.4 Hz, 1H), 2.25 (m, 1H), 1.88 (m, 1H), 1.68 (m , 1H), 1.26 (s, 9H), 0.91 (d, J = 6.8 Hz, 3H), 0.87 (d, J = 6.7 Hz, 3H). * CNMR (100 MHz , CDCI3) 5 177.9, 162.1, BR 146.6, 127.7, 67.9, 58.6, 56.4, 52.5, 40.8, 33.9, 23.1, 19 , 8, 17.4, MS (ES +) m / z, calculated: m + 1, 363.13, found, 363.
Dimethylated compound 10. Sodium hydride (9,689 mmois, 60%, 387 mg) was added to a solution of compound 9 in 6 ml of NN-dimethylformamide (DMF) at 5ºC followed by methyl iodide (607 uL, 9.7 mmois ) after 60 minutes. After stirring the reaction mixture for 3 h, the mixture was poured into an ice-cold saturated NH, CI solution. Ethyl ether was added and the organic layer was washed with brine, dried over MgSO4, anhydrous and concentrated to give a residue. The residue was passed through a column (1: 4 hexane: EtOAc) to give dimethylated compound 10 (314 mg, 0.805 mmol, 33%) as a liquid. * H NMR (400 MHz, CDCl3) 5 8.17 (s, 1H), 4.87 (dd, J = 11.0 Hz, J = 2.5 Hz, 1H), 3.94 (s, 3H) , 3.50 (s, 3H), 3.40 (m, 1H), 2.58 (s, 3H), 1.99 (m, 1H), 1.83 (m, 2H), 1.25 ( s, 9H), 0.98 (d, J = 6.8 Hz, 3H), 0.95 (d, J = 6.7 Hz, 3H) MS (ES +) m / z, calculated: m + 1, 391.16, found, 391.
Monomethyl amine 11. Aqueous HCl (4N, in dioxane, 0.5 ml) was added to a solution of dimethylated compound 10 (370 mg, 0.95 mmol) in 5 ml! of MeOH.
After stirring the reaction mixture for 60 min, it was evaporated in vacuo to give monomethyl amine 11 (362 mg) as its HCI salt which was used for the next step without further purification.
MS (ES +) m / z, calculated: m + 1, 287.14, found, 287. Amide 12. Monomethyl amine 11 (362 mg, 1.412 mmol), composed of Fmoc 22 (prepared by Wipf et al. 2007; 1 , 2 g, 3.38 mmols) and N, N-diisopropylethylamine (DIEA, 976 µl, 5.6 mmols) were mixed in 5 ml of DMF in RT.
After stirring for 24 h, the mixture was concentrated and the residue was dissolved in EtOAc.
The organic phase was washed with NaHCO2, brine, - dried over MgSO, anhydrous and concentrated to give a residue.
The residue was passed through a column (hexane: EtOAt: MeOH 7: 3: 0.6) to give amide 12 (466 mg, 0.75 mmol, 67%) as an oil. (ES +) m / z, calculated: m + 1.622.2, found, 622. Compound 13. Amide 12 (466 mg, 0.75 mmol) was dissolved in 8: ml DCM containing 5% piperidine in RT.
After 1 h, the mixture was evaporated under vacuum and the residue was passed through a column to give an oil (150 mg) which was then mixed with (D) -n-methyl pipecolinic acid 23 ("D-Mep ", prepared by Peltier et al., 2006; 50 mg, 0.35 mmol), N, N, N 'hexafluoro phosphate, Ni-tetramethyl-O- (7-azabenzotriazol-1-i) juronium ("' HATU ", 126 mg, 0.33 mmol), DIEA (152 µL, 0.84 mmol) in 2 ml DCM.
After stirring for 2.5 h, the solvent was evaporated to give a residue which was dissolved in EtOAc.
The organic phase was then washed with NaHCO; saturated, brine, - dried over MgSO, anhydrous and concentrated to give a residue.
The residue was passed through a column (DCM: MeOH 0-10%) to give compound 13 (99 mg, 0.188 mmol, 25%) as an oil.
MS (ES +) m / z, calculated: m + 1, 525.3, found, 525. Acid 14. Compound 13 (99 mg, 0.18 mmol) was dissolved in a mixture of 3 ml MeOH and water (3 : 1 v: v) to which Na-OH (370 µL, 0.37 mmol, 1M) was added. After stirring for two hours, the reaction mixture was neutralized and concentrated to give a residue.
The residue was
used on a C-18 column (water (1% trifluoroacetic acid ("'TFA")): acetonitrile (ACN) (1% TFA), 0-100%) to give acid 14 (78 mg, 0.125 mmol, 69%) as a TFA salt. MS (ES +) m / z, calculated: m + 1, 511.29, found, 511.
Compound 15. DIEA (24 uL, 137 umols) was added to a solution of acid 14 (9 mg, 14.4 umols, TFA salt) and HATU (6 mg, 15 umols) in DMF (0.5 ml ) in RT. Finally, acid 14 was activated (monitored by HPLC), tubphenylalanine (prepared by Peltier et al. 2006; 6.5 mg, 27 umoilis, HCI salt) was added. After stirring for 20 min, the reaction mixture was passed over a C-18 column (water (1% TFA): ACN (1% TFA), 0-100%) to give compound 15 (2.5 mg , 3 umols, 21%) as a white TFA salt. MS (ES +) m / z, calculated: m + 1, 700.4, found, 700. - Val ME x AE 15 o! It is "COH Compound 16. DIEA (20 uL, 0.11 mmol) was added to a solution of acid 14 (12 mg, 0.019 mmol, TFA salt), phenylalanine methyl ester (5.3 mg, 0.024 mmol , as HCI salt) and HATU (11.4 mg, 0.03 mmol) in 0.5 m DMF After 30 min, the reaction mixture was passed through a C-18 column (water (1% TFA): ACN (1% TFA) 0-100%) to give compound 16 (4.2 mg, 0.005 mmol, 26%) as a white TFA salt MS (ES +) m / z, calculated: m +1, 672.89, found, 672.5, Compound 16 is also referred to as compound (II-c) above.
Compound 17. DIEA (7 µL, 0.04 mmol) was added to a solution of acid 14 (5 mg, 0.008 mmol), norvaline methyl ester (CNVaM ", 2 mg, 0.012 mmol) and HATU (4.5 mg, 0.012 mmol) in DMF.After stirring the reaction mixture for 30 min, the crude mixture was passed through a column-C-18 (water (1% TFA): ACN (1% TFA) 0-100%) to give compound 17 (1.3 mg, 0.0017 mmol, 21%) as a white TFA salt. MS (ES +) m / z, calculated: m + 1, 624.85, found, 624, 5. Compound 17 is also referred to as the compound (Ill-e) above.
QE AXL Lay,
ACID 18. Aqueous NaOH (75 µL, 0.75 mmol, 10M) was added to a solution of compound 16 (168 mg, 0.25 mmol) in a mixture of MeOH and THF.
After stirring overnight, the mixture was neutralized and lyophilized to dryness.
The solid was used for the next step without further purification.
MS (ES +) m / z, calculated: m + 1, 658.36, found, 658.4. Acid 18 is also referred to as the compound (Ill-0) above.
Norvalyl amide 19. DIEA (5, uL, 0.03 mmol) was added to a solution of acid 18 (5 mg, 0.006 mmol), HATU (3.5 mg, 0.009 mmol) and NVaM (1.5 mg, 0.009 mmol) in DMF.
After stirring for 30 min, the “10 reaction mixture was passed through a column of C-18 (water (1% TFA): ACN (1% TFA) 0-100%) to give norvalyl amide 19 (2, 2, 0.0025 mmol, 40%) as a white TFA salt.
MS (ES +) m / z, calculated: m + 1, 772.02, found, 771.5. Norvalyl amide 19 is also referred to as compound (III-f) plus
H above.
Compounds 24, 25, and 26. These three acid compounds 14 or 18 were synthesized using procedures analogous to those described above.
The products were all purified by a C-18 column (water (1% TFA): ACN (1% TFA) 0-100%). Yields ranged from 25-50%. Compound 24: MS (ES +) m / z, calculated: m + 1, 743.4, found 743. Compound 25: MS (ES +) m / z, calculated: m + 1, 686.39, found 686, 5. Compound 26: MS (ES +) m / z, calculated: m + 1, 700.40, found 700.5. and. o Lois ME Uncle "24 | O | S 1 H o:
E app —————————————————— »» —— yyyy —————————————————— == 63/114 CX A and res 25
NE SN O o and 8º HH take o o ME LI E 26 Pos E i co Me Compound 24 is also referred to as compound (II-g) plus a-: above. Compound 26a. Compound 14 was coupled with Ala-Phe-OMe - following the same procedure as described for compound 16. The product was purified by a C-18 column (water (1% TFA): ACN (1% TFA ), 0-100%). MS (ES +) m / z, calculated: m + 1, 743, found 743.4. - Compound 26a is also referred to as compound (! III-I) above. no fo "" ME AAA ico "Po Ss Ho i CeHs Example 2 - Scheme 2 This example describes the synthesis of the compounds shown in Scheme 2 (figure 2).
Compound 28. Phenylalanine methyl ester (10 mg, 46.5 moles) and HATU (14.7 mg, 38.6 moles) were added to a solution of compound 27 (prepared by Peltier et al., 2006; 10 mg, 15.5 umols, formate salt) in 0.5 m! DMF followed by DIEA in RT. After stirring for minutes, DMSO (2 ml) was added and the reaction mixture was subjected directly to a C-18 column (water (5 mM ammonium formate, pH 7.2): ACN 0-100%), to give compound 28 (3.2 mg, 25%) as a white solid (formate salt). MS (ES +) m / z, calculated: m + 1, 758.41, found 758.4. Compound 28 is also referred to as compound (IIII-h) above.
- »- AO —— = ————————-----------" À = -— 64/114 Compound 29. Acetic anhydride (30 ul, 290 umols) was added to a solution of compound 28 (3.2 mg, 3 umols, formate salt) in 0.5 ml of pyridine at 0 ° C.
After stirring for 24 h, the solvent was evaporated from the reaction mixture and the residue was passed through a regular silica column (DCM: MeOH 0-10%) to give compound 29 (2.0 mg, 83%) as an oil.
MS (ES +) m / z, calculated: m + 1, 800.42, found 800.4. Compound 29 is also referred to as compound (IIl-i) above.
O-Acetyl, N, O-acetal 29a.
Compound 29 (2 mg, 2.4 umols) was dissolved in 0.5 ml! of MeOH to which a 4N drop of HClem dioxane was added.
After stirring the reaction mixture overnight in RT, the mixture was concentrated and the residue was dissolved in DMSO which was then passed through a C-18 column (water (20 mM ammonium formate, pH 6.1) : ACN (0-100%) to give O-acetyl, N, O-acetal 29a (1.38 mg, 75%) as a white solid (formate salt) after lyophilization.
MS (ES +) m / z, calculated: m + 1.730, found 730.4. O-Acetyl, N, O-acetal 29a is also referred to as the compound (Ill-m) above. i N, O-Acetal 29b.
Compound 28 (5 mg, 6 umols) was dissolved in. MeOH to which 1 drop of 4N HCI in dioxane was added.
After stirring the reaction mixture for 24 h, the solution was concentrated and used for the next step reaction without further purification.
MS (ES +) m / z, calculated: m + 1, 687, found 688.4. N, O-Acetal 29b is also referred to as compound (Ill-n) above.
O-methyl, N, O-acetal 29c.
N, O-Acetal 29b (about 5 mg, 7.2 umols) was dissolved in DMF to which were added dimethyl sulfate (3 ul, 37 umols) and NaH (2 mg, 50 umols, 60% in mineral oil) at 0ºC .
After 1 h, the mixture was absorbed in DMSO and passed through a C-18 column (water (20 mM ammonium formate, pH 6.1): ACN (0-100%) to give O-methyl, N , O-acetal 29c as a semisolid (0.31 mg, 5%; mixture containing an unidentified compound of the same MW) MS (ES +) m / z, calculated: m + 1, 702, found 702.4. -methyl, N, O-acetal 29c is also referred to as compound (III-k) above.
Example 3 - Scheme 3
Scheme 3 (figure 3) shows a procedure for making the compounds according to the formula (Il-b). Alcohol 30. TFA (171 ml) was added to a solution of (S) - tert-butyl-1-hydroxy-3- (4-nitrophenyl) propan-2-ylcarbamate 20 (Erlanson et al, US7.214.487 B2; 13 , 9g, 46.9 ml) in DCM (272 ml) at 0 ° C. The reaction mixture was heated to RT and the reaction was allowed to proceed for 25 minutes. The solution was concentrated to provide 9.2 g of crude (S) -2-amino-3- (4-nitrophenyl) propan-1-ol as a white solid. To a solution of this crude product and sodium carbonate (12.4 g, 117.3 mmols) in THF (87 ml) and water (87 ml) was added N-carbethoxyphthalimide ("CEPT", 12.3 g, 56, 3 mmols). After the reaction mixture was stirred at RT for 4 h, EtOAc - (150 ml) was added. The aqueous phase was extracted with EtOAc. The combined organic layers were washed with brine, dried over Na> SO, anhydrous, filtered and concentrated in vacuo to give a crude residue which was purified by flash chromatography eluting from silica gel with a 0-100 gradient. % EtOAc in hexanes to give 12.3 g of alcohol 30, MS: (+) m / z 327.0 (M + 1). - Triflate 31. To a solution of alcohol 30 (1 g, 3.06 mmols) in anhydrous DCM (18 ml) was added pyridine (0.274 ml, 3.36 mmols) at 78 ° C. After the reaction mixture was stirred at 78ºC for 5 min, trifluoro-romethanesulfonic anhydride (0.568 ml, 3.36 mmols) was added. The reaction mixture was stirred at 78ºC for 45 min, and then at RT for 45 min. After the precipitate was separated by filtration, the filtrate was purified by flash chromatography eluting from silica gel with DCM to yield 0.84 g of triflate
31º'HRMN (400 MHz, CDCI;) 5 8.10 (2H, d, J = 8.8 Hz), 7.81 (2H, m), p7.74 (2H, m), 7.36 (2H, J = 8.8 Hz), 5.43 (1H, t, J = 10.0 Hz), 4.99 (1H, m), 4.80 (1H, dd, J = 4.8, 5.6 Hz), 3.52 (1H, dd, J = 3.2, 11.2 Hz), and 3.27 (1H, dd, J = 5.6, 8.8 Hz).
DIÉSTER 32, Diethyl methylmalonate (0.71 ml, 4.12 mmolis) was added dropwise to a suspension of sodium hydride (0.161 g, 60% dispersion in mineral oil, 4.03 ml) in anhydrous THF (4 , 7 ml) at 0 ° C. The reaction mixture was stirred at 0 ° C for 10 min, and then at RT for 10 min.
The resulting solution was added slowly to a solution of triflate 31 (0.84 g, 1.83 mmol) in anhydrous THF (9.4 ml) at 0 ° C.
After the reaction mixture was stirred at 0 ° C overnight, an aqueous solution of NH, saturated CI (20 ml) was added.
The aqueous solution was extracted with EtOAc, and the combined organic layers were washed with brine, dried over MgSO:, filtered, and concentrated in vacuo to give a residue.
The crude product was purified by flash chromatography eluting from silica gel with a gradient of 0-50% EtOAc in hexanes to provide 0.57 g of diester 32, MS: (+) m / z 483.3 (M + 1). Monoester 33. A solution of diester 32 in 6 N HCI (10 ml) and acetic acid (10 ml) was heated to 145 ° C for 2 days.
The organic solution was concentrated to provide 0.41 g of the crude (R) -4-amino-2-methyl-5- (4-nitrophenyl) pentanoic acid hydrochloride salt as a white solid. 2,2-Dimethoxypropane ("DMP", 4 ml, 32.6 ml) was added to a solution of the hydrochloride salt of the crude product and concentrated HCI (1 ml) in anhydrous MeOH (20 ml). The reaction mixture was heated to 60 ° C overnight.
The organic solution was concentrated to provide 0.43 g of the EF 4-amino-2-methyl-5- (4-nitrophenyl) pentanoate (R) -methyl hydrochloride salt EF as a white solid.
Triethylamine (0.44 ml, 3.1 mmols) was added to a solution of the hydrochloride salt of 4-amino-2-methyl-5- (4-nitrophenyl) Dentonate of (R) - crude methyl and dicarbonate of di-tert-butyl (0.369 g, 1.89 mmol) in ACN (10 ml) in RT.
After the reaction mixture was stirred at RT for 4 h, the solvent was evaporated.
Water (20 ml) was added, and the aqueous solution was extracted with EtOAc.
The combined organic layers were washed with brine, dried over NazSO;, filtered, and concentrated.
The crude product was purified by flash chromatography eluting from silica gel with a gradient of 0-30% EtOAc in hexanes to provide 0.31 g of monoester 33 as a colorless oil.
MS: (+) m / z 267.3 (M-99). Carboxylic acid 34. A solution of monoester 33 (0.31 g, 0.846 mmol) in 6 N HC! was heated to 130ºC for 1.5 h.
The organic solution was concentrated to provide 0.244 g of carboxylic acid 34 as a white solid. MS: (+) m / z 253.1 (M + 1).
Nitro acid 35. Compound 34a (80.4 mg, 0.149 mmol, prepared by Patterson et al. 2008) was added to a 0.2 M solution of pentafluorophenol (41.1 mg, 0.224 mmol) and N, N -di-isopropylcarbodiimide ("DIC", 0.0255 ml, 0.164 mmol) in DCM (0.76 ml) at 0 ° C. The reaction mixture was heated to RT and stirred at RT overnight. The solvent was evaporated. EtOAc (18 ml) was added and the crude product was filtered, rinsing the reaction vessel with EtOAc. The filtrate was concentrated under reduced pressure and the crude material was used without further purification. DMF (0.6 ml) was added to the crude product, followed by carboxylic acid 34 (0.1229 9, 0.448 mmol) and DIEA (0.13 ml, 0.745 mmol). The reaction mixture was stirred - at RT overnight and the solvent was evaporated. The crude product was purified by flash chromatography eluting from silica gel with a gradient of 10-20% MeOH in DCM containing 1% NH.OH to provide 0.11 g of acid 35 as a white solid . MS: (+) m / z 773.4 (M + 1). Amino acid 36. A solution of nitro acid 35 (0.11 g, 0.142 mmol) and palladium on carbon (10%, 15 mg) in MeOH (5 ml) was stirred under E under a hydrogen atmosphere for 4 h. The catalyst was separated by filtration, and the filtrate was concentrated to provide 91 mg of amino acid 36 as a white solid. MS: (+) m / z 743.5 (M + 1). Amino acid 36 is also referred to as the compound (Ill-b) above.
Methyl ester 36a. HCI (1 drop, 37%) was added to a solution of amino acid 36 (1.9 mg, 2.5 mmol) and 2,2-dimethoxypropane ("DMP", 0.05 ml, 0.41 mol) in MeOH (0.5 ml). The reaction mixture was stirred at RT for 2 h and then concentrated. The crude product was purified by preparative HPLC to provide 1.7 mg of methyl ester 36a as a white solid. MS: (+) m / z 757.5 (M + 1). Ester 36a is also described in this specification by the formula (III-t).
Example 4 - Scheme 4 Scheme 4 (figure 4) shows a method for attaching the peptidyl ligands and functional groups reactive to the compounds of this invention, ready for conjugation.
Compound 37. A solution of DIEA, Fmoc-Lys (Boc) -OH (17.3 mg, 0.037 mmol), and HATU (12.8 mg, 0.0336 mmol) in DMF (0.3 ml) was stirred. at RT for 5 min.
The pH of the solution was maintained between 8 and 9. Then a solution of amino acid 36 (25 mg, 0.0336 mmol) in DMF (2 ml) and DIEA was added to the reaction mixture, maintaining the pH between 8 and 9. After stir at RT for 15 min, the saturated NH, CI solution (5 ml) was added to quench the reaction.
The aqueous solution was extracted with EtOAc, and the combined organic layers were dried, filtered, and concentrated.
The crude product was purified by flash chromatography eluting from silica gel with a gradient of 0-20% MeOH in DCM to provide 36.1 mg of compound 37, MS: (+) m / z 1193.6 (M + 1 ). . Compound 38. Piperidine was added to a solution of compound 37 (36.1 mg, 0.0302 mmol) in DMF (2 m!), Maintaining the pH between '9 and 10. After stirring at RT for 20 min, the solution organic was concentrated to provide 29.3 mg of the crude free α-amino compound.
DIEA was added to a solution of 6-maleimidoexanoic acid (7.0 mg, 0.0332 mmol) and HATU (11.5 mg, 0.0302 mmol) It is in DMF (0.3 ml!) Keeping the pH between 8 and 9. The reaction mixture was stirred at RT for 5 min.
Then DIEA and the crude free amino compound in DMF (2ml) was added, maintaining the pH between 8 and 9. After the reaction mixture was stirred at RT for 15 min, the crude product was purified by preparative HPLC to provide 9 , 1 mg of compound 38 as a white solid.
MS: (+) m / z 1164.6 (M + 1). Compound 39. TFA (1.5 ml) was added to a solution of compound 38 (9.1 mg, 0.0078 mmol) in DCM (1.5 ml). After the reaction mixture was stirred at RT for 15 min, the crude product was purified by preparative HPLC to provide 5.0 mg of the desired TFA salt of compound 39 as a white solid.
MS: (+) m / z 1064.8 (M + 1). The free base structure of compound 39 is also shown above, as compound (VI-b). Some amide from compound 39 was also isolated as a by-product in its preparation.
MS: (+) m / z 1063.6 (M + 1). Amide is also described in this specification by the formula (Vl-q).
E ca «« qqqqq ——————— - | ÀnÀ ————— 69/114 oO o À o YA RE Do 7 | > 'CONH, Amide of compound 39 Example 5 - Scheme 5 Scheme 5 (figure 5) shows an alternative procedure for making the compounds according to formula (II-b). Amino ester 42. 4.0 N HCl in 1,4-dioxane (6.7 ml) were added to a solution of compound 41 (prepared by Patterson et al. 2008; 1 g, 2.66 mmols) in ethanol (17 m!). The reaction mixture was stirred at RT for 2 h, and then concentrated to provide 0.82 g of amino ester 42 as a white solid. MS: (+) m / z 273.3 (M + 1). Azido ester 43. Oxalyl chloride (1.71 ml, 19.95 mmolis) and DMF (0.33 ml, 4.26 mmolis) were added to a solution of azole isoleucine (Lundquist et al., Org. Lett. 2001, 3, 781; 0.699 g, 4.26 ml) in hexanes (176 ml). The reaction mixture was stirred at RT for 1 h, filtered, and concentrated to provide the acid chloride. The acid chloride and DI-EA (2.32 ml, 13.3 mmols) were added to a solution of amino ester42 (0.82 g, 2.66 mmols) in DCM (26.7 ml) at 0ºC . The reaction mixture was allowed to warm to RT and stirred at RT overnight. Brine was added to quench the reaction, and the aqueous solution was extracted with E-tOAc. The combined organic layers were dried over NazS0O ;, filtered, and concentrated in vacuo. The crude product was purified by flash chromatography eluting from silica gel with a gradient of 0-50% EtOAc in hexanes to provide 0.86 g of azido ester 43 as a white solid. MS: (+) m / z 412.3 (M + 1).
Triethylsilyl 44 compound. 2,6-Lutidine (1.22 ml, 10.45 mmolis) and triethylsilla trifluoromethanesulfonate (1.14 ml, 5.02 mmols) were added. 25 —cented to a solution of azido ester 43 (0.86 9, 2.09 mmols) in DCM
(11 ml) at 0ºC. The reaction mixture was allowed to warm to RT for 1h, and then stirred at RT for an additional hour. Brine was added to quench the reaction, and the aqueous solution was extracted with EtOAc. The combined organic layers were dried, filtered, and concentrated. The crude product was purified by flash chromatography on silica gel eluting with a gradient of 0-30% EtOAc in hexanes to provide 1.1 g of triethylsilyl 44 compound. MS: (+) m / z 526.4 (M + 1). N-methyl compound 45. A solution of triethylsiline compound 44 (1.04 g, 1.98 mmol) in THF (6.5 ml) was cooled to 45 ° C, and potassium hexamethyldisilazide (0.5 M in toluene, 4.75 ml, 2.37 mmolis) was added. The resulting mixture was stirred for 20 min at 45 ° C. methyl lodide - (0.37 ml, 5.94 mmols) was added, and the reaction mixture was allowed to warm to RT for 4 h at which time the reaction was quenched with ethanol (10: ml). The crude product was diluted with EtOAc and washed with brine, and the aqueous layer was extracted with EtOAc. The combined organic layers were dried over Na> SO ;, anhydrous, filtered, and concentrated in vacuo. The crude product was purified by flash chromatography eluting from silica-E gel with a gradient of 0-30% EtOAc in hexanes to provide 0.91 g of N-methyl 45, MS: (+) m / z 540.4 (M + 1).
Compound 46. A solution of the N-methyl compound 45 (1.0 g, 1.85 mmol) in deoxygenated AcOH / H2O / THF (65 ml, 3: 1: 1, v / v) was stirred at RT for 36 H. Toluene (250 ml) was added and the solution was concentrated. The crude product was purified by flash chromatography eluting from silica gel with a gradient of 0-100% EtOAc in hexanes to provide 0.46 g of compound 46 as an oil. MS: (+) m / z 426.3 (M + 1).
Methyl ether 47. Potassium hexamethyldisilazide ("KHMDS", 0.5 M in toluene, 2.54 ml, 1.27 mmol) was added to a solution of compound 46 (0.45 g, 1.06 mmol) in THF (5 ml) at 78ºC. The reaction mixture was stirred for 20 min at 78ºC. methyl lodide (0.2 ml, 3.18 mmois) was added, and the reaction mixture was allowed to warm to 20ºC for 2 h, during which time the reaction was quenched with NH, CI saturated solution. The aqueous solution was extracted with EtOAc. The combined organic layers were dried over Na7SO, anhydrous, filtered, and concentrated in vacuo. The crude product was purified by flash chromatography eluting from silica gel with a gradient of 0-50% EtOAc in hexanes to provide 0.41 g of compound 47 as a colorless oil. MS: (+) m / z 440.3 (M + 1).
Compound 48. To a solution of D-Mep (0.45 g, 3.14 mmols) in EtOAc (10 ml) was added pentafluorophenol (0.64 g, 3.47 mmols) and NN'-dicyclohexylcarbodiimide ("DCC", 0.72 9, 3.47 mmols). After the reaction mixture was stirred at RT overnight, the precipitate was filtered off, and washed with EtOAc. To the resulting filtrate, compound 47 (0.46 g 1.05 mmol) and palladium on carbon (10% w, 0.36 g) were added. The reaction mixture was stirred under an atmosphere of hydrogen overnight. The catalyst was filtered off, and then the filtrate was concentrated in vacuo. The crude product was purified by flash chromatography eluting from silica gel 'with a gradient of 0-5% MeOH in EtOAc to provide 0.43 g of the compound48 as a colorless oil. MS: (+) m / z 539.4 (M + 1). Carboxylic acid 49. To a solution of compound 48 (0.43 9, 0.80 mmol) in deoxygenated 1,4-dioxane (8 ml) was added a-: aqueous deoxygenated lithium hydroxide solution (0.6 M , 4 ml) in RT. The reaction mixture was stirred at RT for 2 h, and then concentrated in vacuo. The crude product was purified by flash chromatography eluting from silica gel with a gradient of 10-30% MeOH in DCM containing 1% NH.OH to provide 0.3 g of carboxylic acid 49 as a white solid . MS: (+) m / z 511.4 (M + 1).
Nitro acid 50. Carboxylic acid 49 (80 mg, 0.157 mmol) was added to a 0.2 M solution of pentafluorophenol (43.3 mg, 0.235 mmol) and DIC (0.0269 ml, 0.173 mmol) in DCM (0.8 ml) at 0ºC. The reaction mixture was heated to RT, and stirred at such a temperature overnight. The solvent was evaporated. Ethyl acetate (18 ml) was added, and the crude product was filtered, with rinsing EtOAc from the reaction vessel. The filtrate was concentrated under reduced pressure, and the crude material was used without further purification. DMF (0.6 ml) was added to the crude product, followed by carboxylic acid 34 (0.136 g, 0.47 mmol), and DIEA (0.137 ml, 0.785 mmol). The reaction mixture was stirred at RT overnight, and the solvent was then evaporated in vacuo. The crude product was purified by flash chromatography, eluting from silica gel with a gradient of 10-20% Me-OH in DCM containing 1% NH.OH to provide 0.1 g of nitro acid 50 as a white solid. MS: (+) m / z 745.4 (M + 1).
Amino acid 51. A mixture of nitro acid 50 (0.1 g, 0.134 mmol) and palladium on carbon (10%, 14 mg) in MeOH (5 ml) was stirred under an atmosphere of hydrogen for 4 h. The catalyst was separated by filtration, and the filtrate was concentrated in vacuo to provide 87.3 mg of amino acid 51 as a white solid. MS: (+) m / z 715.5 (M + 1). Amino acid 51 is also referred to as compound (II-) above. - Example 6 - Scheme 6 Scheme 6 (figure 6) shows yet another procedure for making the compounds according to formula (II-b). Hydroxy nitro compound 52. Compound 27 (Scheme 2) (16.4 mg, 0.0275 mmol), was added to a 0.2 M solution of pentafluoro-phenol (7.6 mg, 0.0413 mmol) and DIC (0.0094 ml, 0.0606 mmol) in DCM (0.2: ml) at 0 ° C. The reaction mixture was heated to RT, and stirred at RT overnight. The solvent was evaporated. EtOAc (3 ml) was added and the crude product was filtered, rinsing the reaction vessel with EtOAc. The filtrate was concentrated under reduced pressure, and the crude material was used without further purification. DMF (0.1 ml) was added to the crude product, followed by carboxylic acid 34 (Scheme 3) (20.8 mg, 0.083 mmol), and N, N-diisopropylethylamine (0.024 ml, 0.138 mmol). The reaction mixture was stirred in RT overnight, and the solvent was then evaporated. The crude product was purified by flash chromatography eluting from silica gel with a gradient of 0-10% MeOH in DCM to provide 14.9 mg of hydroxy nitro compound 52 as a white solid. MS: (+) m / z 831.5 (M + 1).
Acetyl nitro compound 53. A 0.1 M solution of hydroxy nitro compound 52 (14.9 mg, 0.018 mmol) in pyridine (0.23 ml) was cooled to 0 ° C, and acetic anhydride (0.054 ml, 0.57 mmol) was added. The reaction mixture was allowed to warm to RT for 2 h, and stirred at RT for 24 h.
The reaction mixture was cooled to 0 ° C, and the 1: 1 mixture of 1,4-dioxane and water was added.
The reaction mixture was allowed to warm to RT, followed by stirring at this temperature for 12 h.
The solvent was evaporated, and the residue was purified by preparative HPLC to provide 2.2 mg of the acetyl nitro compound 53 as a white solid.
MS: (+) m / z 873.2 (M + 1). Acetyl amino compound 54. A mixture of acetyl nitro 53 (2.2 mg, 0.0025 mmol) and palladium on carbon (10%, 1 mg) in methane! (0.2 ml) was stirred under an atmosphere of hydrogen for 4 h.
The catalyst was filtered off, and the filtrate was concentrated.
The crude product was purified by preparative HPLC to provide 0.1 mg of the acetyl nitro compound 54 as a white solid.
MS: (+) m / z 843.2 (M + 1). Amino acetyl compound 54 is - also referred to as compound (III-a) above.
Example 7 - Scheme 7] Scheme 7 (figure 7) shows yet another procedure for making compounds of this invention.
Compound 55. Compound 34a (Scheme 3) (70 mg, 0.13 mmol) Ê was added to a 0.2 M solution of pentafluorophenol (35.9 mg, E 0.195 mmol) and DIC (0.0223 ml, 0.143 mmol) in DCM (0.66 ml) at 0 ° C.
The reaction mixture was heated to RT and stirred at RT overnight.
The solvent was evaporated.
EtOAc (16 ml) was added and the crude product was filtered, rinsing the reaction vessel with EtOAc.
The filtrate was concentrated under reduced pressure, and the crude material was used without further purification.
DMF (05 ml) was added to the crude product, followed by p-nitrophenylalanine (82.0 mg, 0.39 mmol) and DIEA (0.114 ml, 0.65 mmol). The reaction mixture was stirred at RT overnight, and the solvent was then evaporated.
The crude product was purified by flash chromatography eluting from silica gel with a gradient of 10-20% MeOH in DCM containing 1% NH, OH to provide 65.2 mg of compound 55 as a white solid.
MS: (+) m / 2z 731.0 (M + 1). Compound 56. A mixture of compound 55 (65.2 mg, 0.089 mmol) and palladium on carbon (10%, 9.4 mg) in MeOH (3 ml) was stirred under an atmosphere of hydrogen for 4 h.
The catalyst was separated by filtration
and the filtrate was concentrated to provide 33.8 mg of compound 56 as a white solid. MS: (+) m / z 701.2 (M + 1). Compound 56 is also referred to as compound (IIII-d) above. Example 8 - Scheme 8 Scheme 8 (figure 8a) shows a method for making a compound according to formula (VIII-b), useful as an intermediate to make the compounds of this invention.
Boc ester 58. To a solution of amino ester 57 (Chem-Impex, 5 g, 19.18 mmois) and di-fer-butyl dicarbonate ("(Boc) 20", Aldrich, 469, 21.10 mmols) in DMF (Acros, anhydrous, 50 ml), triethylamine ("TEA", Aldrich, 8.36 ml, 60 mmols) was added. The reaction mixture was stirred for 0.5 h. HPLC analysis showed that the reaction was completed. The reaction mixture was diluted with EtOAc (500 ml) and the organic layer was washed with E water (200 ml!) And then brine (200 ml), dried over MgSO, anhydrous and concentrated. The crude product was purified on 120 g of CombiFlash column with 0-5% MeOH in DCM to yield Boc 58 ester as a white solid (5.6 g, 81%). * H NMR (DMSO) 5 8.18 (d, 2 H), 7.47 (d, 2 H), 7.38 (d, y 1H), 4.23 (m, 1 H), 3.60 (s, 3 H), 3.15 (m, 1 H), 2.95 (m, 1 H), 1.23 (s, 9H).
Alkene 59. To a solution of Boc 58 ester (230 mg, 0.68 mmol) in DCM (Acros, anhydrous, 2 ml) cooled to -78ºC in dry ice-acetone, DIBAL (Aldrich, 1 M in DCM, 1 ml) was added slowly. The reaction mixture was stirred and heated to 20ºC for 3 h. (1-Ethoxycarbonylethyliden) -triphenylphosphorane (Aldrich, 492 mg, 1.36 mmol) was added. The reaction mixture was stirred at 20 ° C for 1 h. The reaction mixture was diluted with EtOAc (100 ml) and the resulting organics were washed with water (50 ml) and then brine (50 ml), dried over MgSO2, anhydrous and concentrated. The crude product was purified on 10 g of COMBIFLA-SHTY column with 0-50% EtOAc in hexane to yield someone 59 as a white solid (151 mg, 59%). * H NMR (DMSO) 5 8.18 (d, 2 H), 7.47 (d, 2H), 7.22 (d, 1H), 6.51 (d, 1H), 4.48 (m, 1H), 4.11 (q, 2H), 2.80-2.94 (m, 2H), 1.62 (s, 3H), 1.23 (s, 9H), 1.16 (t 3H) . Aryl amine 60. An alkene 59 solution (148 mg, 0.39 mmol)
in EtOH (Acros, anhydrous, 3 ml!) and Pd on charcoal (Aldrich, 10%, 50 mg) was stirred under H> overnight.
The reaction mixture was diluted with DCM (10 ml) and filtered through CELITETY., The filtrate was concentrated and the crude product was purified on 4 g of COMBIFLASHTY column with 0-20% —MeOH in bDCM to yield aryl amine 60 as a white solid (102 mg, 75%). * 'H NMR (DMSO) 5 7.18 (d, 2 H), 7.11 (s, 2H), 6.71 (d, 1 H), 3.98 (q, 2 H), 3.51 (m, 1 H), 2.57 (m, 2 H), 2.41 (m, 1 H), 1.63 (m, 1 H), 1.37 (m, 1 H), 1.29 (s, 9 H), 1.09 (t, 3 H), 0.99 (d, 3 H), MS (ES +) m / z, calculated: m + 1, 351.2, found 351.2. Example 9 - Scheme 9 Scheme 9 (figure 8b) shows another method for making a compound according to the formula (VIII-b), useful as an intermediate to make the compounds of this invention. : Amino acid 61. A mixture of carboxylic acid 24 (Scheme 3, figure 3) (4.4 mg, 0.0025 mmol) and palladium on carbon (10%, 1 mg) in MeOH (0.5 ml) was stirred under a hydrogen atmosphere at night.
The catalyst was filtered off, and the filtrate was concentrated to provide 3.5 g mg of amino acid 61 as a white solid.
MS: (+) m / 2 223.3 (M + 1). Example 10 - Schemes 10, 11, and 12 Scheme 10 (figure 8c) shows another method for making a compound according to the formula (VIII-b), useful as an intermediate to make the compounds of this invention.
Compound 62. A mixture of monoester 33 (Scheme 3, figure 3) (0.34 g, 0.93 mmol) and palladium on carbon (10%, 50 mg) in methanol (20 ml) was stirred under a hydrogen atmosphere overnight .
The catalyst was separated by filtration, and the filtrate was concentrated to provide 0.29 g of compound 62 as a white solid.
MS: (+) m / z 237.3 (without Boc). Scheme 11 (figure 9) illustrates how the compounds according to the formula (VIII-b) can be used to make the compounds of this invention.
Boc 62 ester is converted to Bpoc 62a ester by first protecting the aromatic amine group with an Fmoc group, treatment with TFA to remove the Boc group from the aliphatic amine group, treatment with a, a-
dimethyl-p-phenylbenzyl phenyl carbonic acid (8CI) to install a Bpoc group there, and removal of the Fmoc group with piperidine.
Bpoc 62a ester is coupled with carboxylic acid 63 with HATU to yield an intermediate ester which is then hydrolyzed with LiOH to produce compound 64. Hydrogenation to remove the Cbz protecting group from compound 64, followed by HATU-mediated coupling with 6-maleimidoexanoic acid and removal of the Bpoc group with acetic acid yields amino acid 65, Another HATU-mediated coupling with compound 34a (Scheme 3, figure 3) yields compound 66. Removal of the group of Boc protection with TFA provides compound 67, ready for conjugation.
Yet another way of using the compounds of the formula (VIII-b) is - shown in Scheme 12 (figure 10). From compound 34a, HATU-mediated coupling with compound 68 provides Boc ester 69. Removal of the Boc group with TFA and ester hydrolysis with LiOH provides amino acid 36 which can be made as shown in Scheme 4 (figure 4) to prepare a composition suitable for conjugation.
It is Example 11 - Compound 70: Compound 70. Tubulisin D (made by Peltier et al. 2006; 2 mg, 2.4 umolis) was dissolved in MeOH at 0 ° C.
To this solution, a drop of HCI (0.1M) was added. After stirring the reaction mixture for overnight in RT the solution was evaporated in vacuo to give a residue which was passed through a short column (DCM: MeOH 0-10%) to give compound 70 (1 , 3 mg, 1.6 umol, 67%) as an oil.
MS (ES +) m / z, calculated: m + 1, 772.42, found, 772. o H o O o QL A, IA, TO Do, of 'CO2H Those skilled in the art will appreciate that the general methodology of the Schemes can be adapted to make the compounds of this invention different from those specifically described above.
For example, compound 14 (even though compound 49) can be used to make numerous 77/114 other compounds of this invention by coupling it with other substitutions to the Tup subunit. As another example, changing the reagents used with compound 9 (Scheme 1), compounds 44 and 46 (Scheme 5), variations in the groups R º and R in formula (II) in addition to those specifically exemplified, they can be synthesized.
Example 12 - Preparation of a Conjugate This example describes the preparation of a cytotoxin-ligand (VI-b) construction conjugate and anti-CD70 monoclonal antibody 2H5 (Terrett et al., US 2009/0028872 A1; Coccia et al ., WO 2008/074004 A2). It is representative of the procedure used in the preparation of other conjugates.
Anti-CD70 2H5 antibody at -5 mg / ml in 20 mM sodium phosphate, 50 MM NaCl, 100 µM DTPA, pH 7.5, was thiolated with a 13-fold molar excess of 2-iminothiolane. The thiolation reaction was allowed to proceed for 1 h at RT with continuous mixing. Following thiolation, the antibody buffer was exchanged for conjugation buffer (50 mM HEPES, 5 mM glycine, 2 mM DTPA, pH 6.0); through a PD10 column (Sephadex G-25). The concentration of the anti-: thiolated body was determined at 280 nm. The thiol concentration was measured using a dithiodipyridine assay.
5 MM of a construct raw material (VI-b) in DMSO was added in a 3-fold molar excess per antibody thiol and mixed for 90 min in RT. Following conjugation, 100 mM N-ethylmaleimide in DMSO was added in a 10-fold molar excess of thiol by antibody to quench any unreacted thiol group. This quenching reaction was done for one hour at RT with continuous mixing.
The anti-CD70 antibody / drug conjugate was filtered at 0.2 µm prior to chromatographic purification of cation exchange. The SP SEPHAROSEY High Performance Cation Exchange column (CEX) was regenerated with 5 column volumes (CVs) of 50 mM HEPES, 5 mM glycine, 1 M NaCl, pH 6.0. Following regeneration, the column was equilibrated with 3 CVs of equilibration buffer (50 MM HEPES, 5 mM glycine, pH 6.0). The conjugate was loaded and the column was washed once with the equilibration buffer. The conjugate was eluted with 50 mM HEPES, 5 mM glycine, 200 mM NaCl, pH 6.0. The eluate was collected in fractions. The column was then regenerated with 50 mM HEPES, 5 mM glycine, 1 M NaCl, pH 6.0 to remove protein aggregates and any unreacted (VI-b).
Fractions containing the monomeric antibody conjugate were pooled. Concentration and replacement ratios of the monomeric antibody conjugate were determined by measuring the absorbance at 280 and 252 nm.
The general background of purified eluate had the buffer exchanged in 30 mg / ml of sucrose, 10 mg / ml of glycine, pH 6.0, through dialysis. Dextran 40 was added to the sample at 10 mg / ml post-dialysis. The concentration and replacement ratio (SR) was determined by measuring the absorbance at 280 a and 252 nm. The SR was 2.2 mo of cytotoxin per mole of antibody. Example 13 - Proliferation Tests Ê This example generally describes the procedures used to test the antiproliferative activity of the compounds of this invention or their conjugates. Human tumor cell lines were obtained from É American Type Culture Collection (ATCC), P.O. Box 1549, Manassas, VA D 20108, USA, and cultured according to the ATCC instruction. The cells were seeded at 1.0 x 10º or 1.0 x 10º cells / well in 96-well plates for 3h for ATP assays or * H thymidine assays, respectively. Serial dilutions 1: 3 of the free (unconjugated) compounds or their conjugates were added to the wells. The plates were allowed to incubate for 24 to 72 h. The * H thymidine plates were pulsed with 1.0 pCi * H-thymidine per well for the last 24 hours of the full incubation period, collected, and continued reading with a Top Count Scintillation Counter (Packard Instruments, Meriden , CT). ATP levels on ATP plates were measured using the CELLTI-TER-GLOG Luminescent Cell Viability kit following the manufacturer's manual and read on a GLOMAXO luminometer (20/20 (both from Promega, Madison, WI, USA). values of —ECrs9-the concentration at which an agent inhibits or reduces cell proliferation by 50% - were determined using PRISM'Y software, version 4.0 (GraphPad Software, La Jolla, CA, USA).
Example 14 - Cytotoxin In Vitro Activity Using the H thymidine or ATP luminescence assay, or both, the activities of the compounds of this invention are assayed against the following cancer cell lines: HCT-15 (colorectal, resistant cancer - multi-drug (MDR)); Hep3B (liver cancer); LNCaP (prostate cancer, positive androgen receptor (AR ”)); MDA-MB-231 (breast cancer, estrogen receptor, progesterone receptor, and negative HeR (Triple negative)); A2058 (melanoma); U-87 MG (glioblastoma); NCI-HA460 (NSCLC); AS49 (NSCLC); HPAC (pancreatic cancer, primary); PC3 (prostate cancer, RA); BT474 (breast cancer, highly positive HeR2 (HeR2hi)); SKOV3 (ovarian cancer, HeR Hi); 786-O (kidney cancer); OU-31 (kidney cancer, MDR); - NCI-H740 (SCLC); DMS53 (SCLC); SK-BR3 (breast cancer, HeR Hi); ZR-75 (breast cancer, estrogen receptor positive); OVCAR3 (ovarian cancer); HL-80 (APL); OVCAR / Adr (ovarian cancer, MDR); CEM-C1 (ALL); Nomo-1 (AML); RPMI-8226 (MM)); Raji (lymphoma); SW-480 (colorectal, metastatic cancer); SW-620 (colorectal cancer); and H226 (lung cancer). (Neither: all compounds were tested against all cell lines). . The following compounds were used as reference or comparison cytotoxins: doxorubicin (Dox), Cytotoxin CBI (a secondary DNA groove alkylation agent of the cyclopropalc] benz [e] indol-4-0na class) , tubulisin D (Tub D, Table 1), and the methyl ester of MMAF ("MMAF", a compound related to auristatin; see Sutherland et al., J. Biol. Chem. 2006, 281 (15), 10540- 10547). and
H HO oo N 9 CBI cytotoxin Figures 11a and 11b show illustrative diagrams for * H thymidine proliferation tests for the compounds of this invention, against HL-60 and 786-O cells, respectively, with CBI cytotoxin and tubulisin D as comparative compounds, with an incubation period of 48 h.
PGS CCN LL 80/114 Figures 12a and 12b show illustrative diagrams for ATP luminescence proliferation tests for a second set of compounds of this invention, against HL-60 and 786-O cells, respectively, with an incubation period 72 h.
Figures 12c and 12d show the diagrams for * H thymidine proliferation assays for the same set of compounds, again against HL-60 and 786-O cells, respectively, with an incubation period of 72h.
In each circumstance, doxorubicin was used as a comparative compound.
Table 2 provides the data for the proliferation assays using the H thymidine method, with an incubation period of 72 h.
Dox compound 149 44 130 - 133 - 106 101 CBI 0.040 0.020 0.051 0.019 - 0.14 0.042 Tub D 0.062 0.022 0.36 0.091 - 0.014 0.032 i MMAF 13 011 17 0.29 - 0.12 0.37. 15 67 16 27 13 16 042 2.0 16 284> 100> 100> 100> 100> 100> 100 7 392> 100> 100 84> 100 12> 100 19 1067 52> 100 - 0.13> 100> 100 24 704 32 76 33 0.12 18> 100 280 305 930 236 409 271 306 26 31 18> 3000 15 25 5.2 18 26a> 100 36 80> 100> 100 71> 100 28 223 24 64> 100 0.96> 100> 100 29 0.18 0.041 0.54 0.13 0.40 0.084 0.21 29c 24 30 52 4.8 5.6 051 15 36 64 39 342 -> 100 60 15 52 51 101 42 41 8.7 0.40 0.75 72 54 044 030 16 1.6 0.64 011 0.31 56 2477> 100> 100> 100> 100> 100> 100
—Ú —————————————— E — e hu 81/114 comments [have ECa MR Compound Dox 128 126 276 424 163 168 267 CBI 0.072 0.063 0.049 1.2 0.047 0.035 0.035 Tub D 0.014 0.015 0.038 0.51 0.039 0.15 0.10 MMAF 021 029 038 1/7 0.24 14 7.3 (11-q) - - - - - 7.61 - 2.1 3.0 17 71 2 , 6 - 15 - 16> 100> 100> 100> 100 4 19> 100 17> 100> 100 82> 100 91 32> 100 i 19> 100> 100 2> 100> 100> 100> 100 -> 100
24 38> 100 63> 100 68> 100 -> 100
- 25 270 206 319 804 180 1862 435 26 18 11 16 1 4.6 26 50
E 26a> 100> 100 2> 100 7 47> 100 -> 100 28> 100 34> 100> 100 99 61> 100 29 0.44 0069 021 0.57 0.029 12 0.13 29c 6.5 32 "12 1 , 9 3.9 1.0 36 44 83 66> 100 32> 100 -> 100 51 7.8 6.4 5.6 30 4.4 10 35 54 0.24 083 082 88 0.34 6.9 1 , 3 56> 100> 100> 100> 100> 100 29> 100
(EST ETR bodies Dox Compound 255 979 - 794 258 56 2044 CBI 0.098 1.5 - 1.5 0.071 0.027 0.16 Tub D 22 02 - 17 0.051 0.032 0.17 MMAF 13 10 - 42 0.16 025 25 ( 111-q) - - - - - 15.05 - 23 37 17 -> 100 060 423 - 16> 100> 100 -> 100> 100> 100 8.9 1869 17 32> 100 -> 100> 100> 100 17 2970 Í 19 38> 100> 100 34 53 37 69 24 51> 100 -> 100 3.6 90 6.9> 100 - 25 347 515 1714> 3000 379 308 946 26 30 99 32> 300 3.2 0.45 201 Ú 26a 3.2 2> 100 158 56 21 10 100 28 5.8 2> 100> 100 4.3 31 77 27 29 0.41 0.28 11 3.8 0.02 0.0099 0.70 29c 5.3 76 72 44 3.6 18 14 36> 100> 100 -> 100> 100> 100 107> 100 51 37 24> 100 1.8 2.5 4.2 20 54 10 2.0 11 2.2 3.9 053 21 56> 100> 100 -> 100> 100> 100> 100 -> 3000 ma to Dox 144 105 68 61 CBI 0.11 0.016 0.12 0.013 Tub D 0.018 0.042 0.037 0.013 MMAF 0.17 0, 27 0.24 0.12 0.93 2.3 3.3 0.47 16 1 18 22 28, 17 43 6.8 47 53 19 22 13 23 32 À 24 13 11 17 11
225 116 396 231
; 26 22 0.36 7.7 7.0 26a 10 2.0 22 20
Ú 28 10 0.20 8.7 13 29 0.019 0.0075 0.034 0.024 29c 45 0.43 16 8.5 36 44 124 48 15 51 2.0 3.5 2.2 1.5 54 0.38 0, 77 0.36 0.20 56> 100> 100> 100> 100
Table 3 provides the data for the ATP luminescence proliferation assays, with an incubation period of 48, 72, or 96 h, as observed.
Incubation Period as Observed; Compound / HCT-15 | Hep3B jMDA-MB- / A2058 not AS549 | PC3 (48h) (48h) / 231 (48h) | (48h) ia (48h) | (48h) Dox - 443 - - - 149 1082 CBI - 2.6 - - - 3.0 12 is Tub D - 0.0012 - - - 0.020 0.039 MMAF - 0.058 - - - 0.33 0.43 IS 15 40 6.3 5.6 3.5 6.7 - > 100 16 157 26 28 30 69 -> 100 17 443> 100 65 30 69 -> 100 19 - 18 = ENNNNs - 3 and 24 - 10 - - - - 13 25 - 246 - - - 111 155 26 113 100 120 93 - -> 3000 26a - - - - - - - 28 - 17 - - - - 5.8 29 - 1.6 - - - 3.9 3.4 29c 200 75 52 32 - —— 66 36 - 86 - - - 1.9 78 51 - 3.8 - - - - 16 54 - 1.5 - - - 3.0 3.1 56> 3000 -> 100> 100> 100> 100 -> 100
Incubation Period as Observed 48 h 48 h 48 h 48 h 48 h 48 h 48 h Dox - 674 360 908 - - - CBI - 3.0 16 4.2 - - - Tub D - 0.029 0.022 0099 - - - MMAF - 0 , 19 0.71 2.6 - - - 3.5 4.2 - - 32 3.9 13 is 16 19 18 - - 50 6.6 11 17 23 58 -> 100 —-80 24 24 19 8.8 - -> 100 - 3.9 20 24 4.6 - - 13 - 8.9 8.4 166 - - 759 - 366> 3000 - 1003 26 19 - - 240 - 253 208 - 26a - - - - - - - - 28 12 - - 5.8 - 7.8 16 29 1.5 - - 2.7 5.3 3.6 15 29c 492 - - 26 - 278 136 36 120 - - 8.8 -300> 300> 300 51 n - -> 100 - 13 19 54 4.8 - - - 7.9 6.2 9.6 56> 100 -> 100 - -> 100> 100> 100 84a - - 612 - = - - 84b - - 410 - - - - 109 - - 1038 - = - -
Incubation Period as Observed: Compound / ovary lHi-60 [CEM fnomo-a RPM HOT nosp (48h) (48 h) xl (48 h) S226. AGIA (72h) 48h 72h Dox 632 - en - 600 592 CBI 41 - MN - 34 33 TubD - 0.085 - min - 0.014 0.093 MMAF - 0.17 ”- nin" to 0.075 0.98 F 15> 100 - ni - ba 16> 100 = start - bs i 17> 100 - E = morning
19 25 - mn = 245 - 24 29 - = D = 188 -
> 3000 - 224 - 83 - 366 -
Q 26 e - 61 39 45 - az 26a - - - - - - - 28 14 - nn = 132 - 29> 100 059 - 0H - 45 - 29c - "e" 20 29 70 - 255 36> 300 14 - 34 - 96 -> 300 36a 0048 - - - o 51 5.5 - ENNs - 98 - 54> 100 25 - 31 - 26 11 56> 100 - Maas - = ———— B4a 8.19 1028 - - = 1388 - 84b 4.91 1627 - - - 228 - 109 0018 - - - m— 112 0055 - - - = =
.09
Incubation Period as Observed Compound | MDA-MB- / 'A2058 to NCI-H460 / A5S49 | HPAC | BT474 231 (72h) (72h) o ”(72h) (72h) (72h) (72h) Dox 518 101 324 92 - 215 388 CBI 3.1 0.20 3.3 0.64 - 6.0 5.5 Tub D 0.047 0.00684 0.0054 0.0076 - - 0.021 MMAF - 0.33 0.089 0.052 0.13 - 0.067 0.024 - 15 - - 8.6 - - - - 16 - -> 100 - - - - 17 - - 2 - - - 19 32 26> 100 43 - 0.33 - 24 13 14 18 23 - 11 - í 25 202 212 357 177 - 97 - y 26 - - 94 90 - 279 - 26a - - q - - - - 28 16 20 18 35 - 5.9 - 29 5.1 2.9 49 30 - 4.9 - 29c - - 136 6.0 - 4.6 - 36 9.6 43 37 16 - 2.9 - 51 - 5.5 76 14 - 4.5 - 54 5.6 14 16 16 - 096 - 56 - -> 100 - - - -
—————- xCC --- A NCCCCqC -———————— = - —— "À ãã—" 88/114 Incubation Period as Observed:
(72h) 1i (72h) (72h) | (72h) (72h) | (72h) | (72h) Dox - - - 755 441 236 - CBI - - 2.2 3.8 3.1 3.1 2.2 - Tub D - - 0.022 0.069 0.025 0.034 - MMAF = - - - 4.5 0.16 025 - (N11-q) - 1036 - - - - - It is 15 - 9.4 - - - - -. 16 - 36 - - -— - - 7 to 73 - - - - - 19 15 40 - 87 - - -: 24 K) 36 -> 100 - - - 109 306 - - - - - F 26 38 126 - 193 - - 49 26a - - - - - - - 28 1 29 - 58 - - - 29 1.3 2.8 - - - - - 29c 17 34 - 17 - - 99 36 45 183 - - - - - 36a - 0434 - - - - - 51 10 19 - 46 - - - 54 13 2.6 - - - - - 56 -> 100 - - - - -
109 - - - - - - 0.202
112 - 067 - - - - 0.049 133 - 417 - - - - - 134 - 989 - - - - - 135 - 12.94 - - - - -
Incubation Period as Observed Compound | HL-60 and loyal Nomo-1 Raji | SW480 sor (72h) to (72h) n225 (72 (72h) | (96h) o 72h h 96 h Dox 147 161 338 345 301 215 145 CBI 0.76 0.555 037 4.1 21 0.92 0.33 Tub D 0.0096 0.0030 0.013 0.0051 0.0048 0.020 0.0058 MMAF 0.12 0.11 0.14 0.068 0.084 0.17 0.057 - (Nq) 1427 - - - mn »- 15 2.7 2.6 2.7 2.6 2.5 5.6 3.7 16 2.8 25. 31 15 30 48 29 17 7A 26 3.9 15 27 92 65 19 77 111 5.2 9.6 9.2 52 14 | 24 64 8.7 4.0 8.4 7.9 42 10 - 25 - 176 - 235 209 261 193 26 27 - - - 46 67 48 26a - - - - - - - 28 2.9 1 0.82 10 15 36 21 29 - 085 - 1.0 2.1 2.7 1.5 29c 8.6 - - - 36 41 84 36 - 40 - 62 24 81 45 51 - 4.8 TA 5.2 5.0 13 6.4 54 - 1.2 - 1.6 1.2 1.6 11 56> 100> 100> 100 5.7 24> 100 28 In addition, the following EC values were measured for the following compounds against the H226 cell line, using the ATP assay and 72 h incubation period: compound 36a (0.307 nM); compound 109 (1.609 nM) and compound 112 (0.67-1.16 nM). es were measured for the following compounds against lineage
cell gem of OVACAR $ / Adr, using the ATP assay and 48 h incubation period: compound 36a (17.05 nM); compound 84a (> 300 nM); compound 84b (47.2 nM); compound 109 (24.9 nM); and compound 112 (12 nM). Example 15 - In vitro Conjugate Activity Figure 13 shows the activity of the conjugates of this invention in * H thymidine proliferation assays, measured against 786-O renal cancer cells that are CD70 positive. The incubation period was 72 h.
The values of ECs, 9 extracted from the curves in figure 13 are given in Table 4, along with data from other experiments.
LNCap cell line is a prostate cancer cell line that expresses the prostate-specific membrane antigen (PSMA); H226 is a cell line - of lung cancer that expresses mesothelin.
The antibodies used for conjugation form 2A10, an anti-PSMA antibody (Huang et al., US '2009/0297438); 2H5, an anti-CD70 antibody (Terrett et al, US 2009/0028872); 1F4, an anti-CD70 antibody (Coccia et al, WO 2008/074004); and 6A4, an antimesothelin antibody (Terrett et al., WO i 2009/045957). As controls, Compound J of Sufi et al., WO 2008/083312 "(" Cpd.
J ", a secondary DNA groove binding / alkylating agent) was used as a conjugation pair and diphtheria toxin (" DTX ") was used as an unconjugated non-specific control.
E and ECso (nM) | pesignation - | Cell description 2A10-Comp.
J Conjugate of 2A10 and Comp.
J 786-O 116.7 DTX Non-conjugated non-specific control 786-O 104.4 2H5-Comp. J.
Conjugate of 2H5 and Comp.
J 786-O 0.08592 1F4-Comp.
J Conjugate of 1F4 and Comp.
J 786-O 0.09951 2H5- (Vl-a) Conjugate of 2H5 and Compound (Vl-a) 786-O 0.1151 to 0.0749 2A10- (VI-a) - Conjugate of 2A10 and Compound (Vl- a) 786-O >> 100 2H5- (Vl-b) Conjugate of 2H5 and Compound (VI-b) 786-O 0.06554 2A10- (VlI-b Conjugate of 2A10 and Compound (VlI-b) 786-O >> 100
EEE ECso (nM) | weighting - Cell description 2H5- (Vl-n) 2H5 conjugate and compound (Vl-n) 786-O 0.4384 2H5- (VI-m) - 2H5 conjugate and compound (VI- m) 786-O —0.5899 2H5- (Vl-qg) Conjugate of 2H5 and Compound (Vl-q) 786-O inactive 2H5- (VI-p) Conjugate of 2H5 and Compound (VI-p) 786-O inactive 2H5- (VI-t) Conjugate of 2H5 and Compound (VI-t) - 786-O 0.310 6A4- (VI-t) Conjugate of 6A4 and Compound (VI-t) - H226 0.360 2A10- (VI-t) 2A10 Conjugate and Compound (VI-tl LNCap - 0.570 Data show that a CD70-specific antibody is needed for a conjugate to effectively release a cytotoxin to CD70-positive 786-O cells: antibody conjugates 2A10, which it is specific for a different antigen (PSMA), they have little or no activity.
Conversely, all anti-CD70 antibody conjugates were active.
The conjugates of Compounds (Vl-a) and (VI-b) were comparable in activity to the conjugates of Compounds J, a well-known conjugation pair. and one of whose conjugates is undergoing clinical trials.
It is noteworthy that the compounds of Compounds (Vl-a) and (VI-b) exhibit very little non-specific toxicity: compare the activities of 2A10- (Vl-a) and 2A10- (VI-b) against those of 2A10-CBI .
Example 16 - In vivo Activity of the 770-O CD70-Positive Cells of Human Kidney Cancer (Cat.
CRL-1932 originally purchased from ATCC) were grown in vitro by ATCC instructions.
The cells were harvested, and 2.5 million cells per 200 µl of DPBS / MATRIGEL'Y (1: 1) were implanted subcutaneously in the CB17.SCID mice flank region.
Tumors were measured weekly in 3 dimensions with a Foowler Electronic Digital Calibrator (Model 62379-531; Fred V.
Fowler Co., Newton, MA, USA) and the data were electronically recorded using StudyDirector software from Studylog Inc. (San Francisco South, CA, USA). The animals were checked daily for postural, training, and respiratory changes, as well as lethargy.
The animals were also weekly weighed and euthanized if weight loss was = 20%. When the tumors reached an average size of 194 mm , groups of 6 mice each were treated with a simple intraperitoneal (IP) dose of a test conjugate (eg, 2H5- (VI-b)) and an isotype control (2A10- (VI-b)) at 0.3 umol / kg of body weight.
Tumor volumes (LWH / 2) and mouse weight were recorded over the course of each study, which was allowed to proceed for about 2 months after initial dosing.
An Excel macro spreadsheet was used to calculate the mean, SD, and median values of tumor sizes.
The data were plotted using Prism software version 4.0. The results of the xenograft study are shown in figure 14, where legend markings have the same meaning as in the previous example and in figure 13. The data demonstrate the in vivo activity of the compounds of this invention against 786 cells -The CD70 ”. Both the conjugates of the compounds (Vl-a) and (VI-b) with anti-i CD70 2H5 antibody caused a reduction in the average tumor size to less BR than that portion in the course of the study, while, when the vehicle control or a conjugated to the anti-PSMA antibody 2A10 was administered, the volume - tumor medium more than doubled.
Example 17 - Scheme 13 Scheme 13 (figure 15) shows a method for making enantiomerically pure 4-nitrotubphenylalanines (4-NO2Tup) 82a and 82b which are useful for making the compounds of this invention.
Compound 80. Di-fer-butyl dicarbonate (90.5 mg, 0.42 mmol) was added to a mixture of Compound 34 from Scheme 3 (0.1 g, 0.35 mmol) in 0.7 M NaOH aq. (1 m!). The reaction mixture was stirred at RT for 3 h, and then acidified to pH 3 with 0.5 N HCI.
After the aqueous solution was extracted with EtOAc three times, the combined organic layers were dried, filtered, and concentrated.
The crude product was purified by flash chromatography eluting from silica gel with a gradient of 0-20% methanol in DCM to provide 0.117 g of compound 80 as
A o a a a o o a a o a a o E EE EEE RSS 93/114 a white solid.
MS: (+) m / z 253.1 (M + 1 without Boc). (-) - menthol esters 81a and 81b.
DCC (87.8 mg, 0.43 mmol) was added to a solution of compound 80, (-) - ment! (66.6 mg, 0.43 mmol), and 4- (dimethylamino) pyridine ("DMAP", 10.4 mg, 0.085 mmol) in DCM (1.5 ml)) in RT.
After the reaction mixture was stirred at RT for 3 h, the precipitate was filtered off.
The filtrate was then concentrated.
The crude product was purified by flash chromatography eluting from silica gel with a gradient of 0-20% EtOAc in hexanes to provide 55.7 mg of ester 81a as a white solid, and 55.7 mg of ester 81b as a - white solid.
Ester MS 81a: (+) m / z 391.2 (M + 1 without Boc); Ester MS 81b: (+) m / z 391.2 (M + 1 without Boc). - 4-NO> Tup 82a and 82b.
A solution of ester 81a in 6N HCI (40 mg, 0.082 mmol) was heated to 130 ° C for 1.5 h.
The reaction mixture Ú was concentrated to provide 23.5 mg of 4-NO> Tup 82a as a white solid. * H NMR (D2O, 400 MHz): 5 8.04 (d, 2H, J = 8.4 Hz), 7.33 (d, 2H, J = 8.4 Hz), 3.50 (m, 1H ), 3.03 (dd, 1H, J = 6.8, 14.4 Hz), 2.89 (dd, 1H, J = 7.6 'Hz, 14.4 Hz), 2.45-2, 39 (m, 1H), 1.92-1.84 (m, 1H), 1.62-1.55 (m, 1H), and 0.98 p (d, 3H, J = 7.2 Hz) ; MS: (+) m / z 253.1 (M + 1). 4-NO> Tup 82b was obtained by the same procedure on the same scale as a white solid (23.5 mg). HRMN (DO, 400 MHz): 5 8.03 (d, 2H, J = 8.4 Hz), 7.33 (d, 2H, J = 8.4 Hz), 3.50 (m, 1H), 2.93 (dd, 2H, J = 2.0, 7.6 Hz), 2.54-2.48 (m, 1H), 1.86-1.78 (m, 1H), 1.60- 1.53 (m, 1H), and 0.98 (d, 3H, J = 6.8 Hz); MS: (+) m / z 253.1 (M + 1). Example 18 - Scheme 14 Scheme 14 (figure 16) describes the conversion of 4-NO, sTup 82a and eB82bnos compounds of this invention.
Nitro acid 83a.
Compound 34a from Scheme 3 (10 mg, 0.019 mmol) was added to a 0.2 M solution of pentafluorophene! (5.1 mg, 0.028 mmol) and N, N'-diisopropyl carbodiimide ("DIC", 0.0032 ml, 0.021 mmol) in DCM (0.2 ml) 0 ° C.
The reaction mixture was heated to RT and stirred — at: such a temperature overnight.
The solvent was evaporated.
EtOAc (1.8 ml) was added, and the crude product was filtered, rinsing the reaction vessel with EtOAc.
The filtrate was concentrated under reduced pressure, and the pentafluoro-
crude phenyl was used without further purification.
DMF (0.2 ml) was added to the crude ester, followed by 4-NO; Tup 82a (10.7 mg, 0.037 mmol), and DIEA (0.013 ml, 0.074 mmol). The reaction mixture was stirred at RT overnight, and the solvent was then evaporated.
The crude product was purified by flash chromatography eluting from silica gel with a gradient of 0-20% MeOH containing 1% NH, OH in DCM to provide 12.9 mg of nitro acid 83a as a white solid.
MS: (+) m / z 773.4 (M + 1). Alternative route for nitro acid 83a: DIEA was added to a solution of compound 34a (10 mg, 0.019 mmol), and HATU (7.8 mg, 0.020 mmol) in DMF (0.3 m!), Maintaining the pH at 8 9. The reaction mixture was stirred at RT for 5 min.
Then DIEA and nitro amine 82a (5.4 mg, 0.019 mmol) in DMF (1 ml) was added, maintaining the pH at 8 9. After the reaction mixture was stirred at RT for 15 min, the crude product was purified by preparative H-PLC to provide 13.4 mg of nitro acid 83a as a white solid.
Nitro acid 83b was prepared by the same alternative route, on the same scale and was obtained as a white solid (13.4 mg). MS: (+) m / z E 773.4 (M + 1). Amine 84a.
A mixture of nitro acid 83a (7.5 mg, 0.0097 mmol) and palladium on carbon (10%, 1.1 mg) in MeOH (0.37 ml) was stirred under an atmosphere of hydrogen for 4 h.
The catalyst was filtered off, and the filtrate was concentrated.
The crude product was purified by preparative HPLC to provide 6.2 mg of amine 84a as a white solid. 'H NMR (CD; 3OD, 400 MHz): 5 8.06 (s, 1H), 7.36 (d, 2H, Jy = 8.4 Hz), 7.17 (d, 2H, J = 84 Hz ), 5.70 (dd, 1H, J = 2.8, 10.8 Hz), 4.71 (d, 1H, J = 7.2 H2), 4.44-4.35 (m, 2H) , 3.74 (d, 1H, J = 9.6 Hz), 3.49-3.45 (m, 1H), 3.36-3.35 (m, 1H), 3.30-3.25 (m, 1H), 3.13 (s, 3H), 3.14-3.04 (m, 1H), 2.93 (d, 2H, J = 8.4 Hz), 2.74 (s, 3H), 2.48-2.28 (m, 3H), 2.15 (s, 3H), 2.19-2.03 (m, 2H), 1.95-1.86 (m, 4H) , 1.80-1.71 (m, 2H), 1.71-1.57 (m, 3H), 1.24-1.13 (m, 1H), 1.16 (d, 3H, J = 7.2Hz), 1.04 (d, 3H, J = 6.4H2z), 1.02 (d, 3H, J = 6.8 Hz), 0.94 (t, 3H, J = 7.2 Hz ), and 0.84 (d, 3H, J = 6.8 Hz); MS: (+) m / z 743.4 (M + 1). Nitro acid 83b was hydrogenated with amine 84b using the same
procedure, on an 8 mg scale.
Amine 84b was obtained as a white solid (6.7 mg). '* H NMR (CD3OD, 400 MHz): 5 8.06 (s, 1H), 7.35 (d, 2H, J = 8.4 Hz), 7.16 (d, 2H, J = 8.4 Hz), 5.70 (dd, 1H, J = 2.8, 11.2 Hz), 4.72 (d, 1H, J = 7.2 Hz), 4.49-4.32 (m, 2H ), 3.75 (d, 1H, J = 10.0 Hz), 3.49-3.45 (m, 1H), 3.36-3.35 (m, 1H), 3.33-3, 31 (m, 1H), 3.12 (s, 3H), 3.12-3.04 (m, 1H), 2.91 (d, 2H, J = 7.6 Hz), 2.74 (s , 3H), 2.57-2.52 (m, 1H), 2.45-2.37 (m, 1H), 2.33-2.28 (m, 1H), 2.15 (s, 3H ), 2.19-2.13 (m, 1H), 2.03-1.88 (m, 5H), 1.81-1.57 (m, 5H), 1.24-1.13 (m , 1H), 1.17 (d, 3H, J = 6.8 Hz), 1.04 (d, 3H, J = 6.4 Hz), 1.02 (d, 3H, J = 7.2 Hz) , 0.94 (t, 3H, Jy = 7.2 Hz), and 0.84 (d, 3H, J = 64Hz); MS: (+) m / z 743.4 (M + 1). Compounds 84a and 84b are also described in this descriptive report by the formulas (Ill-r) and (Ill-s), respectively.
Example 19 - Scheme 15 Scheme 15 (figure 17) describes the synthesis of compounds ready for conjugation of this invention having a simple amino acid linker (citrulline). It is Compound 85. A mixture of compound 62 of Scheme 10: (0.22 g, 0.654 mmol), Fmoc-protected citrulline (0.39 g, 0.981 mmol), and N- (3-dimethylaminopropyl) hydrochloride - N'-ethylcarbodiimide ("EDCI", 0.188 g, 0.981 mmol) in DMF (4 ml) was stirred at RT overnight.
The reaction was quenched by the addition of NH, saturated CI, and the aqueous solution was extracted with EtOAc.
The combined organic layers were dried, filtered, and concentrated.
The crude product was purified by flash chromatography, eluting from silica gel with a gradient of 0-100% MeOH in DCM to provide 0.42 g of compound 85 as a white solid.
MS: (+) m / z 716.4 (M + 1). Compound 86. Piperidine was added to a solution of compound 85 (0.248 g, 0.346 mmol) in DMF, maintaining the pH at 9-10. The reaction mixture was stirred at RT for 20 min, and then concentrated to provide 0.17 g of compound 86, MS: (+) m / z 494.4 (M + 1). Compound 87. LiOH (26.6 mg, 1.11 mmol) in water (3 ml) was added to a solution of compound 86 (0.17 g, 0.346 mmol) in THF (2 ml). After the reaction mixture was stirred at RT for 2 h, the solvent was partially removed.
The aqueous solution was acidified to pH 2-3 with HCl and concentrated.
The residue was redissolved in DMF (2 ml), and N-succinimidyl 6-maleimidoexanoate (0.16 g, 0.519 mmol) and DIEA (0.091 ml 0.519 mmol).
After the reaction mixture was stirred at RT for 10 min, the crude product was purified by preparative HPLC to provide 0.198 g of compound 87 as a white solid.
MS: (+) m / z 673.4 (M + 1). Compound 88. TFA (0.5 ml) was added to a solution of compound 87 (12.5 mg, 0.019 mmol) in DCM (0.5 ml!) At room temperature.
The reaction mixture was stirred at RT for 5 min, and then concentrated to provide 12.8 mg of compound 88 as a white solid.
MS: (+) m / z 573.4 (M + 1). Compound 89. DIEA was added to a solution of compound 34a of Scheme 3 (5 mg, 0.0093 mmol) and HATU (3.9 mg, 0.010 mmol) in DMF (0.3 ml), maintaining the pH at 8. The reaction mixture was stirred at RT for 5 min.
Then DIEA and compound 88 (12.8 mg, 0.019 mmol) in: DMF (1 ml) were added, maintaining the pH at 8-9. After the reaction mixture was stirred at RT for 15 min, the crude product was purified by preparative HPLC to provide 8.6 mg of compound 89 as a white solid.
MS: (+) m / z 1093.8 (M + 1). Compound 89 is also described in this specification by the formula (VI-m). Compound 90, DIEA was added to a solution of Compound 49 of Scheme 5 (5 mg, 0.0098 mmol) and HATU (4.1 mg, 0.011 mmol) in DMF (0.3 ml), maintaining PhH; 8389.A reaction mixture was stirred at RT for 5 min.
Then DIEA and compound 88 (13.5 mg, 0.0196 mmol) in DMF (1 ml) were added, maintaining the pH 8-9. After the reaction mixture was stirred at RT for 15 min, the crude product was purified by preparative HPLC to provide 8.9 mg of compound 90 as a white solid.
MS: (+) m / z1065.6 (M + 1). Compound 90 is also described in this descriptive report by the formula (VlI-p). Example 20 - Scheme 16 s—— - .. ————— "" Ú 97/114 Scheme 16 (figure 18) describes the preparation of compounds ready for conjugation of this invention, having a dipeptide linker (citrulline-valine).
Compound 91. DIEA was added to a solution of Fmoc-protected valine (62.3 mg, 0.184 mmol) and HATU (63.6 mg, 0.167 mmol) in DMF (0.5 ml), maintaining the pH at 8 9. The reaction mixture was stirred at RT for 5 min. Then DIEA and Compound 86 from Scheme 15 (82.5 mg, 0.167 mmol) in DMF (1 ml) were added, maintaining the pH at 8 9. After the reaction mixture was stirred at RT for 15 min, the reaction it was quenched by the addition of 0.05% aq. TFA. The aqueous solution was extracted with EtOAcef and the combined organic layers were dried, filtered and concentrated. The crude product was purified by flash chromatography eluting from silica gel with a gradient of 0-20% MeOH in DCM to provide 0.13 g of compound 91 as a white solid. MS: (+) m / z 815.5 (M + 1). Compound 92. Piperidine was added to a solution of compound 91 (0.144 g, 0.177 mmol) in DMF, maintaining the pH at 9-10. The reaction mixture was stirred at RT for 20 min and then concentrated. The residue was dissolved in THF (2.5 ml) and IOL (16.3 mg, 0.681 mmol) in water (1.3 ml) was added. After the reaction mixture was stirred at RT for 2h, the solvent was partially removed. The aqueous solution was acidified to pH 2-3 with HCI and then concentrated. The residue was redissolved in DMF (2.5 m!), And then N-succinimidyl 6-maleimido-hexanoate (0.105 9, 0.341 mmol) and DIEA (0.060 ml, 0.341 mmol) was added. After the reaction mixture was stirred at RT for 10 min, the crude product was purified by preparative HPLC to provide 0.116 g of compound 92 as a white solid. MS: (+) m / z 772.5 (M + 1).
Compound 93. TFA (0.6 ml) was added to a solution of compound 92 (14.4 mg, 0.019 mmol) in DCM (1 ml!) In RT. The reaction mixture was stirred at RT for 5 min and then concentrated to provide 14.7 "mg of compound 93 as a white solid. * H NMR (CD3OD, 400 MHz): 5 7.58 (dd, 2H, J = 1.6, 84 Hz), 7.21 (dd, 2H, y = 2.8, 8.8 Hz), 6 , 79 (s, 2H), 4.48 (m, 1H), 4.13 (d, 1H, J = 7.6 Hz), 3.57-3.46 (m, 3H), 3.33- 3.32 (m, 1H),
3.22-3.09 (m, 2H), 2.91-2.80 (m, 1H), 2.27 (t, 2H, J = 7.2 Hz), 2.09-1.85 ( m, 3H), 1.81-1.54 (m, 8H), 1.35-1.29 (m, 3H), 1.19 (d, 1.5 H, J = 6.8 Hz), 1.18 (d, 1.5 H, J = 7.2 Hz), 0.98 (d, 3H, J = 2.4 Hz), 0.96 (d, 3H, J = 2.8 Hz) ; MS: (+) m / z 672.4 (M + 1).
Compound 94. DIEA was added to a solution of Scheme 34a 34a (11 mg, 0.0204 mmol) and HATU (7.8 ma, 0.0204 mmol) in DMF (0.3 m!), Keeping the pH at 8 9. The reaction mixture was stirred at RT for 5 min. Then DIEA and compound 93 (14.7 mg, 0.019 mmol) in DMF (1 ml) were added, maintaining the pH at 8-9. After the reaction mixture was stirred at RT for 15 min, the crude product was purified by preparative HPLC to provide 18.9 mg of compound 94 as a white solid. MS: (+) m / z 1192.6 (M + 1). Compound 94 is also described in this specification by the formula (Vl-n).
Acetate of compound 27. Acetic anhydride (0.248 ml) was added to a solution of compound 27 in Scheme 2 (Peltier et al., 2006 ;, 0.13 g, 0.218 mmol) in pyridine (2.6 ml) at 0ºC . The reaction mixture was then stirred at RT overnight. After the reaction mixture was cooled to 0 ° C, a solution of water and 1,4-dioxane (12 ml, v / v 1: 1) was added. The reaction mixture was stirred at RT overnight and then concentrated. The crude product was purified by flash chromatography eluting from silica gel with a gradient of 10-20% MeOH in DCM to provide 0.114 g of the compound 27 acetate as a white solid. MS: (+) m / z 639.4 (M + 1). THE
PAIN S x Oo
AA Compound 95. DIEA was added to a solution of compound 27 acetate (3.8 mg, 0.0059 mmol), and HATU (2.5 mg, 0.0065 mmol) in DMF (0.3 ml), keeping the pH at 8-9. The reaction mixture was stirred at RT for 5 min. Then DIEA and compound 93 (5.6 mg, 0.0071 mmol) in DMF (1 ml) were added, maintaining the pH at 8-9. After the reaction mixture was stirred at RT for 15 min, the crude product was purified by preparative HPLC to provide 6.5 mg of compound 95 as a white solid. MS: (+) m / z 1292.7 (M + 1). Compound 95 is also described in this specification by the formula (Vl-o). Example 21 - Scheme 17 This example describes the synthesis of acid 108, a useful intermediate for the preparation of the compounds of this invention, with reference to Scheme 17 (figure 19).
Methyl ester 100, HCl in dioxane (8.3 ml, AM, 33.2 ml) was added to a solution of compound 9 of Scheme 1 (8 g, 22.1 mmols) in MeOH (10 ml). The reaction mixture was stirred at RT. After 20 min, the solution was evaporated in vacuo to give methyl ester 100 as an oil (6.5 g) which was used for the next reaction step without further purification.
Propyl amine 101. Propanal (700 ul, 7.36 mmol) and NaBH (OAc) s (2.8 g, 13.2 mmol) were added to a methyl ester solution: 100 (1.96 g, 6, 6 ml) in DCM (10 ml). The reaction mixture was stirred at: 5 ° C. After 1 h, the mixture was absorbed in EtOAc and washed twice with 7% KCO solution; and then brine. The EtOAc layer was dried over NaSO, anhydrous and then evaporated in vacuo to yield a residue which was passed through a column (MeOH: DCM. 0-10%) to give propyl amine 101 (1.12 g, 60%) like an oil. * H NMR (400 MHz, CDCI;) 5 8.17 (s, 1H), 5.43 (t, J = 4.6 Hz, 1H), 3.93 (s, 3H), 3.07 2, 87 (m, 2H), 2.82 2.70 (m, 1H), 2.54 (s, 1H), 2.45 2.26 (m, 2H), 2.16 2.02 (m, 1H ), 1.73 (m, 2H), 1.05 0.94 (m, 9H). MS m / z CiaH25N2O03S (M + 1) * calculated 301.2, found 301. Compound —102. (Benzotriazol-1-yloxy) tripyrrolidinophosphonium hexafluorophosphate ("PyBop", 1.28 g, 2.47 mol), HOBt (0.33 9, 247 mmol), Boc-protected isoleucine (430 ul, 2.47 mol) were added to a solution of propyl amine 101 (570 mg, 1.9 mmol) in DCM (5 ml). The reaction mixture was stirred at RT. After 20 min, EtOAc (200mL) was added and the organic layer was washed with 10% citric acid (twice), NaHCO; sat., and brine. The EtOAc layer was dried over Na-SO,
a—— c - & —— - - | eeÚeco-.oo— 100/114 anhydrous and then evaporated in vacuo to yield a residue that was passed through a column to give compound 102 (0.55 g) as an oil.
MS m / z CosHaaN3O6sS (M + 1) * calculated 514.3, found 514.3. Azido ester 104. Acid chloride 103 (2 mmols., Lundquist et al 2001; see also above in the preparation of azido ester 43 of Scheme 5) in DCM (3 ml) was added to a solution of compound 102 ( 0.55 g, 1.14 mmol) in DCM (10 ml!) And DIEA (871 µl, 5 mmols). The reaction mixture was stirred at 5 ° C.
After stirring for 10 min, the mixture was evaporated in vacuo to give a residue which was passed through a column to give azido ester 104 (300 mg) as an oil.
MS m / z C3: H53dNsO; S (M + 1) * calculated 653.4, found 653. Compound 106. A solution of pentafluorophenyl ester 105 (2.1 mmolis, Peltier et al. 2006) in 1 ml! of EtOAc was added to a solution of azide ester 104 (300 mg, 0.46 mmol) and Pd / C (10%, 50 mg) in EtOAc (5 mL). The reaction flask was filled with H2 using a flask and stirred overnight at RT.
After stirring overnight, the reaction mixture was filtered, concentrated in vacuo and then passed through a BR column (MeOH: DCM, 0-10%) to give compound 106 (170 mg) as an oil.
MS m / z CasHesN5OgS (M + 1) * calculated 752.5, found 752.5. Compound 107. NaOH (120 µL, 1.2 mmol, 10M) was added to a solution of compound 106 (170 mg, 0.22 mmol) in MeOH (10 mL) in RT.
After stirring for 2 h, the reaction mixture was acidified to pH 2 with concentrated HCI.
The reaction mixture was then evaporated in vacuo and passed through a reverse phase column (ACN: H2O, 0-100% with 0.1% TFA). After lyophilization, compound 107 (63 mg) was obtained as a white powder.
HPLC profile indicated to be a mixture of rotamers.
MS m / z CosHasN4O5sS (M + 1) * calculated 525.3, found 525. Acid 108. Acetic anhydride (60 uL, 0.64 mmol) was added to a solution of compound 107 (63 mg, 0.12 mmol) in pyridine (1 ml) at 5ºC.
The temperature was gradually raised to RT.
After allowing the reaction to proceed overnight, water (100 µL) was added.
After another 5 h, the volatile organics were removed under vacuum to give a residue that was passed if ————— «—x ———---——————- and —————. - [—————.—— n—— 101/114 through a reverse phase column (ACN: H2O, 0-100% with 0.1% TFA) to give acid 108 (42 mg) as a oil. * H NMR (400 MHz, CD; OD) 5 8.35 (s, 1H), 5.71 (dd, J = 11.4, 1.4 Hz, 1H), 4.63 (d, J = 9 , 1 Hz, 1H), 3.97 (t, J = 16.4 Hz, 1H), 3.65 3.42 (m, 2H), 3.21 3.05 (m, 2H), 2.87 (s, 3H), 2.34 2.14 (m, 4H) 2.13 (s, 3H), 2.03 1.46 (m, 10H), 1.29 1.06 (m, 1H), 1.04 0.85 (m, 15H). MS m / z CogHa7N4OsS (M + 1) * calculated 567.3, found 567. Example 22 - Schemes 18 and 19 Scheme 18 (figures 20a and 20b) shows the synthesis of the compounds of this invention using acid 108, prepared in preceding example.
General procedure for HATU-mediated coupling.
HATU (1.2x excess) and DIEA (4x excess) were added in a solution of acid 108 in DMF at 5ºC.
After stirring the reaction mixture for 10 min, the corresponding amine was added.
The reaction mixture was stirred for another 10 min before diluting it with DMSO and 0.1% TFA solution.
The resulting mixture was passed through a reverse phase column (ACN: H2O, 0-100% with 0.1% TFA). The collected fractions were analyzed and the desired U fractions were lyophilized to give the corresponding product. . Compound 109. Obtained from the coupling of acid 108 and phenylalaninamethyl ester.
MS m / z CagH5saN5sO; S (M + 1) * calculated 728.4, found 728.4. Compound 109 is also described above as a structure (Ill-x). Compound 111. Obtained from the coupling of acid 108 and compound 110 (preparation described below). MS m / z Ca2HesaNs6OsS (M + 1) * calculated 827 A, found 827.5. Compound 112. To a solution of compound 111 (5 mg, 6 umols) in 2 ml of MeOH was added Pd / C (10%, 10 mg). The reaction flask was filled with H7, using a flask and stirred for 2 h at RT.
The reaction mixture was then filtered, concentrated in vacuo and passed through a reverse phase column (ACN: H7O, 0-100% with 0.1% TFA) to give compound 112 (2.1 mg) as a white power.
MS m / z Ca2Hs7N5O7S (M + 1) * calculated 799.5, found 799.5. Compound 112 is also described above as a structure (Ill-y). Compound 114. Obtained from the coupling of acid 108 and compound
113 (preparation described below). MS m / z CaiHeaNsO7S (M + 1) * calculated 770.4, found 770.
Compound 116. Obtained from the coupling of acid 108 and compound 115 (preparation described below). MS nm / z CeiHosN11O013S (M + 2) * calculated 610.9, found 611. Compound 116 is also described further above as structure (VI-t).
Compound 117. Obtained from the coupling of acid 108 and alpha-N-acetyl lysine methyl ester. MS m / z C37He3N5OgS (M + 1) * calculated 751.4, found 751.5.
Compound 110. Some 59 of Scheme 8 (as ethyl ester instead of methyl ester, 1 g, 2.6 mmolis) was dissolved in DCM (10 ml) containing 5% TFA and the reaction mixture was stirred at 5 ° C . After 40 min, the mixture was dried in vacuo to give compound 110 (0.3 g, 100%) as a semi-solid. * H NMR (400 MHz, CD3OD) 5 8.22 8.17 (m, 2H), 7.50 (dd, J = 9.0.2.2 Hz, 2H), 6.58 (d, J = 10.0 Hz, 1H), 4.45 (td, J = 9.8, 5.3 Hz, 1H),: 4.19 (q, J = 7.1 Hz, 2H), 3.35 3, 28 (m, 1H), 3.06 (dd, J = 13.2, 9.6 Hz, 1H), 1.55 (d, J = 0.9 Hz, 3H), 1.27 (t, J = 7.1 Hz, 3H).
: Compound 113. HC! (2.5 ml, 10 mmolis, 4 M) was added to a solution of compound 118 (2 g, 5.5 mmolis, Peltier et al. 2006) in MeOH (10 ml) and the reaction mixture was stirred in RT. After 20 min, the reaction mixture was dried in vacuo to give compound 113 (2 g, 100%) as a semi-solid. Crude product was used for the next step reaction without further purification. MS m / z C13H, 9NO> (M + 1) * calculated 222.1, found 222.
Hey
AO TT HCHHAN CO, Me CO, Me 118 113 Scheme 19 (figure 21) shows the synthesis of compound 115, using synthesis of compound 116, above.
Compound 120, DIEA (697 µl, 12 mmol) and valine t-butyl ester 543 (627 mg, 3 mmol) were added in a 10 ml solution! in
DCM of 6-maleimidoexanoic acid ("6G-MHA", 622 mg, 3 ml) and HATU (1.14 g, 3 mmols). After 20 min, EtOAc (200 ml) was added. The organic phase was washed with 10% citric acid, NaHCO solution; sat., and brine, then dried with anhydrous Na2SO and the solvent was removed by evaporation. The resulting residue was passed through a column (Hexane: EtOAc, 0-80%) to give compound 120 ( 900 mg) as an oil. 1 H NMR (400 MHz, CDCl 3) 5 6.66 (s, 2H), 5.94 (d, J = 8.5 Hz, 1H), 4.44 (dd, J = 8.7, 4.5 Hz, 1H), 3.49 (t, J = 7.2 Hz, 2H), 2.31 2.06 (m, 3H), 1.73 1.54 (m, 4H), 1.45 (s , 9H), 1.37 1.25 (m, 2H). MS m / z CioH3: N2Os (M + 1) * calculated 367.2, found 367.
Compound 121. Compound 120 (19g, 2.73 mmolis) was dissolved in 20 ml of DCM with 3 ml of TFA in RT. After 1 h, the mixture was dried by evaporation to give compound 121 (19) as an oil which was used without further purification. MS m / z CisH23N2Os (M + 1) * calculated 311.2, found311. : Compound 123. DIEA (920 µl, 5.28 mmol) and compound 122 (500 mg, 1.32 mmol; see Scheme 22 and Example 25 below) were. added to a 10 ml solution! Fmoc-protected citrulline (524 mg, 1.32 mmol) and HATU (601 mg, 1.58 mmol). After 20 min, 200 ml of EtOAc was added. The organic phase was washed with 10% citric acid, NaHCO solution; sat., and brine. It was then dried with Na> SO, anhydrous and the EtOAc was evaporated. The resulting residue was passed through a column (MeOH: DCM; 0-10%) to give a solid. This solid was dissolved in DMF (5 ml) with 5% piperidine. After 1h, the solution was evaporated and the residue was passed through a reverse phase column (ACN: H2O; 0-100% with 0.1% TFA) to give compound 123 (212 mg). MS m / z C27Ha6N5O6 (M + 1) * calculated 536.3, found 536.4. Compound 124, DIEA (404 µl, 24 mmol) and compound 560 (321 mg, 0.6 mmol) were added in a 5 ml solution! of compound DMF 550 (180 mg, 0.58 mmol) and HATU (220 mg, 0.58 mmol). After 20 min, 200 ml of EtOAc was added. The organic phase was washed with 10% citric acid, NaHCO solution; sat., and brine. It was then dried with
Au «o« or use in a non u ur EEEEEE 104/114 Na2SO, anhydrous and EtOAc is evaporated.
The resulting residue was passed through a column (MeOH: DCM; 0-20%) to give compound 124 (240 mg) as an oil.
MS m / z CaoHesN7O1o (M + 1) * calculated 828.5, found 828.5. | Compound 115, Compound 124 (240 mg, 0.29 mmol) was dissolved in about 5 ml TFA and DCM solution (1: 1). After 3 h the mixture was dried by evaporation and the resulting compound 115 was used without further purification.
From NMR, a mixture of two (5: 1) isomers were obtained.
The main isomer is reported: * H NMR (400 MHz, CD; OD) ô 8.27 (d, J = 7.5 Hz, 1H), 7.58 (dd, J = 8.5, 1, 9 Hz, 2H), 7.21 (d, J = 8.5 Hz, 2H), 6.79 (s, 2H), 4.48 (dd, J = 13.3, 8.1 Hz, 1H) , 4.14 (dd, J = 7.5, 4.9 Hz, 1H), 3.62 3.38 (m, 3H), 3.25 2.97 (m, 3H), 2.96 2, 78 (m, 2H), 2.70 2.40 (m, 1H), 2.32 2.21 (m, 2H), 2.11 1.92 (m, 2H), 1.94 1.83 ( m, 1H), 1.82 1.70 (m, 1H), 1.70 1.49 (m, 7H), 1.19 (d, J = 7.0 Hz, 3H), 0.97 (dd , JU = 6.8, 2.8 Hz, 6H). MS m / z Ca3Hs5oN; 7Os (M + 1) * calculated 672.4, found 672.: Example 23 - Scheme 20 Scheme 20 (figure 22) shows the synthesis of compound 131, a - intermediate used to make the compounds of this invention .
Compound 125. Compound 9 of Scheme 1 (3 g, 8.29 mmols) was dissolved in THF (20 ml) and dimethyl sulfate (1.2 ml, 12.4 mmols). To this solution was added NaH (552 mg, 13.8 mmols) at 5ºC in portions for 1.5 h.
The reaction mixture was then poured into NH, CI sat.
EtOAc was added to the reaction mixture and the organic phase was washed with brine and dried and evaporated in vacuo to give a residue.
The resulting residue was passed through a column (Hexane: EtOAc, 0-100%) to give compound 125 (1.2 g) as an oil. * H NMR (400 MHz, CDCl3) 5 8.12 (s, 1H), 4.95 (dd, JU = 10.0, 3.3 Hz, 1H), 3.89 (s, 3H), 3, 50 (s, 3H), 3.45 3.40 (m, 2H), 1.93 1.79 (m, 2H), 1.74 1.65 (m, 1H), 1.20 (s, 9H ), 0.84 (d, J = 6.8 Hz, 3H), 0.80 (d, J = 6.8 Hz, 3H). MS m / z CisH2oN204S2 (M + 1) * calculated 377.1, found 377.2. Compound 126. HCl in dioxane (1 ml, 4 mmols) was added to a solution of compound 125 (0.7 g, 1.86 mmol) in MeOH (10 ml). THE
—CUÚUÚuÚÚÚ ——— Ú ————————————————- / == 105/114 reaction mixture was stirred at RT. After 20 min, the volatiles were evaporated under vacuum to give compound 126 (0.8 g) as an oil that was used for the next reaction step without further purification. MS m / z C12H21N203S (M + 1) * calculated 273.1, found 273.
Compound 127. To a solution of compound 126 (616 mg, 2 mmol) in DCM (10 ml!) And DIEA (1.8 ml, 10 mmol) at 5 ° C, compound 103 (Scheme 17, 6 mmol) was added in 5 m! of DCM. The reaction mixture was stirred for 3 h at RT. After 3 h, the reaction mixture was poured into NaHCO solution; sat. and EtOAc. The organic phase was washed with brine, dried, and evaporated. The resulting residue was passed through a column (Hexane: EtOAc, 0-50%) to give compound 127 (594 mg, 72%) as a semi-oil. 1 H NMR (400 MHz, CDCl 3) 5 8.18 (s, 1H), 6.47 (d, J = 9.9 Hz, 1H), 4.60 4.52 (m, 1H), 4.23 4.13 (m, 1H), 3.96 3.95 (m, 1H), 3.94 (s, 3H), 3.44 (s, 3H), 2.21 2.08 (m, 1H) , 1.94 1.84 (m, 2H), 1.84 1.71 (m, 1H), 1.52 1.38 (m, 1H), 1.35 1.20 (m, 1H), 1 .07 (d, J = 6.9 Hz, 3H), 0.95 0.85 (m, 9H).
: 1 C NMR (101 MHz, CDCl 3) 5 176.00, 168.63, 161.92, 146.90, 128.24, 78.81, 70.34, 58.97, 52.72, 50.76 , 40.48, 38.62, 32.24, 24.32, 19.13, 18.13, 16.25,. 11.82. MS m / z CisH3oNsO4S (M + 1) * calculated 412.2, found 412.3. Compound 129. Potassium hexamethyldisilazide ("KHMDS", 0.19 mmol, 0.375 ml of toluene solution) was added in a THF solution (0.5 ml!) Of compound 127 (50 mg, 0.12 mmol) to 43ºC. After 20 min, compound 128 (0.36 mmol, 137 µL, Abe et al. 1997) was added. After 2 h, 100 µl of MeOH was added and the reaction mixture was poured into NH, CI sat. EtOAc was then added. After separating the layers, the organic phase was washed with brine, dried with Na2zSO, anhydrous and the solvent removed by evaporation. The resulting residue was passed through a column (Hexane: EtOAc, 0-50%) to give compound 129 (51 mg) as a semi-solid. '* H NMR (400 MHz, CDCI;) 5 8.16 (s, 1H), 5.70 (s, 1H), 5.43 (d, J = 12.4 Hz, 1H), 5.32 ( d, J = 12.3 Hz, 1H), 4.39 (d, J = 10.6 Hz, 1H) 3.92 (d, J = 11.7 Hz, 3H), 3.53 3.44 ( m, 1H), 3.37 (d, J = 10.5 Hz, 3H), 2.41 (d, J = 7.2 Hz, 2H), 2.37 2.11 (m, 4H), 1 , 92 - 1.68 (m, 2H), 1.37 1.21 (m, 1H), 1.12 - 0.85 (m, 18H). C NMR (101 MHz, CDCl3) 5 175.24,
o ———— <ccc dO - »————» q àxo mv »vxpxxq E ———— sssspssss cssmmss = - msm 106/114 172.79, 171.21, 161.90, 147.09, 128 , 25, 78.44, 68.69, 63.35, 58.71, 52.48, 43.23, 38.63, 34.91, 31.01, 25.73, 25.25, 22.58 , 22.56, 22.48, 20.45, 19.62, 16.14, 10.65. MS m / z CoaHaoNsOsS (M + 1) * calculated 526.3, found 424.3 (breakage of N, O acetal). Compound 130. Compounds 129 (200 mg, 0.38 mmol) and 105 (Peltier et al. 2006; 4 mmols) were mixed in 5 ml of EtOAc with Pd / C (150 mg, 10%) in RT. The reaction flask was evacuated and refilled with H using a balloon. After stirring overnight at RT, the mixture was filtered and the solvent evaporated. After column chromatography (SiO3, MeOH: DCM, 0-10%), compound 130 (97 mg) was obtained as a solid. MS m / z C31H53N, O7S (M + 1) * calculated 625.4, found 625.5.
Compound 131. Tribuyltin hydroxide (181 mg, 0.59 mmol) was added to a solution of compound 130 (97 mg, 0.16 mmol) in 10 m! 1,2-dichloroethane. After 22 h at 67 ° C, the mixture was evaporated and passed through a reverse phase column (ACN: (20 mM NH (HCO;) buffer, pH '7), 5-100%) to give compound 131 (34 mg) like a solid. MS m / z CaoHs: N4O7S (M + 1) * calculated 611.3, found 510 (break in N, O. acetal). Example 24 - Scheme 21 Scheme 21 (figure 23) shows the synthesis of the compounds of this invention using compound 131 as a precursor.
Compound 132. Compound 60 (Scheme 8, 200 mg, 0.57 mmol) was dissolved in 2 ml of DOM with 20% TFA in RT. After 1 h, the volatiles were evaporated to give compound 132 (200 mg) as a yellow solid that was used without further purification.
Compound 133. DIEA (43 µl, 0.2 mmol) was added to a solution of DMF (1 ml) of compound 131 (30 mg, 0.049 mmol) and HATU (22.3 mg, 0.059 mmol) at 43 ° C. After 10 min, compound 132 (15 mg, 0.06 mmol) was added. The mixture was then raised to RT. The final mixture was passed through a reverse phase column (ACN: (20 mM NHaA (HCO3) buffer, pH 7), 5-100%) to give compound 133 (20 mg) as a white powder . MS m / z CasH73N6OgS (M + 1) * calculated 843.5, found 843.5.
107/114 Compound 133 is also described further above as structure (Ill-u). Compound 134. Compound 133 (2 mg, 2.4 umols) was dissolved in 0.5 m! of methanol and the pH of the solution was adjusted to 1 with 1M HCI.
After stirring overnight, the volatiles were evaporated and the residue was passed through a reverse phase column (ACN: (20 mM NH, (HCO; 3) buffer, pH 7), 5-100%) to give the compound 134 (0.7 mg) as a white powder.
MS m / z CaoHessNsO; S (M + 1) * calculated 773.5, found 773.5. Compound 134 is also described further above as the structure (Ill-v). Compound 135. Compound 133 (2 mg, 2.4 umols) was dissolved in 0.5 ml of n-propanol and the pH of the solution was adjusted to 1 with IM HCl.
After stirring overnight, the mixture was evaporated and the residue was passed through a reverse phase column (ACN: (20 mM NH, (HCO; 3) buffer, pH 7), 5-100%) to give compound 135 (0.4 mg) as a white powder.
MS m / z Ca2HeoNsO; 7S (M + 1) * calculated 802.5, found 801.5. Compound 135 is also described further above as structure (Ill-w). Example 25 - Scheme 22 Scheme 22 (figure 24) shows a method for making compound 142, useful as an intermediate for making the compounds of this invention.
Compound 136. NaOH (800 µl, 10M, 8 mmols) was added to a solution of 20 ml of THF and MeOH (1: 1) with compound 59 of Scheme 8 (1.65 g, 4.37 mmoles). After stirring overnight, the pH of the solution was adjusted to 1 with 3N HCI at 5 ° C.
After evaporation of the solvents, 200 ml of EtOAc was added.
After separation, the organic phase was washed with brine, dried with Na2zSO, anhydrous and the EtOAc evaporated.
The residue was passed through a column (MeOH: DCM; 0-10%) to give compound 136 (1.2 g) as an oil. * H NMR (400 MHz, CDCI;) 5 8.21 8.12 (m, 2H), 7.41 7.32 (m, 2H), 6.62 (d, J = 8.8 Hz, 1H) , 4.82 4.57 (m, 2H), 3.45 3.02 (m, 1H), 2.90 (dd, J = 13.3, 7.2 Hz, 1H), 1.71 (d , J = 1.2 Hz, 3H), 1.41 (s, 9H). Compound 137. DMF-di-t-Butylacetal (1 ml, 4 mmol) was added to a 6 ml solution of toluene of compound 136 (128 mg, 0.36 mmol) at 133 ° C.
After 10 min, the reaction mixture was cooled and the solvent
—P—— ww es sssc— - 108/114 evaporated.
The residue was passed through a column (Hexane: EtOAc; 0-30%) to give compound 137 (133 mg) as an oil. * H NMR (400 MHz, CDCl3) 5 8.19 8.10 (m, 2H), 7.39 7.30 (m, 2H), 6.39 (dd, J = 9.1, 1.5 Hz , 1H), 4.63 (d, J = 39.1 Hz, 2H), 3.03 (dd, J = 13.2, 6.2 Hz, 1H), 2.90 (dd, JU = 13, 3, 7.0 Hz, 1H), 1.67 (d, J = 1.5 Hz, 3H), 1.47 (s, 9H), 1.39 (s, 9H). Compound 122. Compound 137 (540 mg, 1.22 mmol), Pd / C (136 mg, 10%) and 3N HC! (0.3 ml) were added to a mixture of DCM and MeOH (30 ml: 5 ml). The flask was filled with H2> using a balloon.
After stirring overnight at RT, the mixture was filtered and concentrated to give compound 122 (550 mg) as a semi-solid.
MS m / z Ca1H35N2O, 4 (M + 1) * calculated 379.3, found 223 (loss of Boc). Compound 138. Compound 136 (100 mg, 0.28 mmol) and Pd / C (20 mg, 10%) were mixed in a 5 ml mixture! of MeOH and DCM (1: 1 v: v) under a hydrogen balloon in RT.
After stirring overnight, the mixture was filtered and the solvents evaporated in vacuo to give compound 138: (95 mg) as an oil which was used for the next reaction step without further purification.
MS m / z C17H27N2O, 4 (M + 1) * calculated 323.2, found 223. - Compound 139. Compound 138 (10 mg, 0.03 mmol), tert-butyldimethylsilyl chloride ('TBDMSCI ", 4,5 mg, 0.03 mmol) and imidazole (4 mg, 0.06 mmol) were mixed in 1 mM DMF in RT.
Fmoc-protected citrulline (24 mg, 0.06 mmol), N, N “-disuccinimidyl oxalate (" DSO ", 8 mg, 0.06 mmol) and DIEA (20 µL, 0.142 mmol) were mixed in an additional 1 ml ! of DMF in RT.
After 1 h, the two solutions were mixed and the mixture was maintained in RT.
After stirring overnight, EtOAc was added and the solution was washed with 10% aq. and brine.
The organic phase was then dried with Na2SO, anhydrous and evaporated in vacuo.
The resulting residue was passed through a column (MeOH: DCM, 0-10%) to give compound 139 (7 mg) as an oil.
MS m / z CasHagNsOg (M + 1) * calculated 702, found 702. Compound 141. Compound 139 (10 mg, 0.014 mmol) was dissolved in 1 ml! DMF with 5% piperidine.
After 20 min, the solvent was evaporated in vacuo and the residue was mixed with N-succinimidyl-4-
maleimidobutyrate 140 (5.6 mg, 0.028 mmol) and DIEA (5 µL, 0.028 mmol) in 1 ml of DMF. After 10 min, the solvents were removed from the reaction mixture under vacuum and passed through a column (MeOH: DCM, 0-20%) to give compound 141 (6 mg) as a solid. MS m / z C3a: HasN5Os (M + 1) * calculated —645, found 645.
Compound 142. Compound 141 (6 mg, 0.01 mmol) was dissolved in 1 ml of DCM with 10% TFA. After 10 min, the solvent was evaporated in vacuo to give compound 142 (6 mg), used for the next reaction step without further purification.
Example 26 - Scheme 23 Scheme 23 (figure 25) shows the elaboration of compound 142, made by Scheme 22, in a compound of this invention.
Compound 145, HCI (30 µmols) in 150 µl MeOH was added to a solution of Scheme 2 compound 27 (5 mg, 8.3 µmol) in 0.7 ml MeOH at 5 ° C. The temperature was allowed to rise gradually 'to RT. After stirring overnight, the mixture was evaporated and dissolved in 0.7 pyridine. To this solution, Ac7O (28 ul, 296 ummois) was added - at 5ºC. The temperature was allowed to rise gradually to RT and after stirring overnight 50 µl HO was added. After 3 h, the volatiles were evaporated and the resulting residue was evaporated to give compound 145 (4.7 mg) as a semi-solid. MS m / z Co7HasN4O7S (M + 1) * calculated 569.3, found 569.
Compound 146. DIEA (6 µl, 34 µmol) and compound 142 (5.5 mg, 8.3 µmol) were added to 0.5 ml! of DMF solution of compound 530 (4.7 mg, 8.3 ummols) and HATU (3.2 mg, 8.4 umols) at 5ºC. After 20 min, the resulting mixture was passed through a reverse phase column (ACN: (20 mM NH4 (HCO; 3) buffer, pH 7), 5-100%) to give compound 146 (4.5 mg) like a white solid. MS m / z CsaH7aN0O0138S (M + 1) * calculated 1095.5, found 1095.5. Compound 146 is also described further above as a structure (Vl-r).
Compound 147. DIEA (1.4 µl, 8 umols) and a drop of NH, CI saturated solution were added in a solution of 0.5 ml of DMF of compound 146 (2 mg, 1.8 umol) and HATU ( 1.6 mg, 4.6 umolis). After 10 min, the mixture was passed through a reverse phase column (ACN: (20 mM NH4a (HCO; 3) buffer, pH 7), 5-100%) to give compound 147 (0.5 mg) as a semi-solid. MS m / z Cs3HgoN11O0128S (M + 1) * calculated 1094.6, found
1094. Compound 147 is also described further above as structure (Vl-s). Example 27 - Diastereomers of 4-aminotubphenylalanine Compound 122 (Example 25 above) was determined to be a 3: 1 mixture of diastereomers 148a and 148b as follows. NH, NH BocHN! and COt-Bu v "> COstBu 148a (3: 1 mixture) 148b Compound 122 (10 mg, 0.026 mmol) was dissolved in a mixture of 2mL TFA and DCM (1: 1) in RT. After 3 h, the solvents were evaporated and the residue was passed through a reverse phase column (ACN: H2O; 0-100% with 0.1% TFA) to give a 3: 1 mixture of "compounds 149a and 149b. The main isomer in this mixture was designated structure 149a comparing the NMR spectrum of the mixture with the NMR of an authentic sample of compound 149a made from compound 150. NH3TFA NH TFA TFA-HAN ”! E to C (mixture 3: 1) To Pd H2SO, << HCI-HAN HNO; 3 HCI-H2aN 'COH COH 151 150 HNO; concentrate (10 ul) was added to a solution of
—-—-—— «<-« »c <« aqqus ————— 111/114 200 µl H2SO, 150-tubphenylalanine concentrate (Peltier et al. 2006; 6 mg, 0.025 mmol) at 5 ° C. After 20 min, the solution was poured into 2 ml of cooled 7% K2CO; z solution. 10 ml of EtOAc was then added. After post-separation, the organic phase was dried by evaporation and the residue was passed through a reverse phase column (ACN: H2O; 0-100% with 0.1% TFA) to give the nitro compound 151 (5 mg). * H NMR (400 MHz, CD30D) δ 8.27 8.21 (m, 2H), 7.56 7.49 (m, 2H), 3.69 3.58 (m, 1H), 3.07 ( d, J = 7.2 Hz, 2H), 2.73 2.61 (m, 1H), 2.04 1.91 (m, 1H), 1.64 (ddd, J = 14.7, 8, 2, 4.9 Hz, 1H), 1.20 (d, J = 7.1 Hz, 3H). MS m / z CiH17N204 (M + 1) * calculated 253.1, found 253.
Nitro compound 151 then converted to compound 149a as follows: nitro compound 151 (5 mg, 0.01 mmol) was mixed with Pd / C (10 mg, 10%) in 5 ml! of MeOH in RT. The flask was filled with H2 using a balloon. After 1 h, the mixture was filtered and evaporated to give compound 149a (4.5 mg). 1 H NMR (400 MHz, CD3; OD) 5 7.08 7.03 (m, 2H), 6.83 6.79: (m, 2H), 3.51 3.41 (m, 1H), 2 , 84 2.78 (m, 2H), 2.68 2.58 (m, 1H), 2.04 1.92 (m, 1H), 1.60 (d, J = 7.8 Hz, 1H) , 1.18 (d, J = 7.0, Hz, 3H). MS m / z - Cr12Hi9N20> 2 (M + 1) * calculated 223.1, found 223. This NMR spectrum was the basis for assigning the main component structures of mixtures 148a / 148b and 149a / 149b.
A sample of compound 122 was passed through a reverse phase column (ACN: H2O; 0-100% with 0.1% TFA) and the fractions were collected with the secondary isomer and lyophilized. The resulting product was then treated with TFA and DCM to remove the Boc group. After 1 h, the solvents were evaporated to give a product that was assigned to be compound 149b after comparing its NMR spectrum with that of compound 149a. Compound 149b: '* H NMR (400 MHz, CD; OD) 7.36 7.23 (m, 2H), 7.22 7.09 (m, 2H), 3.59 3.40 (m, 1H) , 3.04 2.84 (m, 2H), 2.61 2.45 (m, 1H) 2.07 1.87 (m, 1H), 1.73 1.58 (m, 1H), 1, 21 1.09 (d, J = 7.2 Hz, 3H).
Compounds 148a, 148b, 149a, and 149b can be used to prepare the compounds of this invention having a 4-aminotubphenylalanine subunit where the stereochemistry of the alpha-methyl group is defined,
«R« —— 2C »* <————————-—————. M <——.——— c« «s — sspc ———.... sssssssS-- .. .-. JJ-sssssssssssssss ss 112/114 using the synthetic approaches exemplified above, mutatis mutandis. Compounds 82a and 82b (Example 17) can also be put to similar use. The previous detailed description of the invention includes passages that S are mainly or exclusively related to the particular parts or aspects of the invention. It is to be understood that this is for clarity and convenience, that a particular feature may be relevant to more than just the passage being described, and that the description here includes all the appropriate combinations of information found in the different passages. Similarly, although the various figures and descriptions here refer to the specific modalities of the invention, it is to be understood that where a specific characteristic is described in the context of a particular figure or modality, that characteristic can also be used, in the appropriate proportion, in the context of another figure or modality, in combination with another characteristic, or in the invention in general. : Yet, although the present invention has been particularly described in terms of certain preferred embodiments, the invention is not limited to such preferred embodiments. Rather, the scope of the invention is defined by the appended claims.
REFERENCES Total citations for the following references cited in abbreviated form by the first author (or inventor) and most recent date in this descriptive report are provided below. Each of these references is incorporated by reference here for all purposes. Abeetal, WO 97/21712 (1997). Boyd et al., US 2008/0279868 A1 (2008). Boyd et al., US 7,691,962 B2 (2010). Balasubramanian et al., Bioorg. Med. Chem. Lett. 2008, 18, 2996-2999. Balasubramanian et al., J. Med. Chem. 2009, 52 (2), 238-240. Davisetal. US 2008/0176958 A1 (2008). Domling, DE 10 2004 030 227 A1 (2006). Domling et al., US 2005/0239713 A1 (2005) [2005a].
———— Ú »—————————— Ô ———» ——— »————— MMMMMM 113/114 Domling et al., US 2005/0249740 A1 (2005) [2005b] . Domling et al., Mol. Diversity 2005, 9, 141-147 [2005c]. Domling et al., Ang. Chem. Int. Ed. 2006, 45, 7235-7239. Ellman et al., WO 2009/012958 A2 (2009). Hameletal, Curr. Med. Chem. - Anti-Cancer Agents 2002, 2, 19-53. Hoefle et al., DE 100 08 089 A1 (2001). Hoefle et al., Pure Appl. Chem. 2003, 75 (2-3), 167-178. Hoefle et al., US 2006/0128754 A1 (2006) [2006a]. Hoefle et al., US 2006/0217360 A1 (2006) [2006b]. Kauretal, Biochem. J. 2006, 396, 235-242. Khalil et al., ChemBioChem 2006, 7, 678-683. Leamon et al., Cancer Res. 2008, 68 (23), 9839-9844. Leamon et al., WO 2009/002993 A1 (2009). Leung et al., US 2002/0169125 A1 (2002). Lowetal. ,, WO 2009/026177 A1 (2009). . Lundquist et al., Org. Lett. 2001, 3, 781-783. Neri et al., ChemMedChem 2006, 1, 175-180. - Patterson et al., Chem. Eur. J. 2007, 13, 9534-9541. Patterson et al., J. Org. Chem. 2008, 73, 4362-4369.
Peltieretal., J. Am. Chem. Soc. 2006, 128, 16018-16019. Reddy et al., Mol. Pharmaceutics 2009, 6 (5), 1518-1525. Reichenbach et al. WO 98/13375 A1 (1998).
Richter, WO 2008/138561 A1 (2008). Sani et al., Angew. Chem. Int. Ed. 2007, 46, 3526-3529.
Sasseetal, J. Antibiotics 2000, 53 (9), 879-885.
Sasse et al., Nature Chem. Biol. 2007, 3 (2), 87-89. Schluep et al., Clin. Cancer Res. 2009, 15 (1), 181-189. Shankar et al., SYNLETT 2009, 8, 1341-1345.
Shibue et al., Tetrahedron Lett. 2009 50, 3845-3848.
Steinmetz etal., Angew. Chem. Int. Ed. 2004, 43, 4888-4892. Ullrich et al., Angew. Chemie Int. Ed. 2009, 48, 4422-4425. Viahov et al., Bioorg. Med. Chem. Lett. 2008, 18 (16), 4558-4561 [2008a].
TCU »—————————— m — m— .ss ss ...
114/1114 Vilahov et al., US 2008/0248052 A1 (2008) [2008b].
Vilahov et al., WO 2009/055562 A1 (2009).
Viahov et al., US 2010/0048490 A1 (2010).
Wang et al., Chem. Biol. Drug. 2007, 70, 75-86.
Wipfetal., Org. Lett. 2004, 6 (22), 4057-4060. Wipf et al., Org. Lett. 2007, 9 (8), 1605-1607. Wipf et al., US 2010/0047841 A1 (20710).

权利要求:
Claims (3)
[1]
1. Compound, characterized by the fact that it presents a structure represented by the formula (1!) Hu o o QU, ALI p Ay to RR O R 'q so) 4 in which ne o, 1, or2; R ', R and R ° are independently H, C1-Cro unsubstituted or substituted alkyl, C2-C1.5 unsubstituted or substituted alkyl, C2-C15 alkyl-. - unsubstituted or substituted nilains, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, (CH2): - 2O (C1-C19 alkyl) unsubstituted or substituted, (CH2) ..> O (C2-C16 alkenyl) unsubstituted or substituted, (CH2): - 20 (C2-Cio alkynyl) unsubstituted or substituted, (CH2) .- 2OC (= O) (C1-C1o alkyl), o (CH2): - 2OC (= O) (C2-C1o / alkenyl ) unsubstituted or substituted, (CH) 20C (= O0X (C2-C1,5 alkynyl) unsubstituted or substituted, C (= O) (C1-C1o alkyl). 'unsubstituted or substituted, C (= O) (C2-C19 alkenyl) unsubstituted or substituted, C (EO) (C2-C10 alkynyl) unsubstituted or substituted, unsubstituted or substituted cycloaliphatic, unsubstituted or substituted heterocycloaliphatic, unsubstituted or substituted arylalkyl, substituted or substituted alkyl, NH; NH; NHz coH coH CoH; NH & O (CH2) 1-3CH3 *% PCcoH; *% CoH; or with:; and Rº is H, C1-Cs alkyl, Cz-Cs alkenyl, C2-Cs alkynyl, CO (C1-Cs alquita), CO (C2-C; s alkenyl), or CO (C2-Cs here nila); or a pharmaceutically acceptable ester thereof, an
pharmaceutically acceptable amide of the same in the carboxyl group of R with the α-amino group of an α-amino acid, or a pharmaceutically acceptable salt thereof.
A compound according to claim 1, characterized by a polyphode that has a structure represented by the formula (Il-a) hu o o RRKR so where Rº is: NH : E, E (CH2) asCHs * COH 2 *% com, or color.
3. Composed according to claim 2, characterized by the fact that it has a structure represented by the formula (Il-a "): oo à oo. No) Ai" (a) oo O NR Ss where Rº is H , Alkyl Cr-Cs, alkenyl C2-Cs, CH2O (C1-Cs alkyl), CH2O (C2-Cs alkenyl), CHO (C = O) (C1-Cs alkyl), or CHIOC (= 0) (C2-Cs alkenyl); and R 'is H, C1-Cs alkyl, C2-Cs alkenyl, C (= 0) C1-Cs alkyl, or C (= 0) C2-C5 alkenyl.
4. Composed according to claim 1, characterized by the fact that it has a structure represented by the formula (1l-b): bz hu o GREAT AA, ab) Dô RR S 'CoH:
5. Composed according to claim 4, characterized by the fact that it has a structure represented by the formula (II-b "):
NH no o 'CL Ee ab) PNR $' COH where Rº is H, Cr-Cs alkyl, CC; alkenyl, CH2O (C1-C5 alkyl), CH2O (C2-Cs5 alkenyl), CHO (C = OX (C1-Cs alkyl), or CHOC (= 0) (C2-Cs alkenyl); and
5. R is H, C1-Cs alkyl, C2-Cs alkenyl, C (= O) C1-Cs alkyl, or C (= 0) C2-Cs alkenyl.
6. Compound according to claim 1, characterized by the fact that it has a structure according to the formula (Ill-a), III-b), (lo), (1d), (Ht-e) , (HIP, (Hi-g), (UT-h), (MLS, (HT), CI-K), (UI-D, CM), (Hl-n), (lilo), (1I-p ), (Hl-g), (HI), CHl-s), (ME, (Hu), (Hlv), (sw), or (Hy) OO 7. A compound according to claim 1, characterized by p - the fact that it has a structure represented by the formula (Il-c) 2 “O! MM” O ex RB 8 COLRS where R "* is Me, n-Pr, CH2OMe, or CHOC (= 0) CHzCH (Me ) 2; R ** is Me orC (= O) Me; and R "* is H or C; -C; alkyl.
8. Conjugate, characterized by the fact that it comprises a compound as defined in claim 1 conjugated to an antibody.
9. Conjugate, characterized by the fact that it has a structure represented by the formula (IV): [DEP) CEP) ImZ (IV) in which D is a compound according to claim 1; Z is an antibody;
Xº and X * are spacer groups; C is a cleavable group at the site of D's intended biological action; each of a and b is independently 0 or 1; and m, 1,2,3,4,5,6,7,8,9, or 10.
10. Substance composition, characterized by the fact that it has a structure represented by the formula (V-a) D 0P) .CEP) o Rº! (va) where R ** is a functional group suitable for reacting with a group. - functional in an antibody; D is a compound according to claim 1; XP and X are spacer groups; C is a cleavable group at the site of the intended biological action of .... 15 Each of a and b is independently O or 1. oO 11. Substance composition, characterized by the fact that it has a structure represented by the formula (Vb) hu oo & QUA ALI A aaa) (Vb) RÔ Rg s / Éd where ne oO, 1, ou2; R ', R and Rº are independently H, C1-Co unsubstituted or substituted alkyl, C2-C; 1.9 unsubstituted or substituted alkenyl, C2-C ,, unsubstituted or substituted alkynyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, (CH2) .- 2O (C1-C109 alkyl) unsubstituted or substituted, (CH2) 1.2O (C2-C109 alkenyl) unsubstituted or substituted, (CH2) 1-20 (C2-Cro alkynyl) unsubstituted or substituted, ( CH2) .- 2OC (= 0) (C1-C15 alkyl), (CH2) -2OC (= 0) (C2-C19 / alkenyl) unsubstituted or substituted, (CH2). 20C (= 0) (C2-C 19 alkynyl) unsubstituted or substituted, C (= O) (C1-C1o alkyl) unsubstituted or substituted, C (= O) (C2-Co alkenyl) unsubstituted or substituted, C ( = EO) (C2-C19 alkynyl) unsubstituted or substituted, cycloaliphatic
substituted or substituted, unsubstituted or substituted heterocycloaliphatic, unsubstituted or substituted arylalquita, or unsubstituted or substituted alkylaryl; D Net NH nt Fa | CORE cof COLOR i NH 2 ne NH i O OP with COLOR co COLOR x co4 * cod, (CH2) o3CH3 where R ' is H, C1-Cs alkyl, C2-Cs alkenyl, or C2-Cs alkynite; and R $ is H, C1-Cs alkyl, C2-Cs alkenyl, C2-Cs alkynyl, CO (C1-Cs alkyl), CO (C2-C; alkenyl), or CO (C2-Cs alkynyl); XP and Xº are spacer groups; C is a cleavable group; and a and b are independently O or 1; wherein the group R * 'is attached to it by means of a carboxyl or amine group in any group Xº in the event of a to be 1 or to the group C in the e-ventodeaserO.
12. Substance composition, characterized by the fact that it has a structure represented by the formula (V-d): o 16 DERA, »ie. TN go where. R "* is Me, n-Pr, CH2OMe, or CHOC (= 0) CHCH (Me)>; R ** is Me or C (= zOMe; Rº is H or CC; alguilaá Rº is (CH) NH or * (CHI); NHC (= O) NHz; R ' Is C (Me) 2 or Me; and foot 0 or 1.
13. Use of a compound as defined in claim 1, or a conjugate as defined in claim 8, characterized by the fact that it is in the preparation of a drug to treat cancer in a subject suffering from such a disease. oo 14. Compound, characterized by the fact that it has a structure according to the formula (VIll-a) NO ç (VIII-a) R'HN
COR where R is H or an amine protecting group and Rº is H, C; -C1, alkyl, C2-C10 alkenyl, C7-C19 alkynyl, aryl, cycloaliphatic, alkylcycloaliphatic, arylalkyl, or alkylaryl.
15. Compound, characterized by the fact that it has a structure according to the formula (VIIl-b) NHRº Cç (VIII-b) R $ ºHN COR!
where Rº and R'º are independently H or an amine protecting group and R ** is H, C1-C19 alkyl, C2a-C10 alkenite, C2-C19 alkynyl, aryl, cycloaliphatic, alkylcycloaliphatic, aritalkyl, or alkylaryl,
NA SN o NS "" DN À 1/27 Fig.
Ta Scheme 1 (part 1 of 2) oEt om OEt o Eto.
OEt Ta ES and EN —— and NE moves Ss Ss 1 2 3 o Hei N - nO Sove Ss | 4 | 8. x TKOEN, 2 XL LDA À No ox "> CITICOIPNs 6 7 9 FE 9 TIOEN, 9 to 9 É PY move Tamo So 0 one S ara RP Ss NaH 8 9 (Rº = H) ——> - 10 (Rº = Me ) Mel HH Oo FmocN ,. r oMe O | ro DS »q 22" FmocN ,,. Ho a Thou 2, AA Ny oe | Sl DIEA ”- s u 12
Fig. 1b Diagram 1 (part 2 of 2) à.
Piperidi | õ HATU ace H o We 9 phenyl methyl ester 23 Nº ”N Qu oros Cx 2 S HATU, DIEA | No. Scom ”| | 13 (RE = Me) “ºH> 14 (RE = H) | CeHs o: Ge A À DX L or NV Tt Co ST NT HATU, DIEA 16 (RF = Me) N2H> 18 (RF = H) H o OMe O Cet as RA Px N. coxMe Pos! S on D 19
3/27 | Fig.
[2]
2 Scheme 2 y o oH,, No. SN oo phenyl methyl ester Da kh, s HATU, DIEA, 27 AA CeHs H o oH w o f Oo.
Ss ”“ o Pyridine 28 AA | the es. o IS o CC 'Hei, ON, N Feb NN TR Co, Me oh' 29 Ah CeHs Nº "EN 7 7 N“ cove MeóOH Po s “o 29b | o à o A oa ne NS ET 'with Me Nat, | LR NY H MezSO, oo 29a! Pa CsHs À À j FNXL go AA AAA cone Po ts Ss 290!
Fig.
[3]
3 Layout 3 Os:)
NY TOO | TFA OD z Eee H i "Do ON“ ow ii. Na; CO, z, CEPT ON “ow | o | NY! (CF38S02), 0 O MeCH (CO2E), and Y Ma nc o 2 Ô Pyridine ON“ ot NaH 31: ox I. HCl, HOAc DS li DMP, HC! NHRS vo tr Y - 4 CO-Et iii, (Boc) 2O, EtN OX Bcc.Rº
ON ON By: Y 32 33 (RS = Me, TC> 34 (RS = H, R '' = Boc) RE = H) o "o O o | CN number you i. Pentafluorophene! J. DIEA Í A Ss 34a
H 9 R 35 RU = NO, & - A o o Pdic Qt IA 36 RH = NH, Nº “O [N E N DMP, ta So HH Hc! . Da 'coH 36a (Methyl ester 36)
Fig. 4 | Scheme 4 the NH Cree Ho Vs the HO xwHEMOS | pes AN A, x A | | DA HATU 9 S CcOoH 36 | (I believe | no 9 MW NHFmoc EEDESS 0 Pra ONO) x 8 Td 84 H tocenaço) - SS 'COH 2 37 | | CC "gp = 9 Wi x PEA o o o SA CLAI, - os" coH 38 R '= NHBoc - TFA 39 R' = NH, and TFA
6/27 | Fig. 5 Scheme 5 o oH o OH o Ss N He! N xx gr om ", HcletHN 7 7 om Ss Ss 441 42 o: o OH o i. Chloride N TESOTI, Non - deoxalia Nor. E oa 2,6-lutidine NS li. Compound 42 ES DIEA | 42a 43 oOTES O o o | o Na ... N Qu on: HOAc, HO Na ... N Qu os: O RK s A Ss | k i. KHIMDS x Lt i. KAMDS L 44 (RÉ = H) -> 45 (RÉ = Me) 46 (Rà = H) - => 47 (Rb = Me) ii. Honey ii. Honey Hx, PIC HE VN A i.Pentafluorophenol, DIC. R 1.Pentafluorophenol, DN ENO A or> QL To! S ii. Cpd. 34, DIEA as 2OC6Fs v Pd; 48 (RU = Et) FP »49 (RV = H)
RN OESDES: a). N Ppdc TAC "E" A 51 RN = NH, 'COH i 71/27 Fig. 6 Scheme 6 o OH NO RL. N qo i.Pentafluorophenol, DIC Dor, Ss ii. DIEA, 27 dh Compound 42 o NO,
AQ ITA v N ,. N ACO AAA, O COH Pyridine 52 AA |
WED à N Ha, PIC N N O o. ——. oh, Ss COH 53 AA o NH> ev,. , N
EO oh, $ COH “2 54 AA
Fig. 7 Scheme 7 o: N N i.Pentafluorophenol, DIC vw TC) 7 janoPhe o S DEEM 34a Ô NO, i Êp oO as o - vw N ,. N Ha, Pd / C N N Cr Neo A—— | | O . | Ss 55 o NH> ng O a o & ", N Nº Ne a Pa COH Po! S 56
Fig. 8a Scheme 8 SI oe (Boc); SI one i.
DIBAL: CA í e ON Co Me TEA ON CO Me à POEhs 57 58 Treo OE Ha, PdiC Cx, í - iON Sa HJ Na 59 60 Fig. 8b 'Diagram 9 - DK - Hz Pe OE ON Se - Ho Se 34 61 Fig. 8c Figure 10 E, Ha, Pale SI with ON one HAN Neon 33 62
| 10/27 | Fig. 9 Scheme 11 NH> NH (Boc) -; HATU + 7, LOH (Bpoc) HN HO. À E NHCbz 'CO Me VT 62a 63 (CO risoo NÃ i. H / Pd-C MW NHCbz = jiHATU Oo ——-———
NV i (Bpoc) HN "HOCN AN $ coH il. HOAC (Cras o AR
NA AN AN HATU YR Cpd. 34a Õ o = —— HoN 65 | 'coH
CF "o x TA o o dA N CT POST 1 o S with 66 RP = Boc - TFA 67 RP = H
| 11/27 Fig. 10 Scheme 12 the NHBoc in the Ps o ais AN, A Ny on + HATU to! Ss HoN "CO Me 34a 68 o NHBoc - o Ps o 1 TFA À N - Nº“ CON PY ii. LIOH: Pak! Ss SS 'COsMe | 69 o NH> o a o
H GA, AA, E s SS COoH 36
Fig. 11a | HL-60 * H Thymidine Proliferation Assay | E | õ 25000 <= = Compound 54 | It's 20000: ”Y Compound 29 | E and A CBI - 15000 SE VV x v Tub.D | ; * e * Compound 51 S 10000 | 8 à S 5000 W à Ns. 8 0 o Get out | And 10th 10th 102 107 10º 10 '10º 10º Concentration (nM) Fig. 11b * H Thymidine 786-0 proliferation assay
Ê = 40000 "= = Compound 54 Ss ns to E v Compound 29 = 30000 CIA
E R A CBI = à | V À v Tub.D. ”20000: À Wo x Compound 51 2 ó 8 Ai: & 10000: S À gs S õ V & A 8 o pt s & 10º 103 10º 107 10º 10! 102 10th Concentration (lv)
| | Fig. 12a HL-60 "Dox ATP luminescence test
1500000.0 Y Compound (lll-p) Z Y Compound (lll-q) s -T 8 Compound 56 TM er Zz RARAS v TubD & 1000000.0: SA IF v TA, Compound 36 y) k kV S% * Compound 51 Ê 500000.0: A * Compound29a> 0.0: Dr. E Ai at 8 10 * 109º 10º 10º 10º 10º 10º 10 10th Concentration (nM) Fig. 12b ATP luminescence test of 786-0 "Dox Y Compound (Ill-p)
7500000.0 x Z y Compound (I11-q) s FS ss: A Compound 56 AND sleep 9 PESA. v TubD 5 YW 8 h Compound 36 & YW 1 À X% Compound 51 À 2500000.0 À à * Compound 29a É À o Sd À
It's Y NA 3 go AN Ja CARD
0.0 = Y 104 10th 102nd 107 10th 10th 10th 10th 103 10th Concentration (nM)
Fig. 1T2c * H H-60 Thymidine test = "Dox = 225000 Y Compound (Ill-p) S 200000 À Compound if + O: 1750004 E4XTSE
S 150000 NET ERES RN y TubD E 125000 SAS T o Compound 36 E A 3 AV 7% «Compound 51 ', 100000 T SS v X À and Compound 29a So 75000! IN T & 50000 N 25000 5 NI - 0 pnESAÇS Ê 10º 10º 10º 107º 10º 107 10º 103 10º
Concentration (nM)
| Fig. 12d * H Thymidine test of 786-0 "D = ox = v Compound (Ill-p) 400000 8 v Compound (1! | -Q) oo IS 300 RH NE A Compound 56 = 000 EX À AND IN THIS A v TubD = v R.
NS: Compound 36 and 20000 | NS À Wo 0 MW À * Compound 51 Ss V e * Compound 29a É 100000 RW 3 ANIS S 0 Ea Ê 10º 103 102 107 10º 10º 10º 103 10th Concentration (nM)
Fig. 13 Conjugate activity in vitro 786-0 cells, * H thymidine proliferation assay 200000 Ss = 2A10-CBI O & 150000 a and 4 Diphtheria toxin 2nd E 1 ER y 2H5-CBI OXX + IF4- CBI & & 100000 Ni * 2H5- (VI-a) SE, xn 2A10- (VI-a) SE soooo ea 2 2H5- (VI-D) v 2A10- (VI-b) o 107 10th 107 10th 10th! 10th 103 Concentration! (nM) - Fig 14 In vivo activity of the conjugate Average tumor volume of 786-0 ”700: T = Vehicle & 600 Ft 2A10- (VI-a) E soo LJ —e 2H5- (VI-a) = 400 = Ã —— 2A10- (VI-b) | 8 300 is - = - 2H5- (VI-b) 2 200% 8 “E 100 tt E o = 10 20 30 40 Days after dosing
Fig. 15 Scheme13 NO, NO, Mouth, NaOH (-) - menthol On —— H2N HO BocHN DCC, DMAP CcoH co H 34 80 (as hydrochloride) NO, NO : BocHN De + BocHN Ds O À à 81a 81b 6N HCl 6N HCl NO, NO,
HCFHAN HCFHHAN OH and OH O o 82a 82b
Fig. 16 Diagram 14 nu 9 a ENS Mr or Po A S Compound 34a. 82a NO Compound | o o A o 82b
A N o $ Co 83a: o NO, - Ho, no as o Pdic w N .., N x O Ss with 83b o NH Ha, no Pdic
POOR ow 3 'Cco2H 84a the NH no a SN, N
ELOA o:; "" CoH 84b
Fig. 17 Layout 15 na, À f Lt
NH, Ninth Citrulline protected TOR with Fmoc ————————————— BocHN EDCI, DMF BocHN CO. Me CO, Me 62 85 Rº = Fmoc Piperidine 86 Rº = H 'HAN N Yf kt | IA - 1. LiOH, HO Yes A 2 o o NV o * oxho Ed E RRHN = what do you eat and R = Boc 2e TFA 88 RR = H (TFA salt)
H Compound 34a HA or compound 49 o Lt = x Oo HATU, DIEA NH Ys A o O NILO o ORº o A Ss NH s - coH 89 R $ = C (= O) Me 90 Rº = Me
Fig. 18 Layout16
HAN N HAN N '2) Y X 2! Y 4 o: o e RA no, Valina [Di NHFmoc rr 2 protected YO with Fmoc Ô - BocHN HATU BocHN COaMe Cove 86 1 non, HM s kt o oo Compound 34a 'RA | or acetate of the 3-step TX p and composed of 27 | . LA o HATU, DIEA RAN 92 RT = Boc | COoH TFA 93 RT = H (TFA salt) Hen H - UM o H od o x TORCE o o o 9 o KR. N YY | CS) os; Co 94 RU = Me 95 RU = CHOC (= 0) CH, CH (Me),
Fig. 19 Scheme17 o OH o OH o ER N He! N A N C 7 OMe> HCiH CT ”moves Ss Ss 8 100
E OH o 0% oo NaBH (OAOa - HN Ny out ESSAS one o SÍ Ro S Ú CH; CHCHO S Isoleucine S protected 101 with Boc 102 | E. DIEA o 0 oo Ha, Pd / C x Nasc Ny mov Nas do Ss Í QN pocos “103“ 1 o 108 104
E H o 09% O H oORY o Nº “ON one NaOH, Nº E ON Qu on o Ss Do Ss 8 106 V = 107 R '= H i. Py, AGO li. HO 108 RY = Ac
Fig. 20a Scheme 18 (part 1 of 2 in OAc o “NON, N Nº AN | Ay or [Ss HATU, DIEA | Horno 103 v with Me 108 o QAc o A, N v Cf 7 o. Ss HATU v ms 'coMe Noz 114 HATU TFAHNTD 110 DIEA Coser Phenyl methyl ester NO, OAc o JR, NO s S' COLEt 11 QN AIN AE Fi AN Pdire N CON NY 'CoMe
QE NH> 108 o Ac o À AR, N
TEC SO | The “Ss COZEI | 112 |
| - Fig. 20b Scheme 18 (part 2 of 2) 1 AIN A *. "N HATU, DIEA, v] N Ay or N-acetyl Lys and S Ss Methyl ester 108 o OA O EQ, BIPEA 117 ACHN" “CO , Me o 'H (CH) NH-C-NH, o
WON H - o x eso HN 9 o with 1u5
Q H (CHANH-C-NH2-— WYONH "À y o Ac O Paço) NS SN Pr" o Ô o sl H - "s CcOoH 116
Fig. 21 Diagram 19 fe o o à, BU, NH - HATU, DIEA Rº Ice] E-MHA o fo 119 120 Rº = t-Bu de | 121 RU = H Ha, N | 2) | Tl | O
H NH NA i. DIEA, HATU, FYÓONH Citrulline protected o - with Fmoc | BocHN ii. BocHN piperidine. CO2t-Bu CO2t-Bu 122 123 Ha, N 2) Pf kt o o NÃ v N tero) s = N | YO Yº 2) s o * o d BocHN 124 'COt-Bu | 115
Fig. 22 Layout 20 x 9 o CT Oo Ss N Hel N a N CJ OMe> HelHN 7 “oe H Ss s 9 RX = H 126 NaH, 125 RX = Me - MezSOa o o DIEA Na. N KHMDS> o N CD OMe —— - rn o - S to
LO O - 103 128 | 127 | j É À Ha, PdiC KW q É j | NaN PY moves NUS SON My or | TA Ss! LC 8 Y o NUS OCS o o | AA E to AA 129 130 RY = Me | BusSnoH 131 Rí = H
- Fig. 23 Scheme 21 NH2 "TFA o fo o À N HATU, Nº" CN CO COH + TFAHA ——. DEL Ss DIEA SS UU 'COLEt o 131 132 NH o o o
RN N ê t 7 US 'COLEt c HCl, 133 n-ProH NH HCl, fo o MeCH À KR N and AA, ow o $ 'COZEt MV 135
NH o fo o o $ CO2Et 134
: 2: 26/27:: Fig. 24 - Diagram 22 's 2 NO; NO, NH; : Di-t-butyl; í: RS .º + ": acetal zo Hs of. io PeeEN A or BN o e a BedNTA | Ns Too coH 10, eOaBa ST o“> costBu '136 137 122: 2 fes | Ha, PdrC 2 A; MHANÇN% Pos É kt 2: PoGoONOS and NH es NMucA ooo,: LT Nemóe 2 & ". . > Oo o 'ó + LTBDMSCI imidazole: BocHN li protected citrulline =: - BocHN, if Co with Fmoc, DSO, DIEA' co '
F 138. 139 1 a! Y NA AA 4: only LL. ORAS OO - 1-Pipeúdina & ARA NRCAÃAQ UT CO TO »o À YIN - sn:" CGL DIEEA, Roe! RA. O: F OQ o ESA o: SK o .. Soto and NS, e.: Oz A “ 7 2 Boy 141 Rd = NHBoc 14 CoH | rea '142 Rº = NH; yTFA i 27127 Fig. 25 Scheme 23 io pes AN A QN PV AROS SN o Ns From AE ii. Py, HO Do, “and T o 27 145 Han, À:
PV 9 kh o g NA Ao. DIEA, HATU the JON eras N, | Compound 142 o º o
TR N Po OH 146 | '9 nn, À
P O k o HR z A os DIEA, HATU x TA (CHIaN | NHCI H o o “9 Ô pes AN A 2 Do Da k, S NH 147 | o

类似技术:

---

公开号 | 公开日 | 专利标题

---

BR112012002615A2|2020-11-03|antiproliferative compounds, conjugates, substance composition and use thereof

---

CA2900854C|2017-08-22|Tubulysin compounds, methods of making and use

---

CA2864420C|2016-11-15|Enediyne compounds, conjugates thereof, and uses and methods therefor

---

ES2719756T3|2019-07-12|Tubulisin analogs and methods of manufacture and use

同族专利:

---

公开号 | 公开日

---

HK1164751A1|2012-09-28|

---

HRP20140976T1|2015-01-02|

---

MX2012001665A|2012-03-26|

---

WO2011017249A1|2011-02-10|

---

PE20121087A1|2012-08-17|

---

IN2012DN00860A|2015-07-10|

---

CN102725001B|2015-01-14|

---

NZ597985A|2013-08-30|

---

EA201270242A1|2012-07-30|

---

CL2012000302A1|2012-07-20|

---

EA022288B1|2015-12-30|

---

US8772543B2|2014-07-08|

---

US20140323690A1|2014-10-30|

---

SMT201400183B|2015-01-15|

---

IL217717D0|2012-03-29|

---

KR20120047998A|2012-05-14|

---

JP5859964B2|2016-02-16|

---

TW201106976A|2011-03-01|

---

EP2461830B1|2014-09-24|

---

US20160060294A1|2016-03-03|

---

US20130197259A1|2013-08-01|

---

AR077701A1|2011-09-14|

---

US9580467B2|2017-02-28|

---

SG10201503332XA|2015-06-29|

---

US8772542B2|2014-07-08|

---

ES2525351T3|2014-12-22|

---

CN104592351A|2015-05-06|

---

PT2461830E|2014-12-11|

---

US20110027274A1|2011-02-03|

---

SI2461830T1|2015-01-30|

---

US9226974B2|2016-01-05|

---

CO6501196A2|2012-08-15|

---

IL217717A|2017-06-29|

---

SG178095A1|2012-03-29|

---

JP2013501055A|2013-01-10|

---

CA2770042A1|2011-02-10|

---

US8802632B2|2014-08-12|

---

PL2461830T3|2015-03-31|

---

CN102725001A|2012-10-10|

---

AU2010279674B2|2015-05-07|

---

EP2461830A1|2012-06-13|

---

DK2461830T3|2015-01-12|

---

HUE026997T2|2016-08-29|

---

US8394922B2|2013-03-12|

---

CA2770042C|2017-02-28|

---

US20130189256A1|2013-07-25|

---

KR101759359B1|2017-07-18|

---

AU2010279674A1|2012-02-23|

---

TWI469794B|2015-01-21|

---

US20130204033A1|2013-08-08|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

WO1981001145A1|1979-10-18|1981-04-30|Univ Illinois|Hydrolytic enzyme-activatible pro-drugs|

---

US4475196A|1981-03-06|1984-10-02|Zor Clair G|Instrument for locating faults in aircraft passenger reading light and attendant call control system|

---

US4447233A|1981-04-10|1984-05-08|Parker-Hannifin Corporation|Medication infusion pump|

---

US4631190A|1981-06-26|1986-12-23|Shen Wei C|Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers|

---

US5144011A|1981-06-26|1992-09-01|Boston University|Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers|

---

US4439196A|1982-03-18|1984-03-27|Merck & Co., Inc.|Osmotic drug delivery system|

---

US4522811A|1982-07-08|1985-06-11|Syntex Inc.|Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides|

---

US4447224A|1982-09-20|1984-05-08|Infusaid Corporation|Variable flow implantable infusion apparatus|

---

US4487603A|1982-11-26|1984-12-11|Cordis Corporation|Implantable microinfusion pump system|

---

US4486194A|1983-06-08|1984-12-04|James Ferrara|Therapeutic device for administering medicaments through the skin|

---

MX9203291A|1985-06-26|1992-08-01|Liposome Co Inc|LIPOSOMAS COUPLING METHOD.|

---

US4698420A|1985-02-25|1987-10-06|Xoma Corporation|Antibody hybrid molecules and process for their preparation|

---

US4596556A|1985-03-25|1986-06-24|Bioject, Inc.|Hypodermic injection apparatus|

---

US5374548A|1986-05-02|1994-12-20|Genentech, Inc.|Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor|

---

US4941880A|1987-06-19|1990-07-17|Bioject, Inc.|Pre-filled ampule and non-invasive hypodermic injection device assembly|

---

US4790824A|1987-06-19|1988-12-13|Bioject, Inc.|Non-invasive hypodermic injection device|

---

US5108921A|1989-04-03|1992-04-28|Purdue Research Foundation|Method for enhanced transmembrane transport of exogenous molecules|

---

US5312335A|1989-11-09|1994-05-17|Bioject Inc.|Needleless hypodermic injection device|

---

US5064413A|1989-11-09|1991-11-12|Bioject, Inc.|Needleless hypodermic injection device|

---

US5383851A|1992-07-24|1995-01-24|Bioject Inc.|Needleless hypodermic injection device|

---

US6214345B1|1993-05-14|2001-04-10|Bristol-Myers Squibb Co.|Lysosomal enzyme-cleavable antitumor drug conjugates|

---

TW420681B|1995-12-08|2001-02-01|Lederle Japan Ltd|Carbapenem-3-carboxylic acid ester derivatives|

---

DE19638870B4|1996-09-23|2009-05-14|Helmholtz-Zentrum für Infektionsforschung GmbH|Tubulysins, methods for their production and agents containing them|

---

US7214487B2|1998-06-26|2007-05-08|Sunesis Pharmaceuticals, Inc.|Methods for identifying compounds that modulate enzymatic activities by employing covalently bonded target-extender complexes with ligand candidates|

---

KR20020047132A|1999-08-24|2002-06-21|메다렉스, 인코포레이티드|Human ctla-4 antibodies and their uses|

---

DE10008089A1|2000-02-22|2001-10-31|Biotechnolog Forschung Gmbh|Production of tubulysin compounds comprises multi-stage process including condensation of N-methylpipecolinoyl-isoleucine with substituted thiazole-4-carboxylic acid derivative|

---

PE20020908A1|2001-03-21|2002-10-26|Cell Therapeutics Inc|RECOMBINANT PRODUCTION OF POLYANIONIC POLYMERS AND USE OF THE SAME|

---

CN1463270A|2001-05-31|2003-12-24|梅达莱克斯公司|Disulfide prodrugs and linkers and stablizers useful therefore|

---

US7091186B2|2001-09-24|2006-08-15|Seattle Genetics, Inc.|p-Amidobenzylethers in drug delivery agents|

---

EP1471938A4|2002-01-09|2008-03-05|Medarex Inc|Human monoclonal antibodies against cd30|

---

WO2004005327A1|2002-07-09|2004-01-15|Morphochem Ag Komb Chemie|Novel tubulysin analogues|

---

US7776814B2|2002-07-09|2010-08-17|R&D-Biopharmaceuticals Gmbh|Tubulysin conjugates|

---

DE10241152A1|2002-09-05|2004-03-18|GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH |Tubulysin biosynthesis genes|

---

FR2845630B1|2002-10-09|2005-09-30|Helitest Ags|DEMASTICATING DEVICE, IN PARTICULAR FOR REFLECTING JOINTS IN AIRCRAFT TANK STRUCTURES AND CONTAINER INTERVENTION|

---

DE10254439A1|2002-11-21|2004-06-03|GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH |Tubulysins, manufacturing processes and tubulysin agents|

---

JP4753867B2|2003-04-15|2011-08-24|グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー|Conjugates containing human IL-18 and substitutional variants thereof|

---

PE20050712A1|2003-07-22|2005-11-02|Schering Ag|RG1 ANTIBODIES|

---

US7375078B2|2004-02-23|2008-05-20|Genentech, Inc.|Heterocyclic self-immolative linkers and conjugates|

---

US7714016B2|2005-04-08|2010-05-11|Medarex, Inc.|Cytotoxic compounds and conjugates with cleavable substrates|

---

US7691962B2|2004-05-19|2010-04-06|Medarex, Inc.|Chemical linkers and conjugates thereof|

---

CA2564076C|2004-05-19|2014-02-18|Medarex, Inc.|Chemical linkers and conjugates thereof|

---

US7541330B2|2004-06-15|2009-06-02|Kosan Biosciences Incorporated|Conjugates with reduced adverse systemic effects|

---

DE102004030227A1|2004-06-23|2006-01-26|Dömling, Alexander, Dr.|Treatment of diseases associated with angiogenesis comprises administration of carbamide compounds|

---

AU2005286607B2|2004-09-23|2011-01-27|Genentech, Inc.|Cysteine engineered antibodies and conjugates|

---

PL1851250T3|2005-02-18|2012-10-31|Squibb & Sons Llc|Human monoclonal antibody to prostate specific membrane antigen |

---

EP3530736A3|2005-05-09|2019-11-06|ONO Pharmaceutical Co., Ltd.|Human monoclonal antibodies to programmed death 1 and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics|

---

MX2007015944A|2005-06-20|2008-03-07|Medarex Inc|Cd19 antibodies and their uses.|

---

JP5475992B2|2005-08-19|2014-04-16|エンドサイト，インコーポレイテッド|Multidrug ligand conjugate|

---

AU2006294554B2|2005-09-26|2013-03-21|E. R. Squibb & Sons, L.L.C.|Antibody-drug conjugates and methods of use|

---

NZ566395A|2005-09-26|2012-03-30|Medarex Inc|Human monoclonal antibodies to CD70|

---

BRPI0619331A2|2005-10-26|2011-09-27|Medarex Inc|method for making a compound to prepare a cbi cc-1065 analog, method for making a cbi cc-1065 analog and compound|

---

WO2007059404A2|2005-11-10|2007-05-24|Medarex, Inc.|Duocarmycin derivatives as novel cytotoxic compounds and conjugates|

---

JP5714212B2|2005-12-08|2015-05-07|メダレックス・リミテッド・ライアビリティ・カンパニーＭｅｄａｒｅｘ， Ｌ．Ｌ．Ｃ．|Human monoclonal antibody against O8E|

---

RS52804B|2005-12-08|2013-10-31|Medarex Inc.|Human monoclonal antibodies to protein tyrosine kinase 7 and their use|

---

KR101552735B1|2006-12-01|2015-09-14|메다렉스, 엘.엘.시.|22 human antibodies that bind cd22 and uses thereof|

---

CA2672468A1|2006-12-14|2008-06-19|Medarex, Inc.|Human antibodies that bind cd70 and uses thereof|

---

UY30776A1|2006-12-21|2008-07-03|Medarex Inc|CD44 ANTIBODIES|

---

TWI412367B|2006-12-28|2013-10-21|Medarex Llc|Chemical linkers and cleavable substrates and conjugates thereof|

---

US20080176958A1|2007-01-24|2008-07-24|Insert Therapeutics, Inc.|Cyclodextrin-based polymers for therapeutics delivery|

---

EP2121667B1|2007-02-21|2016-06-08|E. R. Squibb & Sons, L.L.C.|Chemical linkers with single amino acids and conjugates thereof|

---

US20100047841A1|2007-02-27|2010-02-25|University Of Pittsburgh-Of The Commonwealth System Of Higher Education|Synthesis of desacetoxytubulysin h and analogs thereof|

---

CN101678124A|2007-03-14|2010-03-24|恩多塞特公司|Binding ligand linked drug delivery conjugates of tubulysins|

---

CA2723671C|2007-05-10|2018-06-19|R & D Biopharmaceuticals Gmbh|Tubulysine derivatives|

---

CN101784565B|2007-06-25|2014-12-10|恩多塞特公司|Conjugates containing hydrophilic spacer linkers|

---

US7387981B1|2007-06-28|2008-06-17|Lyondell Chemical Technology, L.P.|Direct epoxidation catalyst and process|

---

EP2181101A2|2007-07-20|2010-05-05|Helmholtz-Zentrum für Infektionsforschung GmbH|Tubulysin d analogues|

---

PT2187965T|2007-08-17|2020-01-17|Purdue Research Foundation|Psma binding ligand-linker conjugates and methods for using|

---

EP2185188B1|2007-08-22|2014-08-06|Medarex, L.L.C.|Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions|

---

US8268970B2|2007-10-01|2012-09-18|Bristol-Myers Squibb Company|Human antibodies that bind mesothelin, and uses thereof|

---

CA2703491C|2007-10-25|2017-06-13|Endocyte, Inc.|Tubulysins and processes for preparing|

---

EP2174947A1|2008-09-25|2010-04-14|Universität des Saarlandes|Bioactive pre-tubulysins and use thereof|

---

US8394922B2|2009-08-03|2013-03-12|Medarex, Inc.|Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof|

---

WO2011057805A1|2009-11-12|2011-05-19|R&D Biopharmaceuticals Gmbh|Tubulin inhibitors|US8288557B2|2004-07-23|2012-10-16|Endocyte, Inc.|Bivalent linkers and conjugates thereof|

---

CN101678124A|2007-03-14|2010-03-24|恩多塞特公司|Binding ligand linked drug delivery conjugates of tubulysins|

---

CN101784565B|2007-06-25|2014-12-10|恩多塞特公司|Conjugates containing hydrophilic spacer linkers|

---

US9877965B2|2007-06-25|2018-01-30|Endocyte, Inc.|Vitamin receptor drug delivery conjugates for treating inflammation|

---

PT2187965T|2007-08-17|2020-01-17|Purdue Research Foundation|Psma binding ligand-linker conjugates and methods for using|

---

IT1394860B1|2009-07-22|2012-07-20|Kemotech S R L|PHARMACEUTICAL COMPOUNDS|

---

US8394922B2|2009-08-03|2013-03-12|Medarex, Inc.|Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof|

---

US9951324B2|2010-02-25|2018-04-24|Purdue Research Foundation|PSMA binding ligand-linker conjugates and methods for using|

---

MX336540B|2010-06-08|2016-01-22|Genentech Inc|Cysteine engineered antibodies and conjugates.|

---

SI2686334T2|2011-03-16|2020-10-30|F. Hoffmann-La Roche Ag|Ion exchange chromatography with improved selectivity for the separation of polypeptide monomers, aggregates and fragments by modulation of the mobile phase|

---

RU2617402C2|2011-06-10|2017-04-25|Мерсана Терапьютикс, Инк.|Protein-polymer-drug conjugates|

---

AU2013359506B2|2012-12-10|2018-05-24|Mersana Therapeutics, Inc.|Protein-polymer-drug conjugates|

---

WO2013126797A1|2012-02-24|2013-08-29|Purdue Research Foundation|Cholecystokinin b receptor targeting for imaging and therapy|

---

US20140080175A1|2012-03-29|2014-03-20|Endocyte, Inc.|Processes for preparing tubulysin derivatives and conjugates thereof|

---

EP2849797B1|2012-05-15|2019-12-18|Concortis Biosystems, Corp|Drug-conjugates, conjugation methods, and uses thereof|

---

EP3210627A1|2012-07-12|2017-08-30|Hangzhou Dac Biotech Co., Ltd|Conjugates of cell binding molecules with cytotoxic agents|

---

EP2708243A1|2012-09-17|2014-03-19|OntoChem GmbH|Receptor ligand linked cytotoxic molecules|

---

MX2015004757A|2012-10-16|2015-07-17|Endocyte Inc|Drug delivery conjugates containing unnatural amino acids and methods for using.|

---

CN108042811A|2012-11-15|2018-05-18|恩多塞特公司|For treating the conjugate of the disease as caused by PSMA expression cells|

---

AU2012395148B2|2012-11-24|2016-10-27|Hangzhou Dac Biotech Co., Ltd.|Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules|

---

WO2014093640A1|2012-12-12|2014-06-19|Mersana Therapeutics,Inc.|Hydroxy-polmer-drug-protein conjugates|

---

RS56169B1|2013-02-14|2017-11-30|Bristol-Myers Squibb Company|Tubulysin compounds, methods of making and use|

---

US20140249315A1|2013-03-01|2014-09-04|Endocyte, Inc.|Processes for preparing tubulysins|

---

PL2968440T3|2013-03-15|2019-12-31|Zymeworks Inc.|Cytotoxic and anti-mitotic compounds, and methods of using the same|

---

JP6171435B2|2013-03-18|2017-08-02|富士通株式会社|Semiconductor device and manufacturing method thereof, power supply device, and high-frequency amplifier|

---

WO2015057585A1|2013-10-14|2015-04-23|Regents Of The University Of Minnesota|Therapeutic compounds|

---

PE20160678A1|2013-10-18|2016-08-06|Deutsches Krebsforsch|MARKED MEMBRANE-SPECIFIC PROSTATIC ANTIGEN INHIBITORS , THEIR USE AS IMAGING AGENTS AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF PROSTATE CANCER|

---

US20170168074A1|2013-11-25|2017-06-15|Ontochem Gmbh|Method for diagnosing G-protein coupled receptor-related diseases|

---

WO2015095953A1|2013-12-27|2015-07-02|The Centre For Drug Research And Development|Sulfonamide-containing linkage systems for drug conjugates|

---

RU2714933C2|2013-12-27|2020-02-21|Займворкс Инк.|Var2csa-drug conjugates|

---

WO2015113760A1|2014-01-28|2015-08-06|Tube Pharmaceuticals Gmbh|Cytotoxic tubulysin compounds for conjugation|

---

AU2014384434B2|2014-02-28|2016-11-03|Hangzhou Dac Biotech Co., Ltd|Charged linkers and their uses for conjugation|

---

WO2015135659A1|2014-03-14|2015-09-17|Ontochem Gmbh|Receptor ligand linked cytotoxic molecules|

---

AU2015231210B2|2014-03-20|2019-09-12|Bristol-Myers Squibb Company|Stabilized fibronectin based scaffold molecules|

---

WO2015157594A1|2014-04-11|2015-10-15|Medimmune Llc|Tubulysin derivatives|

---

WO2015187540A1|2014-06-03|2015-12-10|Shaosong Chu|Peptide-drug conjugates|

---

CN104262455B|2014-08-22|2017-05-03|亚飞（上海）生物医药科技有限公司|Tumor microenvironment targeted activation docetaxel derivatives, preparation thereof and uses of the derivatives|

---

EP3184540A4|2014-08-22|2018-03-21|Yafei Shanghai Biolog Medicine Science& Technology|Specifically activated micromolecular target coupling body in tumor microenvironment and use thereof|

---

SG10202006505UA|2014-09-11|2020-08-28|Seattle Genetics Inc|Targeted delivery of tertiary amine-containing drug substances|

---

KR20170052600A|2014-09-12|2017-05-12|제넨테크, 인크.|Cysteine engineered antibodies and conjugates|

---

AU2015318556C1|2014-09-17|2021-01-07|Zymeworks Inc.|Cytotoxic and anti-mitotic compounds, and methods of using the same|

---

US10077287B2|2014-11-10|2018-09-18|Bristol-Myers Squibb Company|Tubulysin analogs and methods of making and use|

---

MX2017006624A|2014-11-21|2017-08-21|Bristol-Myers Squibb Company|Antibodies against cd73 and uses thereof.|

---

ES2826566T3|2014-11-21|2021-05-18|Squibb Bristol Myers Co|Antibodies comprising modified heavy constant regions|

---

SG11201703760WA|2014-11-25|2017-06-29|Bristol-Myers Squibb Company|Novel pd-l1 binding polypeptides for imaging|

---

US10188759B2|2015-01-07|2019-01-29|Endocyte, Inc.|Conjugates for imaging|

---

EP3261443B1|2015-02-25|2021-04-28|William Marsh Rice University|Desacetoxytubulysin h and analogs thereof|

---

EP3268048B1|2015-03-10|2019-05-08|Bristol-Myers Squibb Company|Antibodies conjugatable by transglutaminase and conjugates made therefrom|

---

SG10202008304TA|2015-05-29|2020-10-29|Squibb Bristol Myers Co|Antibodies against ox40 and uses thereof|

---

US9839687B2|2015-07-15|2017-12-12|Suzhou M-Conj Biotech Co., Ltd.|Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule|

---

US10584160B2|2015-09-23|2020-03-10|Bristol-Myers Squibb Company|Glypican-3-binding fibronectin based scaffold molecules|

---

EP3165532B1|2015-11-03|2018-12-19|Industrial Technology Research Institute|Auristatin derivatives, linker-drugs and ligand-drug conjugates|

---

KR20180090290A|2015-12-04|2018-08-10|시애틀 지네틱스, 인크.|Conjugates of Quaternized Tubular Compounds|

---

MX2018007479A|2015-12-21|2018-08-01|Squibb Bristol Myers Co|Variant antibodies for site-specific conjugation.|

---

WO2017134547A1|2016-02-01|2017-08-10|Pfizer Inc.|Tubulysin analogs and methods for their preparation|

---

EA201891983A8|2016-03-04|2020-05-28|Бристол-Майерс Сквибб Компани|COMBINED THERAPY BY ANTIBODIES TO CD73|

---

CN109620949A|2016-03-13|2019-04-16|曹帅|It is a kind of for treating the pharmaceutical composition of osteocarcinoma|

---

US20170326249A1|2016-05-10|2017-11-16|Bristol-Myers Squibb Company|Antibody-drug conjugate of an anti-glypican-3 antibody and a tubulysin analog, preparation and uses|

---

JP2019518013A|2016-05-10|2019-06-27|ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ|Antibody drug conjugates of tubulysin analogues with improved stability|

---

US10106560B2|2016-06-16|2018-10-23|Bristol-Myers Squibb Company|Process and intermediates for making tubulysin analogs|

---

KR20190039570A|2016-08-19|2019-04-12|브리스톨-마이어스 스큅 컴퍼니|Seco-cyclopropapyrroloindole compounds, their antibody-drug conjugates, and methods of manufacture and use|

---

US20190218294A1|2016-09-09|2019-07-18|Bristol-Myers Squibb Company|Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment|

---

US10517958B2|2016-10-04|2019-12-31|Zymeworks Inc.|Compositions and methods for the treatment of platinum-drug resistant cancer|

---

US10398783B2|2016-10-20|2019-09-03|Bristol-Myers Squibb Company|Antiproliferative compounds and conjugates made therefrom|

---

NZ752394A|2016-11-14|2021-07-30|Hangzhou Dac Biotech Co Ltd|Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers|

---

JP6585650B2|2017-03-23|2019-10-02|ハンヂョウ ディーエイシー バイオテック カンパニー リミテッド|Conjugates of cytotoxic agents and cell-bound receptors|

---

CA3064321A1|2017-05-25|2018-11-29|Bristol-Myers Squibb Company|Antibodies comprising modified heavy constant regions|

---

WO2019108685A1|2017-11-29|2019-06-06|William March Rice University|Tubulysin analogues as anticancer agents and payloads for antibody-drug conjugates and methods of treatment therewith|

---

US20210053979A1|2018-04-24|2021-02-25|Bristol-Myers Squibb Company|Macrocyclic toll-like receptor 7agonists|

---

SG11202011739SA|2018-05-29|2020-12-30|Squibb Bristol Myers Co|Modified self-immolating moieties for use in prodrugs and conjugates and methods of using and making|

---

US11020490B2|2018-06-22|2021-06-01|Bristol-Myers Squibb Company|Antibody-drug conjugate with a tubulysin analog warhead having a stabilized acetate group in the TUV subunit|

---

EP3887397A1|2018-11-28|2021-10-06|Bristol-Myers Squibb Company|Antibodies comprising modified heavy constant regions|

---

AU2019386945A1|2018-11-30|2021-07-22|Bristol-Myers Squibb Company|Antibody comprising a glutamine-containing light chain C-terminal extension, conjugates thereof, and methods and uses|

---

KR20210102334A|2018-12-12|2021-08-19|브리스톨-마이어스 스큅 컴퍼니|Antibodies modified for transglutaminase conjugation, conjugates thereof, and methods and uses|

---

AU2019403554A1|2018-12-21|2021-06-17|Regeneron Pharmaceuticals, Inc.|Tubulysins and protein-tubulysin conjugates|

---

CA3145050A1|2019-06-29|2021-01-07|Robert Zhao|Conjugates of tubulysin derivatives and cell binding molecules and methods of making|

---

WO2021055306A1|2019-09-16|2021-03-25|Bristol-Myers Squibb Company|Dual capture method for analysis of antibody-drug conjugates|

法律状态:
2020-11-17| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|

---

2020-12-15| B25A| Requested transfer of rights approved|Owner name: MEDAREX, L.L.C. (US) |

---

2020-12-22| B07D| Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]|Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |

---

2020-12-29| B07D| Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]|Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |

---

2021-01-05| B25A| Requested transfer of rights approved|Owner name: E.R. SQUIBB AND SONS, LLC (US) |

---

2021-03-16| B07E| Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]|

---

2021-03-23| B06U| Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]|

---

2021-06-08| B08F| Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]|Free format text: REFERENTE A 11A ANUIDADE. |

---

2021-07-06| B11B| Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements|

---

2021-12-07| B350| Update of information on the portal [chapter 15.35 patent gazette]|

优先权:

---

申请号 | 申请日 | 专利标题

---

US23093209P| true| 2009-08-03|2009-08-03|

---

US61/230,932|2009-08-03|

---

US23288309P| true| 2009-08-11|2009-08-11|

---

US61/232,883|2009-08-11|

---

PCT/US2010/044078|WO2011017249A1|2009-08-03|2010-08-02|Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof|

---